Chromatin Structure in Cell Differentiation, Aging and Cancer by Kheradmand Kia, S. (Sima)
 
 
 
 
 
 
Chromatin Structure in Cell 
Differentiation, Aging and Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sima Kheradmand Kia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Sima Kheradmand Kia 
 
The research presented in this thesis was performed at the Department of Biochemistry within 
the Erasmus Medical Center, Rotterdam, The Netherlands. 
 
The research has been supported by a European Commission (EC) grant “Epigenetic plasticity 
of the genome”. 
 
Financial support by the Erasmus MC and SSCD for the publication of this thesis is gratefully 
acknowledged. 
 
Cover Design: Gazelle Pezeshkmehr 
 
Layout: Parham & Kourosh 
 
Printed by Wöhrmann Print Service, Zutphen 
 
 
 
Chromatin Structure in Cell Differentiation, 
Aging and Cancer 
 
 
Chromatine Structuur in Cel Differentiatie, 
Veroudering en Kanker 
 
 
 
 
Proefschrift 
 
 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
 
 
Prof. dr. S. W. J.  Lamberts 
en volgens besluit van het College voor Promoties 
 
 
 
De openbare verdediging zal plaatsvinden op  
Woensdag 3 juni 2009 om 11.45 
 
 
door 
 
 
 
Sima Kheradmand Kia 
geboren te Tehran, Iran 
 
 
 
 
 
Promotie commissie 
 
 
Promotor:  Prof.dr. C.P. Verrijzer 
 
 
Overige leden:  Prof.dr. F.G. Grosveld 
   Prof.dr. R. Fodde 
Prof.dr. J.N.J. Philipsen 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It does not matter where I am. 
The sky is always mine. 
Windows, ideas, air, love, 
earth, all mine. 
So who cares if sometimes the leaves of solitude 
may grow all around. 
 
The Footsteps of Water (Seday-e Pay-e Ab ) by Sohrab Sepehri, Iranian poet (1928 - 1980)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my elder sister 
Simin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
 
 
Chapter1 Introduction         9 
 Outline of the thesis       26 
 
Chapter2 Global Gene Expression Regulation by hSNF5    27    
 
Chapter3 Cancer-associated mutations in chromatin remodeller    45 
hSNF5 promote chromosomal instability by  
compromising the mitotic checkpoint 
   
Chapter4  SWI/SNF mediates polycomb eviction and epigenetic    53 
reprogramming of the INK4b-ARF-INK4a locus 
 
Chapter5 An EZH2-Dependent Repressive Chromatin     63 
Loop Controls Human INK4a and INK4b  
Expression During Cell Differentiation, Aging  
and Senescence 
 
Chapter6 Discussion and Future Prospects     83 
 
 Summary        97 
  
 Samenvatting       99 
 
 Curriculum Vitae      101 
 
 Publication list      102 
 
 PhD portfolio      103 
 
 Acknowledgement      104 
  
 List of Abbreviations      106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter1 
Introduction 
 
 
 
 
Chapter1
 
 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction
 
 11 
Chromatin structure 
     Chromatin is the structure that the eukaryotic genome is packaged into, allowing over a 
metre of DNA to fit into the small volume of the nucleus. It is composed of DNA and proteins, 
most of which are histones. This DNA-protein complex is the template for a number of 
essential cell processes including transcription and replication. The basic structural unit of 
chromatin is the nucleosome. Nucleosomes comprise around 146 base pairs of DNA wrapped 
in a left-handed superhelix 1.7 times around a core histone octamer. This 11nm fibre is often 
referred to as ‘beads on a string’ (Figure 1A). Chromatin assembly involves wrapping of DNA 
around histone octameres producing repetitive nucleosomal array followed by folding of 
chromatin fibre into solenoid-like structure and deposition of non-histone proteins (19, 25, 52, 
55).  
 
Figure1. Schematic model for Chromatin Structure and ATP-dependent Chromatin remodelling. 
(A) Each DNA strand wraps around groups of small protein molecules called histones, forming a series of bead-like 
structures, called nucleosomes, connected by the DNA strand. Under the micros-cope, uncondensed chromatin has a "beads 
on a string" appearance. The string of nucleosomes, already compacted by a factor of six, is then coiled into an even denser 
structure known as a solenoid that compacts the DNA by factor of 40. The solenoid structure then coils to form a 
chromosome (Figure adapted from www.epitron.eu). (B) ATP-dependent chromatin remodelling complexes use the energy 
derived from  ATP hydrolysis to alter histone-DNA contacts in such a way that (I) nucleosomes slide to another position, (II) a 
remodelled state is created in which the DNA becomes more accessible but histone remain bound, (III) DNA and histone 
dissociate completely, or (IV) histone (variant) replacement ( figure adapted from Ref.28). 
 
     Chromatin is a dynamic structure that modulates the access of regulatory factors to the 
genetic material of eukaryotes and hence controls at a high level the machinery of DNA 
replication, transcription and repair. For this reason, chromatin needs to be remodelled. The 
regulated alteration of chromatin structure, termed remodelling can be accomplished by 
covalent modification of histones or by the action of ATP-dependent remodelling complexes. 
Remodellers are DNA-translocating motors that utilize the energy of ATP to disrupt histone-
DNA contacts (26, 50, 72, 73, 95, 100, 102). ATP-dependent chromatin remodelling factors 
(remodellers) expose DNA to be accessible for transcription regulators. There are several 
A B
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possible outcomes of the ATP-dependent chromatin remodelling reaction including nucleosome 
sliding, creation of DNA loops on the surface of nucleosomes, nucleosome displacement and 
histone exchange (Figure1B)(26, 50, 72, 73, 95, 100, 102). A precise coordination of events 
in opening and closing of the chromatin is crucial to ensure that the correct spatial and 
temporal epigenetic code is maintained within the eukaryotic genome. 
 
ATP-dependent chromatin remodelling factors 
     Remodellers are typically large, multiprotein complexes assembled around the SNF2-like 
ATPase ‘engine’ protein(20-22, 24, 86). The SNF2 superfamily of chromatin remodelling 
ATPases can be divided into various families based on the presence of additional domains(24). 
Four different classes of remodelling complexes have been recognized: SWI/SNF, ISWI, Mi-2 
and Ino80. Recent survey of SNF2 superfamily members reveals 24 distinct groups, 
suggesting a large structural variety among ATP-dependent chromatin remodelling 
enzymes(24). We will focus on the highly conserved SWI/SNF family of ATP-dependent 
chromatin remodelling factors. 
 
The SWI/SNF complex 
     The first chromatin remodelling factor identified was ySWI/SNF. It contains 11 known 
subunits, including SWI2/SNF2. Subunits of the ySWI/SNF were initially identified based on 
two independent screens for mutants affecting either mating type switching or growth in 
sucrose, thereby SWI stands for SWItching defective and SNF – for Sucrose Non-Fermenting. 
In agreement with the phenotypes caused by mutations in the ySWI/SNF subunits, this 
complex is required for the activation of a number of specific genes such as HO endonuclease, 
SUC2, GAL1 and GAL10, which are involved in mating-type switch and sucrose and galactose 
fermenting(63). The SWI/SNF complex is evolutionary highly conserved and homologous 
complexes have been identified in Drosophila and mammals. The SWI/SNF group of 
remodellers can be subdivided further into two distinct highly conserved   subclasses, yeast 
SWI/SNF, fly BAP, mammalian BAF or yeast RSC, fly PBAP and mammalian PBAF (Figure 2).  
     In mammals, BAF and PBAF complexes share most core subunits except the two 
SWI2/SNF2-type ATPases: BRG1 (Brahma-Related Gene 1) and hBrm (human Brahma). BAF 
subfamily contains either BRG1 or BRM (hBRM in human and mBRM in mice) as well as the 
distinct BAF250 subunit, whereas the PBAF subfamily is uniquely built on BRG1 ATPase(47, 
57, 97, 98) and also distinctly contains BAF180 and BAF200 subunits. In addition to this, 
several tissue specific subunits can be identified(58). In Drosophila, RNAi knockdown of the 
BAP subunits results in accumulation of the cells in G2/M phase of the cell cycle, whereas 
depletion of the PBAP specific subunits has no significant effect on growth and cell cycle 
progression(56). 
        Together, BAP and PBAP have a critical role for both SWI/SNF complexes in the 
recruitment of the basal transcription machinery(2). The core subunits and the BAP-specific 
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subunit OSA have been implicated in the regulation of expression of homeotic genes, 
repression of the Wingless target genes and regulation of the genes involved in the Notch 
signalling pathway during development(3, 16, 85). In mammals it has been shown that both 
BAF and PBAF complexes regulate expression of distinct interferon-responsive genes(98). 
Furthermore, both complexes seem to cooperate with distinct nuclear hormone receptors. 
 
Figure 2. SWI/SNF family of ATP-dependent chromatin remodellers is divided into two evolutionary conserved subfamilies 
characterized by the presence of subfamily specific signature subunits (shown for human “h”, Drosophila – “d”–and yeast “y”)  
 
     Knockout (KO) mice for PBAF specific subunit BAF180 show only mild effect on embryonic 
development like defects in placental trophoblast and heart development(94). Depletion of the 
BAF-specific subunit BAF250 results in more severe developmental defects similar to those 
obtained after knockout of one of the core subunits (94). This further substantiates the idea 
that, unlike yeast ySWI/SNF complex, metazoan BAP/BAF complex plays more prominent 
function in cell proliferation and viability than PBAP/PBAF complex. In mice, targeted 
disruption of SWI/SNF core subunits usually results in embryonic lethality with the exception 
of BRM; this is thought to be due to up regulation of and compensation by BRG1(14, 28, 38, 
ySWI/SNF ySWI/SNF 
hPBAF hBRM/BAF hBRG1/BAF 
dPBAP dBAPD 
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41, 67, 68). BRG1 knockout results in severe developmental defects. BRG1-/- embryos dye at 
pre-implantation stage and neither trophectoderm nor inner cell mass of blastocysts 
survives(14). These results suggest that BRG1-containing BAF complex is critical for early 
embryo development and cell viability and reveal further functional diversification between 
mammalian BRM and BRG1-containing BAF complexes. The requirement of the SWI/SNF 
complex for heart development, embryonic brain development, regulation of neuronal 
differentiation and vascular development during murine embryogenesis, embryonic and adult 
β-globin transcription and erythropoiesis and T-cell development has been shown and 
reviewed in (17, 42).   
 
The SWI/SNF complex and Cancer 
     Thus far there is strong evidence supporting a role for SWI/SNF complexes in cancer 
development, as several subunits possess intrinsic tumour suppressor activity or are required 
for the activity of other tumour suppressor genes (8, 18, 34, 66, 76, 77, 91, 96). Inactivating 
mutations or aberrant expression of the genes encoding SWI/SNF core subunits have been 
found in different human tumour cell lines and primary tumours (18). BRG1 and BRM 
mutations are frequently observed in various tumour cell lines including pancreatic, breast, 
lung and prostate cancer cells. Lack of expression of both SWI/SNF ATPase subunits BRG1 
and hBRM correlate with poorer prognosis in patients with non-small-cell lung cancer (66). 
Human SNF5 (hSNF5, INI1 or SMARCB1) located in the chromosomal region 22q11.2, is a 
core component of the hSWI/SNF and it has been implicated in gene regulation, cell division 
and tumourigenesis (32). Mice heterozygous for SNF5 are predisposed to tumours with 
features similar to the human Malignant Rhabdoid tumours (MRTs), which are frequently 
metastatic to the lung and/or lymph node. SNF5-deficient tumours undergo loss of 
heterozygosity (LOH), which results in SNF5 depletion (14, 28, 41, 68).  Unlike SNF5-deficient 
tumours, BRG1-mutated tumours occur at different locations such as the neck or inguinal 
regions, display different features of epitheloid origin, and appear not to undergo LOH (96).  
     The SWI/SNF complex associates directly with cancer-related molecules such as BRCA1 
and c-Myc and beta-catenin (4, 9, 15, 84). BRCA1 activates p53-dependent transcription, 
which is abrogated by a dominant-negative mutant form of BRG1 (9). SNF5 also interacts 
directly with c-Myc and this interaction is important for trans-activating the function of c-Myc 
(15). SWI/SNF complex has been shown to interact directly with myeloid/lymphoid or Mixed-
Lineage Leukaemia (MLL), human homolog of Drosophila trithorax (trxG), through SNF5 
subunit. SWI/SNF and MLL activate oncogenesis through different mechanisms, such as 
inhibition of GADD34 induced apoptosis and aberrant activation of MLL target genes (reviewed 
in [70]). Collectively these observations point to the function of SWI/SNF complexes as 
tumour suppressors. 
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Malignant rhabdoid tumour and Atypical teratoid rhabdoid tumour 
     The term malignant rhabdoid tumour (MRT) has been used to describe a heterogeneous 
group of neoplasms, having in common distinct so-called "rhabdoid" cytologic features. The 
rhabdoid cell is a medium-sized, round-to-oval cell with distinct borders, an eccentric nucleus, 
and a prominent nucleolus. The cell of origin of malignant rhabdoid tumour remains an 
enigma. Malignant rhabdoid tumour may arise either de novo from non-neoplastic cells or 
through tumour progression from other types of neoplasms. These latter tumours, in which 
other nonrhabdoid tumour components are identified, may be termed composite MRT. 
Rhabdoid tumours were reported in many tissues including the kidney, the liver, soft tissue, 
and the central nervous system (8, 71, 77, 91). The cerebellum is the most common location 
for primary intracerebral MRT. Malignant rhabdoid tumour (MRT) of the CNS is known as 
Atypical teratoid/rhabdoid tumour (AT/RT).  In the United States, three children per 
1,000,000 or around 30 new AT/RT cases are diagnosed each year. AT/RT represents around 
3% of pediatric cancers of the central nervous system (CNS). ATRT/MRTs are highly 
aggressive cancer of early childhood and despite intensive therapies 80-90% of children die 
within first year of diagnosis. About 50% of atypical teratoid/rhabdoid tumours arise in the 
posterior fossa, 40% are supratentorial, and the rest are pineal, spinal, or multifocal. Both 
ATRTs and MRTs are characterized by the presence of rhabdoid cells carrying vacuolated 
nuclei and Periodic Acid-Shiff (PAS) cytoplasmic inclusions, however the histological diagnosis 
can be difficult (29).  Biallelic inactivating mutations and deletions of the SWI/SNF core 
subunit SNF5/INI1 have been identified in the majority of kidney malignant rhabdoid tumours 
(MRT) and brain atypical teratoid/rhabdoid tumours (ATRT) However, at least 20% of cases 
do not have genomic alterations of hSNF5, despite showing loss of immunostaining for the 
SNF5 protein (8, 76, 77, 91). In several cases germline mutations in SNF5/INI1 gene 
accompanied by somatic loss or mutation of the remaining allele were documented in patients 
with ATRT/MRTs indicating that SNF5/INI1 is a classical tumour suppressor gene (8, 77). Loss 
of SNF5/INI1 has been also detected in a number of tumours histologically distinct from 
ATRT/MRTs such as paediatric choroid plexus carcinoma, meningioma, medulloblastoma (70). 
 
hSNF5 is a tumour suppressor gene 
     The SWI/SNF complex is also involved in various cellular processes that are potentially 
associated with tumour formation including DNA synthesis, virus integration, DNA repair, and 
mitotic gene regulation (70). Numerous studies to dissect the connection between these 
activities and tumour formation are currently in progress. The molecular mechanisms 
underlying tumour development in mice with inactivation of BRG1 or SNF5 are still unclear. A 
mouse strain carrying reversibly inactivating SNF5/INI1 allele by applying LoxP-Cre 
recombination system has been generated to find the mechanisms of tumourigenesis caused 
by loss of SNF5/INI1 (69). 100% of the resultant mice develop short latency highly aggressive 
tumours such as CD8+ T cell lymphomas and rhabdoid tumours (69). Paradoxical observations 
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that phenotypes induced by BRG1 or SNF5 deficiency in mouse embryonic fibroblasts (MEFs) 
are very similar to those of cancer cells whose BRG1 or SNF5 are ectopically over-expressed. 
Both cell lines undergo cell cycle arrest, cell death, or senescence (69).  
     Although the molecular mechanisms for SNF5/INI1 function in cell survival in normal cells 
is not yet known for mammals, in recent years significant progress has been made in 
understanding of SNF5/INI1 role in tumour suppression. It appeared, that re-expression of 
SNF5/INI1 in human MRT cell lines leads to an accumulation in G0/G1 phase, cellular 
senescence and in some cases apoptosis (1, 7, 60, 90, 93, 101). We have shown that 
SNF5/INI1 binds to the promoter of p16ink4a tumour suppressor gene and recruits BRG1-
containing SWI/SNF complex resulting in transcription activation (Figure 2, chapter 3) (37, 
60). 
      p16ink4a gene encodes a specific cyclin-dependent kinase (CDK)4/CDK6 inhibitors, which 
targets retinoblastoma (pRb) protein for phosphorylation (51). Hyperphosphorylated pRb 
dissociates from E2F transcription factor allowing S phase specific genes expression and 
promoting cell proliferation. Therefore, increased p16ink4a expression upon SNF5/INI1 
induction in MRT cells (lacking hSNF5) results in pRb hypophosphorylation and inhibits cell 
cycle progression (Figure 2). Interestingly, MRT cell lines lacking p16ink4a activity or expressing 
p16ink4a-insensitive mutant of CDK4 continue to grow after SNF5/INI1 re-expression 
supporting a role of SNF5/INI1 in p16ink4a-CDK4/Cyclin D1-pRB/E2F pathway (60, 93). Several 
groups have also shown that SNF5/INI1 can repress Cyclin D1 expression in ATRT/MRTs by 
recruiting HDACs to the promoter, or it can function in the repression of E2F target genes via 
direct association with pRb, thereby causing cell-cycle arrest in G1 phase (99, 101). In 
agreement with a role of SWI/SNF ATP-dependent chromatin remodellers in the regulation of 
pRb/E2F transcriptional circuitry, genome-wide expression profiling revealed down regulation 
of some of the E2F-target genes in MRT cell lines, including mitotic checkpoint gene Mad2 
(93)(and chapter2). Over-expression of Mad2 leads to chromosomal instability and 
tumourigenesis (81, 89). 
 
The Ink4-Arf locus 
     The Ink4b-Arf-Ink4a locus, spanning an approximately 40 kb stretch of the human 
chromosome 9p21 (chromosome 4 in mouse), encodes three distinct tumour suppressors, 
p15Ink4b, p16Ink4a and p14ARF (p19ARFin mice) whose expression enhances the growth-
suppressive functions of the retinoblastoma (Rb) and p53, respectively (Figure 3). Both 
p15Ink4b and p16Ink4a are able to induce cell cycle arrest in G1 by inhibiting cyclin dependent 
kinase CDK4 and CDK6 to inactivate retinoblastoma (RB)(59). Because only p16Ink4a can form 
stable, binary complex with both CDK4 and CDK6, p16Ink4a is likely the most effective inhibitor 
of CDK4 and CDK6 (61). The unrelated p14ARF protein acts via MDM2 to activate the key check 
point protein TRP53, thereby inducing either cell cycle arrest (both in G1 and G2) or apoptosis 
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(65). The locus p14ARF (named ARF because it uses the second exon of Ink4a in an Alternative 
translational Reading Frame) is implicated in various types of cancer (reviewed in (27, 78)).  
 
 
Figure 2. Mammalian ATRT/MRT tumour 
cells lack SNF5/INI1 function resulting in 
increased CDK4/cyclin D1 activity. This 
triggers pRb hyperphosphorylation and 
unleashes transcription of E2F-dependent 
genes causing increased proliferation, 
chromosomal instabilities and cancer. Re-
expression of SNF5/INI1 reverses cell 
proliferation and leads to G0/G1 arrest, 
senescence and apoptosis primarily due to 
activation of p16INK4a tumour suppressor 
gene expression and repression of cyclin 
D1 gene expression. 
 
 
      
 
 
 
 
In mice, ectopic expression of FOXO transcription factor (which regulates cell cycle 
progression, cell survival and DNA-repair pathways) cause increased level of Ink4b and Arf 
but not Ink4a(36). In a variety of tumours, p16INK4a is inactivated through epigenetic 
silencing, involving PcG (Polycomb groups) proteins and DNA methylation (27, 33, 82). 
Significantly, the PcG protein BMI1 promotes oncogenesis in mice through silencing of the 
Ink4a-Arf locus (31). Both the PRC1 and PRC2 PcG complexes directly bind and silence the 
Ink4a-Arf locus (12, 37, 43). In MRT cells, human embryonic fibroblasts (TIG3) and human 
neonatal fibroblast, both Polycomb-Repressive Complexes (PRC1 and PRC2) bind to Ink4a and 
Ink4b (this thesis). It has been shown that depletion of EZH2 subunit of the  PRC2 in response 
to stress causes the loss of H3K27me3, displacement of BMI1 subunit of the PRC1 and 
transcription activation of INK4a (12). In agreement with this we showed depletion of EZH2 
during aging and differentiation causes displacement of BMI1 and activation of Ink4a and 
Ink4b (This thesis).  
 
 
 
 
 
 
     Figure 3. Organization of the human INK4b-ARF-
INK4a locus (not drawn to scale). The genomic locus 
spans approximately 40 Kbp of human chromosome 9, 
and encodes three distinct proteins, p15INK4b, p14ARF and 
p16INK4a. The 5’ and 3’ untranslated regions (yellow 
boxes), the coding sequences of p15INK4b (green), p14ARF 
(blue) and p16INK4a (red) are indicated. 
E2F controls 
G1/S  
transition 
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     Numerous studies showed that promoter hypermethylation of CpG island (CGI) sequences 
is the most frequent pathway for inactivation of p16INK4a in human carcinomas, including those 
that arise in the lung, oropharynx, bladder, cervix, liver, colon, pancreas, and other sites (5). 
The H3K36 demethylase JmjC domain-containig histone demethylase 1b in primary MEFs 
regulates cell proliferation and senescence through Ink4b (30). The Ink4/Arf locus is normally 
expressed at very low levels in most tissues of young organisms(45). It is well established 
that the Ink4/Arf locus is activated during organismal ageing in both rodents and humans, and 
the levels of p16INK4a constitute an impressively good overall biomarker of ageing(40). These 
observations point to p16Ink4a both serving as a brake for the proliferation of cancer cells, and 
also limiting the long-term renewal of stem cells. The Ink4a-Arf locus responds to stress 
signals, limiting cell proliferation and modulating oncogene-induced apoptosis (reviewed in 
(51)). A challenging issue which remains is to understand the interplay between signalling and 
PcG control of InK4b-Arf-Ink4a locus. 
 
Polycomb group complex 
     Polycomb group proteins were first identified in Drosophila melanogaster as mutants 
deregulating Hox gene expression pattern during fly early development. The PcG are required 
to maintain chromatin in a repressed state while the trithorax-group (trxG) proteins (including 
the hSWI/SNF complex) are necessary for the maintenance of transcriptional activity of 
several developmental genes. The PcG is a diverse group of proteins that form at least three 
different complexes: Polycomb repressive complex 1 and 2 (PRC1 and PRC2) and 
pleiohomeotic (Pho) repressive complex (PhoRC) (75). A list of the proteins pertaining to any 
of the complexes, the respective human and mouse homologues and some of  the known 
function can be found in table1 ( adapted from(54)). 
     The main function of the PRC1 proteins is to inhibit chromatin remodelling and maintain 
the repressed state of chromatin by out-competing the trxG protein complexes such as 
SWI/SNF chromatin-remodelling complex. PRC2 on the other hand is known to be the initiator 
of the suppression process in which chromatin and or DNA are marked for repression. The key 
component of PRC2 is the SET domain H3 methyltransferase protein enhancer of Zeste (E(Z)). 
E(Z), when assembled in the complex methylates H3K27. In human cells, PRC2 can physically 
associate with HDACs 1 and 2. HDACs can deacetylate H3K27 to make it available for 
methylation by PRC2 (46). In vivo, trimethylation of H3K27 is characteristic of PcG target 
genes (74). The H3K27me3 mark is thought to act as a docking site for chromo-domain of the 
CBX family proteins, which recruit other members of the PRC1 complex (6). Genome wide 
mapping of Polycomb target genes revealed only depletion of EZH2 causes induction of 
Ink4b(11). 
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          Polycomb complexes function as global enforcers of epigenetically repressed states, 
balanced by an antagonistic state that is mediated by trithorax. These epigenetic states must 
be reprogrammed when cells become committed to differentiation. Mammalian Polycomb 
group (PcG) proteins are essential transcription silencers that control multiple development 
processes, including stem cell self-renewal, cell differentiation  
and have been implicated in several types of cancers (10, 49, 53, 88).  
 
EZH2 a key for differentiation, aging and cancer 
     EZH2 is the catalytic subunit of PRC2, which is a highly conserved histone 
methyltransferase that targets lysine-27 of histone H3. This methylated H3-K27 chromatin 
mark is commonly associated with silencing of differentiation genes in organisms ranging from 
flies to human. EZH2 is frequently over-expressed in wide variety of cancerous tissue types 
including prostate, breast, lymphoma, myeloma, bladder, colon, skin, liver, endometrial, lung, 
gastric (80). EZH2 and EED co- immunoprecipitate with all three human DNMTs ( DNA methyl-
transfrases) and silencing of certain target genes requires both EZH2 and DNMTs (92). EZH2 
and EED are targets of the pRB-E2F pathway, and deregulation of the pathway, as is 
frequently observed in human cancer, would result in higher levels of EZH2 and EED. The 
EZH2 and EED promoters are direct targets of the E2F transcription factors in vivo. Over-
expression of EZH2 shortens the G1 phase of the cell cycle, results in accumulation of cells in 
the S phase of the cell cycle, and confers a proliferative advantage when ectopically expressed 
in primary MEFs. The role of E2F and pRB in the control of embryonic development is likely 
related to their ability to regulate the abundance of the PRC2 complex (13). EZH2 is 
accumulated in undifferentiated progenitor cell population, such as haematopoietic cells(83). 
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Genome wide mapping of PRC2 target genes in different cells in human, mouse and 
Drosophila by ChIP-on-ChIP method have been performed by different groups. These studies 
revealed that PRC2 target genes are highly enriched for transcription factors and signalling 
components that control cell differentiation (reviewed in (80). Correspondence between 
silenced genes bound by Oct4, Sox2 and Nanog, which promote expression of proliferation 
genes and silencing of differentiation genes, with PRC2 target genes suggests that PRC2 is a 
key co-repressor in ES cells(49, 62). Recently it has been shown that epidermal basal cells 
like ES cells are rich in EZH2 and other PcG proteins, but as they differentiate EZH2 
expression is turned off and the cells exit the cell cycle concomitant with induction of INK4b/a. 
Loss of PcG function makes the binding site available for AP1 transcription factors, which are 
major effectors of the  expression of epidermal genes associated with terminal differentiation, 
and thereby permits the expression of terminal differentiation genes(23, 64). How PcG genes 
themselves are regulated still remains unresolved. It is not mechanistically clear how PcG 
proteins repress their targets, PcG and histone marks may silence target genes through the 
looping process. It has been shown recently that PcG-occupied region can form chromatin 
loops and physically interact in cis around a single gene in mammalian cells. EZH2 knock 
down was shown to affect this long-range interaction(87). 
 
 
 
 
 
Introduction
 
 21 
References 
1. Ae, K., N. Kobayashi, R. Sakuma, T. Ogata, H. Kuroda, N. Kawaguchi, K. Shinomiya, and Y. 
Kitamura. 2002. Chromatin remodelling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-
deficient cells. Oncogene 21:3112-20. 
2. Armstrong, J. A., O. Papoulas, G. Daubresse, A. S. Sperling, J. T. Lis, M. P. Scott, and J. W. 
Tamkun. 2002. The Drosophila BRM complex facilitates global transcription by RNA polymerase II. 
Embo J 21:5245-54. 
3. Armstrong, J. A., A. S. Sperling, R. Deuring, L. Manning, S. L. Moseley, O. Papoulas, C. I. Piatek, C. 
Q. Doe, and J. W. Tamkun. 2005. Genetic screens for enhancers of brahma reveal functional interactions 
between the BRM chromatin-remodelling complex and the delta-notch signal transduction pathway in 
Drosophila. Genetics 170:1761-74. 
4. Barker, N., A. Hurlstone, H. Musisi, A. Miles, M. Bienz, and H. Clevers. 2001. The chromatin 
remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. Embo J 20:4935-43. 
5. Baylin, SB., J.G. Herman. J.R Graff,  P.M. Vertino, and J.P. Issa. 1998. Alterations in DNA 
methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 72:141-96. 
6. Bernstein, E., E. M. Duncan, O. Masui, J. Gil, E. Heard, and C. D. Allis. 2006. Mouse Polycomb 
Proteins Bind Differentially to Methylated Histone H3 and RNA and Are Enriched in Facultative 
Heterochromatin, p. 2560-2569, vol. 26. 
7. Betz, B. L., M. W. Strobeck, D. N. Reisman, E. S. Knudsen, and B. E. Weissman. 2002. Re-expression 
of hSNF5/INI1/BAF47 in pediatric tumour cells leads to G1 arrest associated with induction of p16ink4a 
and activation of RB. Oncogene 21:5193-203. 
8. Biegel, J. A., J. Y. Zhou, L. B. Rorke, C. Stenstrom, L. M. Wainwright, and B. Fogelgren. 1999. 
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumours. Cancer Res 59:74-9. 
9. Bochar, D. A., L. Wang, H. Beniya, A. Kinev, Y. Xue, W. S. Lane, W. Wang, F. Kashanchi, and R. 
Shiekhattar. 2000. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin 
remodelling to breast cancer. Cell 102:257-65. 
10. Boyer, L. A., K. Plath, J. Zeitlinger, T. Brambrink, L. A. Medeiros, T. I. Lee, S. S. Levine, M. 
Wernig, A. Tajonar, M. K. Ray, G. W. Bell, A. P. Otte, M. Vidal, D. K. Gifford, R. A. Young, and R. 
Jaenisch. 2006. Polycomb complexes repress developmental regulators in murine embryonic stem cells. 
Nature 441:349-353. 
11. Bracken A.P., N. Dietrich, D. Pasini, K.H. Hansen, K. Helin. 2006. Genome-wide mapping of Polycomb 
target genes unravels their roles in cell fate transitions. Genes Dev 20:1123-36. 
12. Bracken, A. P., D. Kleine-Kohlbrecher, N. Dietrich, D. Pasini, G. Gargiulo, C. Beekman, K. 
Theilgaard-Monch, S. Minucci, B. T. Porse, J.-C. Marine, K. H. Hansen, and K. Helin. 2007. The 
Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. 
Genes Dev 21:525-530. 
13. Bracken AP, D. Pasini, M. Capra, E. Prosperini, E. Colli, K. Helin. 2003. EZH2 is downstream of the 
pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22:5323-35. 
14. Bultman, S., T. Gebuhr, D. Yee, C. La Mantia, J. Nicholson, A. Gilliam, F. Randazzo, D. Metzger, P. 
Chambon, G. Crabtree, and T. Magnuson. 2000. A Brg1 null mutation in the mouse reveals functional 
differences among mammalian SWI/SNF complexes. Mol Cell 6:1287-95. 
15. Cheng, S. W., K. P. Davies, E. Yung, R. J. Beltran, J. Yu, and G. V. Kalpana. 1999. c-MYC interacts 
with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22:102-5. 
16. Collins, R. T., and J. E. Treisman. 2000. Osa-containing Brahma chromatin remodelling complexes are 
required for the repression of wingless target genes. Genes Dev 14:3140-52. 
17. de la Serna, I. L., Y. Ohkawa, and A. N. Imbalzano. 2006. Chromatin remodelling in mammalian 
differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 7:461-473. 
18. Decristofaro, M. F., B. L. Betz, C. J. Rorie, D. N. Reisman, W. Wang, and B. E. Weissman. 2001. 
Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J 
Cell Physiol 186:136-45. 
19. Dorigo, B., T. Schalch, A. Kulangara, S. Duda, R. R. Schroeder, and T. J. Richmond. 2004. 
Nucleosome arrays reveal the two-start organization of the chromatin fiber. Science 306:1571-3. 
Chapter1
 
 22 
20. Durr, H., A. Flaus, T. Owen-Hughes, and K. P. Hopfner. 2006. Snf2 family ATPases and DExx box 
helicases: differences and unifying concepts from high-resolution crystal structures. Nucleic Acids Res 
34:4160-7. 
21. Durr, H., C. Korner, M. Muller, V. Hickmann, and K. P. Hopfner. 2005. X-ray structures of the 
Sulfolobus solfataricus SWI2/SNF2 ATPase core and its complex with DNA. Cell 121:363-73. 
22. Eisen, J. A., K. S. Sweder, and P. C. Hanawalt. 1995. Evolution of the SNF2 family of proteins: 
subfamilies with distinct sequences and functions. Nucleic Acids Res 23:2715-23. 
23. Ezhkova, E., H. A. Pasolli, J. S. Parker, N. Stokes, I. h. Su, G. Hannon, A. Tarakhovsky, and E. 
Fuchs. 2009. Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem 
Cells.  136:1122-1135. 
24. Flaus, A., D. M. Martin, G. J. Barton, and T. Owen-Hughes. 2006. Identification of multiple distinct 
Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res 34:2887-905. 
25. Francis, N. J., R. E. Kingston, and C. L. Woodcock. 2004. Chromatin compaction by a polycomb group 
protein complex. Science 306:1574-7. 
26. Fyodorov, D. V., and J. T. Kadonaga. 2002. Dynamics of ATP-dependent chromatin assembly by ACF. 
Nature 418:897-900. 
27. Gil, J., and G. Peters. 2006. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or 
one for all. Nat Rev Mol Cell Biol 7:667-677. 
28. Guidi, C. J., A. T. Sands, B. P. Zambrowicz, T. K. Turner, D. A. Demers, W. Webster, T. W. Smith, 
A. N. Imbalzano, and S. N. Jones. 2001. Disruption of Ini1 leads to peri-implantation lethality and 
tumourigenesis in mice. Mol Cell Biol 21:3598-603. 
29. Haas, J. E., N. F. Palmer, A. G. Weinberg, and J. B. Beckwith. 1981. Ultrastructure of malignant 
rhabdoid tumour of the kidney. A distinctive renal tumour of children. Hum Pathol 12:646-57. 
30. He, J., E. M. Kallin, Y.-i. Tsukada, and Y. Zhang. 2008. The H3K36 demethylase Jhdm1b/Kdm2b 
regulates cell proliferation and senescence through p15Ink4b. Nat Struct Mol Biol 15:1169-1175. 
31. Jacobs, J. J. L., K. Kieboom, S. Marino, R. A. DePinho, and M. van Lohuizen. 1999. The oncogene and 
Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 
397:164-168. 
32. Johnson, C. N., N.L. Adkins, and P. Georgel. 2005. Chromatin remodelling complexes: ATP-dependent 
machines in action. Biochem Cell Biol. 83:405-17. 
33. Jones, P. A., and S. B. Baylin. 2007. The Epigenomics of Cancer. Cell 128:683-692. 
34. Judkins, A. R., J. Mauger, A. Ht, L. B. Rorke, and J. A. Biegel. 2004. Immunohistochemical analysis of 
hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 28:644-50. 
35. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. 
J. Sherr. 1997. Tumour Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading 
Frame Product p19 ARF.  91:649-659. 
36. Katayama K, N. A., Sugimoto Y, Tsuruo T, Fujita N. 2008. FOXO transcription factor-dependent 
p15(INK4b) and p19(INK4d) expression. Oncogene 27:1677–1686. 
37. Kheradmand Kia S., M. Gorsky, S. Giannakopoulos, and C.P. Verrijzer. 2008. SWI/SNF Mediates 
Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus. MCB 28:3457-3464. 
38. Kim, J. K., S. O. Huh, H. Choi, K. S. Lee, D. Shin, C. Lee, J. S. Nam, H. Kim, H. Chung, H. W. Lee, 
S. D. Park, and R. H. Seong. 2001. Srg3, a mouse homolog of yeast SWI3, is essential for early 
embryogenesis and involved in brain development. Mol Cell Biol 21:7787-95. 
39. Kim, S. H., J. Rowe, H. Fujii, R. Jones, B. Schmierer, B. W. Kong, K. Kuchler, D. Foster, D. Ish-
Horowicz, and G. Peters. 2006. Upregulation of chicken p15INK4b at senescence and in the developing 
brain, p. 2435-2443, vol. 119. 
40. Kim, W. Y., and N. E. Sharpless. 2006. The Regulation of INK4/ARF in Cancer and Aging.  127:265-
275. 
41. Klochendler-Yeivin, A., L. Fiette, J. Barra, C. Muchardt, C. Babinet, and M. Yaniv. 2000. The murine 
SNF5/INI1 chromatin remodelling factor is essential for embryonic development and tumour suppression. 
EMBO Rep 1:500-6. 
42. Ko, M., D.H.  Sohn. D., H. Chung, R.H. Seong. Mutat Res. 2008 Dec 1;647(1-2):59-67. Epub 2008 Aug 
20. Chromatin remodelling, development and disease. Mutat Res. 647:59-67. 
Introduction
 
 23 
43. Kotake, Y., R. Cao, P. Viatour, J. Sage, Y. Zhang, and Y. Xiong. 2007. pRB family proteins are required 
for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumour 
suppressor gene. Genes Dev 21:49-54. 
44. Krimpenfort, P., A. Ijpenberg, J.-Y. Song, M. van der Valk, M. Nawijn, J. Zevenhoven, and A. Berns. 
2007. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448:943-946. 
45. Krishnamurthy J, T. C., Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE. 2004. Ink4a/Arf 
expression is a biomarker of aging. J Clin Invest. 114:1299-307. 
46. Kuzmichev A, N. K., Erdjument-Bromage H, Tempst P, Reinberg D. 2002. Histone methyltransferase 
activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes 
Dev 16:2893-905. 
47. Kwon, H., A. N. Imbalzano, P. A. Khavari, R. E. Kingston, and M. R. Green. 1994. Nucleosome 
disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 370:477-81. 
48. Latres E, M. M., Sotillo R, Martín J, Ortega S, Martín-Caballero J, Flores JM, Cordón-Cardo C, 
Barbacid M. 2000. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in 
proliferation and tumourigenesis. EMBO J. 19:3496-506. 
49. Lee, T. I., R. G. Jenner, L. A. Boyer, M. G. Guenther, S. S. Levine, R. M. Kumar, B. Chevalier, S. E. 
Johnstone, M. F. Cole, K.-i. Isono, H. Koseki, T. Fuchikami, K. Abe, H. L. Murray, J. P. Zucker, B. 
Yuan, G. W. Bell, E. Herbolsheimer, N. M. Hannett, K. Sun, D. T. Odom, A. P. Otte, T. L. Volkert, D. 
P. Bartel, D. A. Melton, D. K. Gifford, R. Jaenisch, and R. A. Young. 2006. Control of Developmental 
Regulators by Polycomb in Human Embryonic Stem Cells.  125:301-313. 
50. Lia, G., E. Praly, H. Ferreira, C. Stockdale, Y. C. Tse-Dinh, D. Dunlap, V. Croquette, D. Bensimon, 
and T. Owen-Hughes. 2006. Direct observation of DNA distortion by the RSC complex. Mol Cell 21:417-
25. 
51. Lowe, S. W., and C. J. Sherr. 2003. Tumour suppression by Ink4a-Arf: progress and puzzles. Current 
Opinion in Genetics & Development 13:77-83. 
52. Luger, K., A. W. Mader, R. K. Richmond, D. F. Sargent, and T. J. Richmond. 1997. Crystal structure 
of the nucleosome core particle at 2.8 A resolution. Nature 389:251-60. 
53. Lund AH, v. L. M. 2004. Epigenetics and cancer. Genes Dev 1:2315-35. 
54. MateosLangerak, J., G. Cavalli, and E. H. Veronica van Heyningen and Robert. 2008. Chapter 2 
Polycomb Group Proteins and Long[hyphen (true graphic)]Range Gene Regulation, p. 45-66, Advances in 
Genetics, vol. Volume 61. Academic Press. 
55. Mohd-Sarip, A., and C. P. Verrijzer. 2004. Molecular biology. A higher order of silence. Science 
306:1484-5. 
56. Moshkin, Y. M., L. Mohrmann, W. F. van Ijcken, and C. P. Verrijzer. 2007. Functional differentiation 
of SWI/SNF remodellers in transcription and cell cycle control. Mol Cell Biol 27:651-61. 
57. Nie, Z., Y. Xue, D. Yang, S. Zhou, B. J. Deroo, T. K. Archer, and W. Wang. 2000.  A specificity and 
targeting subunit of a human SWI/SNF family-related chromatin-remodelling complex. Mol Cell Biol 
20:8879-88. 
58. Olave, I., W. Wang, Y. Xue, A. Kuo, and G. R. Crabtree. 2002. Identification of a polymorphic, neuron-
specific chromatin remodelling complex. Genes Dev 16:2509-17. 
59. Ortega, S., M. Malumbres, and M. Barbacid. 2002. Cyclin D-dependent kinases, INK4 inhibitors and 
cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1602:73-87. 
60. Oruetxebarria, I., F. Venturini, T. Kekarainen, A. Houweling, L. M. Zuijderduijn, A. Mohd-Sarip, R. 
G. Vries, R. C. Hoeben, and C. P. Verrijzer. 2004. P16INK4a is required for hSNF5 chromatin 
remodeller-induced cellular senescence in malignant rhabdoid tumour cells. J Biol Chem 279:3807-16. 
61. Parry, D., D. Mahony, K. Wills, and E. Lees. 1999. Cyclin D-CDK Subunit Arrangement Is Dependent 
on the Availability of Competing INK4 and p21 Class Inhibitors, p. 1775-1783, vol. 19. 
62. Pasini, D., A. P. Bracken, J. B. Hansen, M. Capillo, and K. Helin. 2007. The Polycomb Group Protein 
Suz12 Is Required for Embryonic Stem Cell Differentiation, p. 3769-3779, vol. 27. 
63. Peterson, C. L., and I. Herskowitz. 1992. Characterization of the yeast SWI1, SWI2, and SWI3 genes, 
which encode a global activator of transcription. Cell 68:573-83. 
64. Pirrotta, V. 2009. Polycomb Repression under the Skin.  136:992-994. 
Chapter1
 
 24 
65. Pomerantz, J., N. Schreiber-Agus, N. J. Liégeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, 
I. Orlow, H.-W. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a Tumour Suppressor Gene 
Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53.  92:713-723. 
66. Reisman, D. N., J. Sciarrotta, W. Wang, W. K. Funkhouser, and B. E. Weissman. 2003. Loss of 
BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. 
Cancer Res 63:560-6. 
67. Reyes, J. C., J. Barra, C. Muchardt, A. Camus, C. Babinet, and M. Yaniv. 1998. Altered control of 
cellular proliferation in the absence of mammalian brahma (SNF2alpha). Embo J 17:6979-91. 
68. Roberts, C. W., S. A. Galusha, M. E. McMenamin, C. D. Fletcher, and S. H. Orkin. 2000. 
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumours in mice. Proc 
Natl Acad Sci U S A 97:13796-800. 
69. Roberts, C. W., M. M. Leroux, M. D. Fleming, and S. H. Orkin. 2002. Highly penetrant, rapid 
tumourigenesis through conditional inversion of the tumour suppressor gene Snf5. Cancer Cell 2:415-25. 
70. Roberts, C. W., and S. H. Orkin. 2004. The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer 
4:133-42. 
71. Rorke LB, P. R., Biegel J. 1995. Central nervous system atypical teratoid/rhabdoid tumours of infancy and 
childhood. J Neurooncol. 24:21-8. 
72. Saha, A., J. Wittmeyer, and B. R. Cairns. 2002. Chromatin remodelling by RSC involves ATP-dependent 
DNA translocation. Genes Dev 16:2120-34. 
73. Saha, A., J. Wittmeyer, and B. R. Cairns. 2005. Chromatin remodelling through directional DNA 
translocation from an internal nucleosomal site. Nat Struct Mol Biol 12:747-55. 
74. Schwartz YB, K. T., Nix DA, Li XY, Bourgon R, Biggin M, Pirrotta V. 2006. Genome-wide analysis of 
Polycomb targets in Drosophila melanogaster. Nat Genet 38:700-5. 
75. Schwartz, Y. B., and V. Pirrotta. 2007. Polycomb silencing mechanisms and the management of genomic 
programmes. Nat Rev Genet 8:9-22. 
76. Sevenet, N., A. Lellouch-Tubiana, D. Schofield, K. Hoang-Xuan, M. Gessler, D. Birnbaum, C. 
Jeanpierre, A. Jouvet, and O. Delattre. 1999. Spectrum of hSNF5/INI1 somatic mutations in human 
cancer and genotype-phenotype correlations. Hum Mol Genet 8:2359-68. 
77. Sevenet, N., E. Sheridan, D. Amram, P. Schneider, R. Handgretinger, and O. Delattre. 1999. 
Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 
65:1342-8. 
78. Sharpless, N. E. 2005. INK4a/ARF: A multifunctional tumour suppressor locus. Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis 576:22-38. 
79. Sharpless, N. E., M. R. Ramsey, P. Balasubramanian, D. H. Castrillon, and R. A. DePinho. The 
differential impact of p16INK4a or p19ARF deficiency on cell growth and tumourigenesis. Oncogene 
23:379-385. 
80. Simon, J. A., and C. A. Lange. 2008. Roles of the EZH2 histone methyltransferase in cancer epigenetics. 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 647:21-29. 
81. Sotillo, R., E. Hernando, E. Diaz-Rodriguez, J. Teruya-Feldstein, C. Cordon-Cardo, S. W. Lowe, and 
R. Benezra. 2007. Mad2 overexpression promotes aneuploidy and tumourigenesis in mice. Cancer Cell 
11:9-23. 
82. Sparmann, A., and M. van Lohuizen. 2006. Polycomb silencers control cell fate, development and 
cancer. Nat Rev Cancer 6:846-856. 
83. Su, I.H., A. Basavaraj, A.N. Krutchinsky AN, O. Hobert, A. Ullrich, B.T. Chait, and A. Tarakhovsky. 
2003. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat 
Immunol 4:124-31. 
84. Takayama, M. A., T. Taira, K. Tamai, S. M. Iguchi-Ariga, and H. Ariga. 2000. ORC1 interacts with c-
Myc to inhibit E-box-dependent transcription by abrogating c-Myc-SNF5/INI1 interaction. Genes Cells 
5:481-90. 
85. Tamkun, J. W., R. Deuring, M. P. Scott, M. Kissinger, A. M. Pattatucci, T. C. Kaufman, and J. A. 
Kennison. 1992. brahma: a regulator of Drosophila homeotic genes structurally related to the yeast 
transcriptional activator SNF2/SWI2. Cell 68:561-72. 
Introduction
 
 25 
86. Thoma, N. H., B. K. Czyzewski, A. A. Alexeev, A. V. Mazin, S. C. Kowalczykowski, and N. P. 
Pavletich. 2005. Structure of the SWI2/SNF2 chromatin-remodelling domain of eukaryotic Rad54. Nat 
Struct Mol Biol 12:350-6. 
87. Tiwari VK, C. L., McGarvey KM, Ohm JE, Baylin SB. 2008. A novel 6C assay uncovers Polycomb-
mediated higher order chromatin conformations. Genome Res. 18. 
88. Valk-Lingbeek, M. E., S. W. M. Bruggeman, and M. van Lohuizen. 2004. Stem Cells and Cancer: The 
Polycomb Connection.  118:409-418. 
89. van Deursen, J. M. 2007. Rb loss causes cancer by driving mitosis mad. Cancer Cell 11:1-3. 
90. Versteege, I., S. Medjkane, D. Rouillard, and O. Delattre. 2002. A key role of the hSNF5/INI1 tumour 
suppressor in the control of the G1-S transition of the cell cycle. Oncogene 21:6403-12. 
91. Versteege, I., N. Sevenet, J. Lange, M. F. Rousseau-Merck, P. Ambros, R. Handgretinger, A. Aurias, 
and O. Delattre. 1998. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 
394:203-6. 
92. Vire, E., C. Brenner, R. Deplus, L. Blanchon, M. Fraga, C. Didelot, L. Morey, A. Van Eynde, D. 
Bernard, J.-M. Vanderwinden, M. Bollen, M. Esteller, L. Di Croce, Y.  de Launoit, and F. Fuks. 2006. 
The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874. 
93. Vries, R. G., V. Bezrookove, L. M. Zuijderduijn, S. K. Kia, A. Houweling, I. Oruetxebarria, A. K. 
Raap, and C. P. Verrijzer. 2005. Cancer-associated mutations in chromatin remodeller hSNF5 promote 
chromosomal instability by compromising the mitotic checkpoint. Genes Dev 19:665-70. 
94. Wang, Z., W. Zhai, J. A. Richardson, E. N. Olson, J. J. Meneses, M. T. Firpo, C. Kang, W. C. 
Skarnes, and R. Tjian. 2004. Polybromo protein BAF180 functions in mammalian cardiac chamber 
maturation. Genes Dev 18:3106-16. 
95. Whitehouse, I., C. Stockdale, A. Flaus, M. D. Szczelkun, and T. Owen-Hughes. 2003. Evidence for 
DNA translocation by the ISWI chromatin-remodelling enzyme. Mol Cell Biol 23:1935-45. 
96. Wong, A. K., F. Shanahan, Y. Chen, L. Lian, P. Ha, K. Hendricks, S. Ghaffari, D. Iliev, B. Penn, A. 
M. Woodland, R. Smith, G. Salada, A. Carillo, K. Laity, J. Gupte, B. Swedlund, S. V. Tavtigian, D. H. 
Teng, and E. Lees. 2000. BRG1, a component of the SWI-SNF complex, is mutated in multiple human 
tumour cell lines. Cancer Res 60:6171-7. 
97. Xue, Y., J. C. Canman, C. S. Lee, Z. Nie, D. Yang, G. T. Moreno, M. K. Young, E. D. Salmon, and W. 
Wang. 2000. The human SWI/SNF-B chromatin-remodelling complex is related to yeast rsc and localizes 
at kinetochores of mitotic chromosomes. Proc Natl Acad Sci U S A 97:13015-20. 
98. Yan, Z., K. Cui, D. M. Murray, C. Ling, Y. Xue, A. Gerstein, R. Parsons, K. Zhao, and W. Wang. 
2005. PBAF chromatin-remodelling complex requires a novel specificity subunit, BAF200, to regulate 
expression of selective interferon-responsive genes. Genes Dev 19:1662-7. 
99. Zhang, H. S., M. Gavin, A. Dahiya, A. A. Postigo, D. Ma, R. X. Luo, J. W. Harbour, and D. C. Dean. 
2000. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-
Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101:79-89. 
100. Zhang, Y., C. L. Smith, A. Saha, S. W. Grill, S. Mihardja, S. B. Smith, B. R. Cairns, C. L. Peterson, 
and C. Bustamante. 2006. DNA translocation and loop formation mechanism of chromatin remodelling by 
SWI/SNF and RSC. Mol Cell 24:559-68. 
101. Zhang, Z. K., K. P. Davies, J. Allen, L. Zhu, R. G. Pestell, D. Zagzag, and G. V. Kalpana. 2002. Cell 
cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 22:5975-88. 
102. Zofall, M., J. Persinger, S. R. Kassabov, and B. Bartholomew. 2006. Chromatin remodelling by ISW2 
and SWI/SNF requires DNA translocation inside the nucleosome. Nat Struct Mol Biol 13:339-46. 
 
 
Chapter1
 
 26 
Outline of the thesis 
     
 The mammalian SWI/SNF ATP-dependent chromatin remodeling complexes are highly 
conserved molecular motors that play crucial roles in a variety of cellular processes, including 
differentiation, proliferation. Human SNF5/INI1 is a subunit of SWI/SNF and tumour-
suppressor lost in malignant rhabdoid tumors (MRTs), rare but highly aggressive paediatric 
cancers. Previously our group found that re-expression of hSNF5 in MRT cells caused an 
accumulation in G0/G1, cellular senescence and apoptosis. Cellular senescence is largely the 
result of direct transcriptional activation of the tumor-suppressor p16INK4a by hSNF5. We 
have developed MRT-derived G401 cell lines lacking genomic hSNF5 gene, which can express 
wild type or mutant hSNF5 (S284L) upon induction. We also transduced wild type hSNF5 to 
parental malignant rhabdoid MON cell lines lacking endogenous hSNF5. 
      To elucidate the pathways controlled by hSNF5 in rhabdoid tumor cells, in chapter2 we 
performed a cDNA microarray analysis to compare the temporal expression profile in MRT cells 
trasduced with GFP to those transduced with wild type hSNF5 or cancer related mutation 
(S284L) in different time course (24h, 48h and 5 days). To investigate direct targets of hSNF5 
we performed chromatin immunoprecipitation on some of the genes which were up or down 
regulated by hSNF5. The aim of this chapter was to identify the downstream targets of the 
chromatin remodelling factor hSNF5 in two different MRT cells. 
      As uncontrolled cell proliferation and chromosomal instability is a hallmark of many 
cancers, we decided to investigate the role of hSNF5 in ploidy control. In chapter3, we report 
that loss of hSNF5 function in MRT-derived cells leads to polyploidization and chromosomal 
instability. We also examined the pathway through which hSNF5 controls cellular ploidy.  
     It is well known that both Polycomb repressive complex (PRC1 and PRC2) directly bind and 
silence the INK4a-ARF locus. In chapter4 we wondered whether this is also the case in MRT 
cells and, more interestingly, how SWI/SNF might overcome PcG silencing. We explored the 
molecular mechanism by which restoration of SWI/SNF functionality through hSNF5 re-
expression overcomes epigenetic silencing and mediates p16INK4a transcriptional activation in 
MRT cells.  In chapter 5 we present evidence using human cells in which p15INK4b and p16INK4a, 
but not p14ARF, are coordinately induced during cellular aging, multi-potent progenitor cell 
differentiation or induction of senescence. We showed that EZH2 depletion is sufficient for loss 
of PcG silencers from the INK4b and INK4a loci, and induction of the INK4a and INK4b 
expression. We showed that there is a physical and spatial interaction between p15INK4b and 
p16INK4a but not p14ARF. This repressive chromatin loop disappears during aging, concomitant 
with EZH2 depletion and INK4a/b de-repression. Our results demonstrate that PcG proteins 
dynamically regulate higher order chromatin structure to balance proliferation and 
differentiation of human cells. 
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Abstract 
     hSNF5/INI1 is a member of the ATP-dependent hSWI-SNF chromatin-remodeling complex. 
This gene is a tumor suppressor gene and frequently mutated in malignant rhabdoid tumours 
(MRT). We have developed MRT-derived G401 cell lines lacking genomic hSNF5 gene, which 
can express wild type or mutant hSNF5 (S284L) upon induction. We also transduced wild type 
hSNF5 to parental malignant rhabdoid MON cell lines lacking endoegenous hSNF5. We studied 
time course variation (24h, 48h and 5 days) of 22,500 genes/expressed sequence tags upon 
hSNF5/INI1 or mutant hSNF5 (S284L) induction or transfection. A total of 2404 responsive 
probe sets were identified after transduction of wild type hSNF5 in MON cell lines. After 5 days 
induction of wild type hSNF5 and mutant hSNF5 (S284L), 1705 and 444 responsive probe sets 
were significant, respectively. The expression levels of identified genes were evaluated by 
quantitative RT-PCR. The identified genes were functionally clustered into specific categories 
and probability of each category was determined using the computer program EASE. Our 
genome wide expression suggests that hSNF5 can function in both transcription activation and 
repression. Whole genome expression profiling of hSNF5 cells revealed expression change of 
many E2F targets, including mitotic control genes and pre-replication complex. This study 
identifies hSNF5/INI1 target genes and provides evidence that hSNF5/INI1 may modulate cell 
cycle control through the regulation of the p16 INK4A-cyclinD/CDK4-pRb-E2F pathway.  
 
Introduction 
     ATP-dependent chromatin-remodelling factors (remodellers) are critical for the 
transmission, maintenance and expression of the eukaryotic genome. They function by 
mobilizing nucleosomes at the sites of DNA replication/repair and transcription 
activation/repression thus opening or closing chromatin for DNA-binding proteins. ATP-
dependent chromatin remodeling complex can affect gene expression, cell cycle progression, 
and cell differentiation(3). The multi subunit SWI/SNF complex is evolutionary highly 
conserved and present in all eukaryotes(28). Human SNF5 (hSNF5, INI1 or SMARCB1) is a 
core component of the hSWI/SNF and it has been implicated in gene regulation, cell division 
and tumorogenesis(20). A significant majority of malignant rhabdoid tumors (MRTs) carry 
specific, biallelic, inactivating mutations in hSNF5. These tumors are extremely aggressive 
malignancies of early childhood. The most common sites of tumor are kidney and central 
nervous system (Atypical Teratoid/Rhabdoid Tumors (ATRT)(5, 37, 39, 44). Loss of SNF5/INI1 
has been also detected in pediatric choroid plexus carcinoma, meningioma, medulloblastoma 
and primitive neuroectodermal tumours, which are histologically distinct from ATRT/MRTs(36). 
Inherited mutation of SNF5 leads to rhabdoid predisposition syndrom (5,39). As the majority 
of these extremely aggressive cancers have an entirely normal karyotype with only loss of 
SNF5, these tumors may be a result of extensive epigenetic changes caused by lack of 
SNF5(10, 38). Although most of the biallelic mutations in SNF5 are deletions, truncating 
nonsense or frameshift mutations and a number of point mutations resulting in single amino 
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acid substitutions (Figure 1A) have been identified in tumors (9, 39). These include proline 48 
to serine (P48S), arginine 127 to glycine (R127G), serine 284 to leucine (S284L), and proline 
116 to threonine (P116T).  S284 is located within one of the most highly conserved regions of 
SNF5, which forms part of direct repeat 2 (RPT2) and it is conserved during evolution 
(Figure1B).  
        The ability of SNF5 to function as a tumor suppressor has been confirmed in studies 
utilizing SNF5-deficient mice. Homozygous deficiency of Snf5 results in early embryonic 
lethality prior to implantation, while heterozygous mice are predisposed to develop tumours in 
which there is loss of hetrozygocity for SNF5(13, 23, 35).    
     Re-expression of hSNF5 in MRT cells caused an accumulation in G0/G1, cellular 
senescence and apoptosis. Cellular senescence is largely the result of direct transcriptional 
activation of the tumour-suppressor p16INK4a by hSNF5(1, 4, 31, 43, 45, 48). Loss of hSNF5 
function in MRT cells promotes chromosomal instability by compromised mitosis(45). hSNF5 
activates the mitotic checkpoint through the p16INK4a-cyclinD/CDK4-pRb-E2F pathway, 
revealing a convergence of tumour suppressor pathways. 
 
  
 
 
 
Figure1: Cancer associated 
amino acid substitution of 
hSNF5 
 
A) Schematic representation 
of hSNF5 depicting the two 
repeats (RPT1 and RPT2) 
and cancer-associated amino 
acid substitution mutations. 
B) Conservation of cancer-
associated amino acid 
substitution mutations from 
Human to Yeast 
      
      
 
     To identify the target genes of hSNF5 we carried out cDNA microarray analysis to 
determine the expression changes of genes in two hSNF5 deficient Rhabdoid cell lines (Mon 
and G401) upon re-introduction of hSNF5. We compared our data with other previously 
reported global gene expression profiles of hSNF5 in different human and mouse cell lines (7, 
27, 29, 34, 35). Our genome wide expression suggests that hSNF5 can function in both 
transcription activation and repression. 
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Methods 
Cell lines, Lentivirus production and Transduction.  
     All tissue cultures were according to standard protocols. Stable cell lines were generated 
using the LacSwitchTM II system (Stratagene). First pCMVLac1 followed by either pOPRSVI or 
pOPRSVI-hSNF5-FLAG, generated with a PCR-based strategy, encoding hSNF5 with a C-
terminal FLAG epitope, were stably integrated in G401 MRT cells. FuGENE 6 (Roche Applied 
Science) was used for transfections. The resulting Lac-Empty or Lac-hSNF5 lines were isolated 
and most experiments were repeated using independent lines. Cells were maintained in 
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM 
glutamine, 500 µg/ml G418, 100 µg/ml Hygromycin (Invitrogen). Mutants were generated 
using QuickChange mutagenesis (Stratagene). 
     The hSNF5 expressing lentiviral vector was generated by replacing the GFP encoding 
sequence of pRRLsin.sPPT.CMV.GFP.Wpre (12) with the hSNF5 cDNA (31). High titer vector 
stocks were produced in 293T cells by co-transfection of transfer vector constructs with the 
packaging constructs using standard transfection procedures (12). Mon cells were transduced 
with the appropriate vector. 
 
RNA purification and Real- time RT-PCR analysis.  
     Total RNA was extracted from the MRT cells at 24 and 48 hours and 5 days post-
stimulation using the SV Total RNA Isolation System (Promega) and cDNA synthesized from 1 
µg of total RNA using random hexamers and SuperscriptTM II RNase H- Reverse Transcriptase 
(Invitrogen). Quantitative real-time PCR (MyIQ, Bio Rad) was performed using SYBR Green I. 
PCR primers were designed by Beacon designer (Premier Biosoft). The qPCR Core Kit 
(Invitrogen) was used with 400 nM of each primer under the following cycling conditions: 
95°C for 3 min, 40 cycles of 10 s at 95°C, 45 s at 60°C. We used Usp14 as an endogenous 
normalization control. Enrichment of specific DNA sequences was calculated using the 
comparative CT method (24). Primer sequences are provided in Table 1B. 
 
Cell extracts and western blotting.   
     Cell extracts were prepared in RIPA buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
Nonidet P-40, 1% NaDOC, 0.1% SDS), assayed for protein concentration, and 50 µg of extract 
was resolved by SDS-PAGE, and analyzed by immunoblotting. Primary antibodies: SNF5 
(Abcam; ab12167) and Histone H3 (Abcam; ab1791). Western blots were developed with the 
ECL detection kit (PIERCE) according to the supplier’s instructions. 
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Chromatin Immunoprecipitation (ChIP) assays. 
     ChIPs were performed as described by the Upstate protocol (http://www.upstate.com). 
Cross-linked chromatin was prepared from ~2x107 cells 48h following transduction with 
lentiviruses expressing either hSNF5 or GFP as a control.  Cells were treated with 1% 
formaldehyde for 20 min at room temperature. Chromatin isolation, sonication yielding 
fragments of 300−600 bp and immunoprecipitations were performed according to protocol. 
The following antibodies were used:  SNF5 (Abcam; ab12167), BRG1 (Abcam; ab4081), POL 
II (Santa Cruz; Sc-899), Histone H3 (Abcam; ab1791). The abundance of specific DNA 
sequences in the immunoprecipitates was determined by qPCR and corrected for the 
independently determined amplification curves of each primer set. ChIP using species and 
isotype-matched immunoglobins directed against an unrelated protein (GST) were used to 
determine background levels. Finally, DNA was purified by conventional phenol-chloroform 
extraction followed by ethanol precipitation and analyzed by qPCR. Enrichment of specific DNA 
sequences was calculated using the comparative CT method (24). PCR primer sequences are 
provided in Table 1A. All data presented are the result of at least 3 independent ChIP 
experiments and triplicate qPCR reactions. Results were averaged and standard errors were 
determined using the R free software (http://www.r-project.org). ChIP levels for each region 
are presented as percentage of input chromatin.  
 
Table 1. Primers used for (A) ChIP, (B) mRNA expression 
A: Primers used for ChIP (q PCR)    
  Forward Primer   Reverse Primer 
ANGPT2  5’-GTTGGAGGGCAGGCATTC  5’-AGTTGATAAGAGCAGCCAGAC 
ADAM19  5’-GGAGAGGGGTCCAGTTTAAC  5’-GGAGGAGGGATTTGTGGTG 
ETS2  5’-GGGCTTCCTGGACTCCTTTC  5’-GCCTCCTGTCTGCTCTGG 
INTGB5  5’-TAATCTCGGCTCGCCTAATAC  5’-CAGGTGGAAGTCGCTTGC 
MAD2L1  5’-CGCAAAGGACCTGACGAC  5’-AACCACAGCGGCTCCAAC 
P14  5’-CGCCGTGTCCAGATGTCG  5’-TGCTCTATCCGCCAATCAGG 
TRIM22  5’-GTCCTGTTCTAAATCTCTGTAAAAG 5’-CAGTGCTGAGAATGTTGAAGG 
 
B: Primers used for mRNA Expression (q PCR)  
  Forward Primer   Reverse Primer 
ANGPT2  5'-GCAGCTACACTTTCCTCCTG  5'-TTGTTTTCCATGATGTTCTCC 
CASP4  5’-TCATGTCTCATGGCATCCTG  5’-TGACCTTGGGTTTGTCCTTC 
CCNF  5’-CTCTCGCTTCTTCAGTCTCG  5’-CTCTGCAGCTGGCACTCTG  
CDC25A  5’-AAGCTGTTTGACTCCCCTTC  5’-CAGACATGCTCTTCCTCCTC 
CENPA  5’-CGAAAGCTTCAGAAGAGCAC  5’-CTTCTGCTGCCTCTTGTAGG 
CENPE  5’-TTTTCCTGGGACCAGTTCAG  5’-AAACTTGGGCAGTTTCTCCA 
CHAF1B  5’-GGACGGTTACTGCTCATTTG  5’-CCTCGATGTGTCTGACTCTTG 
DR6  5’-CCAACGCGAAACTTGAGAAT  5’-GAGCCGCTGGATGTAGAGTC 
ETS2  5’-ACTCCCAAAGACCACGACTCC  5’-GAAGCTCTCGAAGGAAGGAACC 
E2F1  5’-ACTGAATCTGACCACCAAGC  5’-CAAGGACGTTGGTGATGTC 
GAPDH  5’-GCCAAAAGGGTCATCATCTC  5’-GGTGCTAAGCAGTTGGTGGT 
GAS6  5’-ATCAAGGTCAACAGGGATGC  5’-CTGCACGAGGTCCTTCTCAT 
ITGB5  5’-GCAAACCTTGTCAAAAATGG  5’-CCTGTGGTGTCATCTGAATG 
FAS  5’-GCCCAAGTGACTGACATCAA  5’-GACAGGGCTTATGGCAGAAT 
MAD2L1  5’-ATACGGACTCACCTTGCTTG  5’-CCAGGACCTCACCACTTTC  
MAP1B  5’-GAAGGGGACTGGAAGAACTC  5’-GATGGGACTTCCACTGATTC 
MCM5  5’-TGCTGCCAACTCAGTGTTC  5’-ACATCCCTCTCCTCATTGTG 
P16 INK4a  5’-CCCCTTGCCTGGAAAGATAC  5’-AGCCCCTCCTCTTTCTTCCT 
POLD3  5’-CAAGTGAGACACAAGCCAAC  5’-TTCTTGGGTTTTAGCAGCAG 
SERPINE2  5’-AGTCGAGGCCTCATGACAAC  5’-TACGCCGTATCTCATCACCA 
TRIM22  5’-AGCAGAGAGAGCTGCAAAAG  5’-GCTGGAGATCTGAGATGAGC 
Global Gene Expression Regulation by hSNF5
 
 33 
 
Gene Expression profiling. 
     MRT cells were grown to optimal densities. RNA was isolated and tested on an Agilent 
BioAnalyzer (Agilent). Samples with RNA integrity numbers of >8 were selected. Labelling, 
hybridization, washes, and staining of AffymetrixU133A microarrays were performed according 
to Affymetrix geneChip manual. We have used the R and Bioconductor free software 
(http://www.bioconductor.org) to get the intensities and the calls. Intensity values for all 
genes were scaled using the quantile normalization and further normalized with Ominiviz 
software 3.6 (BIOwisdom, Maynard, MA). Intensity values<40were set to 40. Differential gene 
expression was based on log2 transformed distances to the geometric mean for each probe 
set. Unsupervised Pearson correlation were performed on <-2 and >2 and <-1.5 and >1.5 
log2 geometric mean. Patterns of correction were revealed by applying a matrix-ordering 
method that sorts samples into correlated blocks, resulting in highly similar plots and identical 
grouping for LogGM<-2 and>2 or Log2GM<-1.5 and>1.5 probe subsets. 
 
Biological Pathway analysis. 
     First the down stream genes of hSNF5 were evaluated for biological function and network 
interactions by using Ingenuity pathway analysis software (www.ingenuity.com). Genes were 
ranked by their ingenuity score, reflecting their involvements in biological networks are unique 
but not mutually exclusive. Ingenuity also identifies the most relevant biological processes 
among the signature genes by gene ontology analysis and calculates the significance of 
association of signature genes with canonical pathways and diseases. Second, the identified 
genes were functionally clustered into specific categories and probability of each category was 
determined using the computer program EASE. 
Results 
hSNF5 Can Function in Transcription Activation and Repression of the Genome 
     To study the function of hSNF5 in MRT cells, we established two distinct strategies to re-
express hSNF5 in G401 and Mon, two different MRT cell lines. We reintroduced hSNF5 gene 
under Lac repressor-operator control in G401 cell line; in parallel hSNF5 was transduced to 
Mon cells using lentiviral transfection.  
     Samples were harvested 24 hours, 48 hours and 5 days after induction of wild-type hSNF5 
expression in G401 MRT-derived cell line or 48 hours after transduction of either GFP or SNF5 
in MON cells. hSNF5 is not essential for SWI/SNF complex integrity (10, 30, 31). Moreover, 
induced exogenous hSNF5 expression levels were comparable to the endogenous levels in a 
variety of cell lines (11, 31). 
     To elucidate pathways controlled by hSNF5 in rhabdoid tumor cells, we performed cDNA 
microarray analysis. Temporal gene expression profile in G401 cells lacking hSNF5 compared 
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to those induced by adding IPTG to express either wild type or mutant hSNF5, serine 284 to 
leucine (S284L). The same comparison was performed for Mon cells trasduced with GFP to 
those transduced with hSNF5.  hSNF5 expression could be clearly detected 24 h after either 
induction or transduction. Three different time points, 24 h, 48 h and 5 days were harvested 
for microarray studies. RNA isolated at three time points from G401, and last time point from 
Mon cells, labeled, and used for cDNA microarray analysis. Differentially expressed genes 
above 1.5 fold threshold were selected. We found 26 consistently differentially expressed 
genes (24 up; 4 down) by hSNF5 in all data points and different MRT cells. Further we focused 
on consistent differentially expressed genes upon wild type hSNF5 induction after 5 days in 
both MRT cell lines. We found 179 and 177 genes were up and down-regulated, respectively, 
in G401 cells and Mon cells. 
     The majority of the up-regulated genes encode proteins involved in extracellular matrix 
remodelling, adhesion or cell migration (SERPINE2, ITGB5, MAP1B), apoptosis (DR6, FAS, 
CASP4, GAS6, ADAM19), and cancer related pathway or other specialized functions (CDKN2A, 
ETS2 and TRIM22). This group of genes did not change or were down-regulated upon mutant 
SNF5 induction. The majority of down-regulated genes by hSNF5 encode proteins playing a 
key role during the cell cycle (i.e. CENPE, POLD3, CENPA, CDC25A, CCNF and MAD2) and 
remain unchanged upon mutant hSNF5 induction.  These results suggested misexpression of 
mitotic checkpoint components might cause abnormal ploidy of MRT cells. For example, over-
expression of Mad2 and its regulator E2F1 was implicated in mitotic defects leading to 
aneuploidy (16). In our microarray experiments both genes were down-regulated following 
hSNF5 induction. We used qRT-PCR to corroborate our microarray results (Figure. 2). We 
found that Mad2, E2F1and E2F1 target genes are highly expressed in MRT cells, but are 
strongly down-regulated following hSNF5 induction. 
     Further we transduced GFP or SNF5 in MRT (G401 and MON), Hela and U2OS cells using 
lentiviral transduction. Western immunoblot analysis of extracts from cells transduced by 
lentiviruses expressing GFP (lanes 1,3,5 and 7, Figure. 3A) or SNF5 (lanes 2,4,6 and 8) 
revealed normal hSNF5 expression in G401 and Mon cells (lane 2,4) and over-expression in 
Hela and U2OS cells compare to endogenous levels (lane 6 and 8). Antibodies directed against 
histone H3 were used as loading control. qRT-PCR revealed up-regulation of FAS, ETS2, 
TRIM22, GAS6, ADAM19 and SERPINE2 in MRT cells upon SNF5 induction while they remain 
unchanged or down-regulated in either Hela or U2OS cells (Figure. 3B-G). 
        To investigate direct targets of hSNF5, we performed chromatin immunoprecipitation on 
some of up or down regulated genes by hSNF5. MRT cells transduced with lentivirus (or 
induced with IPTG). hSNF5 was expressed to detectable levels at 48 hours post stimulation 
(data not shown). Chromatin was prepared from cells at 48 hours post-stimulation and 
subjected to chromatin immunoprecipitation with an antibody specific for hSNF5. Quantitative 
PCR analysis performed on immunoprecipitated material using primers specific for promoters 
for genes of interest as indicated in Table1B. As shown in Figure.4A our results indicate while 
hSNF5 is initially absent from TRIM22, ETS2, ANGPT2 and MAD2L genes, it is specifically 
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recruited to these promoters in response to SNF5 expression induction.  hSNF5 expression 
does not result in recruitment of SNF5 to the adjacent P14, ADAM19 and INTGB5 promoters. 
Taken together these results demonstrate that re-expression of hSNF5 in MRT cells results in 
specific recruitment of hSNF5 to TRIM22, ETS2, ANGPT2 promoters, up-regulated genes by 
hSNF5, and MAD2L promoters, down regulated gene by hSNF5, but not P14, ADAM19 and 
INTGB5 promoters, no significant change and up-regulate genes by hSNF5, respectively. Our 
data therefore supports the notion that hSNF5, an essential subunit of SWI/SNF complexes 
directly mediates both activation and repression of its target genes most likely in collaboration 
with gene-specific transcription factors and other chromatin modifying complexes, such as 
histone acetylases and deacetylases (22, 32). 
 
Figure2. QRT-PCR analysis of gene regulated by hSNF5 identified by whole-genome expression profiling. 
RT-qPCR analysis of gene expression in MRT cells reveals hSNF5-dependent induction of genes involved in A) apoptosis 
pathway B) Cell migration and invasion C) Other pathway and D) depletion of E2F and E2F target genes affected. Cells were 
collected 48 hours following transduction with lentiviruses expressing either GFP (yellow bars) or hSNF5 (blue bars). mRNA 
levels were plotted as percentage of GAPDH mRNA. The bar graphs represent the mean of three independent biological 
replicates, each analyzed by three separate qPCR reactions. Standard deviations are indicated. 
 
hSNF5 Mediates BRG1 (SWI/SNF) Recruitment 
     Previously we showed that hSNF5 is required for BRG1 recruitment to the p16INK4a and 
P15ink4b promoters(21, 31). We now examined whether hSNF5 also mediates the recruitment 
of BRG1 to the TRIM22, ETS2, ANGPT2 and MAD2L Promoters. We used chromatin 
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immunoprecipitation (ChIP) to study the occupancy of TRIM22, ETS2, ANGPT2, P14, ADAM19, 
INTGB5 and MAD2L promoters in MRT cells either lacking or induced to express SNF5. 
Chromatin isolated from MRT cells, 48 hours post-stimulation, immunoprecipitated using 
antibodies specific for BRG1 and species- isotype-matched immunoglobulins. 
Immunoprecipitated chromatin was analyzed by real time PCR using primer sets specific for 
promoter regions of genes of interest indicated in table1. While initially absent from these 
target genes. Following hSNF5 induction, BRG1 specifically bound to the TRIM22, ETS2, 
ANGPT2 and MAD2L promoters. Neither hSNF5 nor BRG1 were detected at the P14, ADAM19 
and INTGB5 promoters prior or after induction. 
     These results suggest that hSNF5 mediates recruitment of BRG1, the catalytic subunit of 
SWI/SNF to TRIM22, ETS2, ANGPT2 and MAD2L promoters to either stimulate or repress 
transcription.  
 
 
Figure3. RTQ-PCR analysis of gene regulated by hSNF5 in different cells 
(A)Western immunoblotting analysis of hSNF5 expression in MON. G401, Hela and U2OS cells transduced with lentiviruses 
expressing either GFP (lanes 1, 3, 5,7) or hSNF5 (lanes 2,4,6,8). Cell lysates were resolved by SDS-PAGE and analyzed by 
Western immunoblotting using antibodies directed against hSNF5. Histone H3 serves as a loading control. (B-E) RTQ-PCR 
analysis of genes upon induction or over expression of hSNF5 in two MRT cells (Mon, G401) Hela and U2OS cells. PCR 
revealed induction of (B) FAS, (C) GAS6, (D) SERPINE2, (E) TRIM22, (F) ETS2 and  (G) ADAM19  in MRT cells upon 
induction of SNF5 while they remain unchanged or down-regulated in either Hela or U2OS cells. Procedures were as described 
in the legend to Figure. 2.  
Global Gene Expression Regulation by hSNF5
 
 37 
 
 
 
 
 
 
 
 
Figure4. hSNF5 Mediates BRG1 Recruitment to the 
MAD2, TRIM22, ETS2 and ANGPT2 promoters 
(A)ChIP-qPCR analysis of hSNF5 binding to the 
MAD2, TRIM22, ETS2 and ANGPT2 ,p14Arf, INTGB5 
and ADAM19 revealed that hSNF5 binds directly to 
the MAD2, TRIM22, ETS2 and ANGPT2  promoters, 
but not to p14Arf. Cross-linked chromatin was 
isolated from MRT cells that either lack- (light  bars) 
or express hSNF5 (dark  bars). (B) BRG-1 binding to 
the MAD2, TRIM22, ETS2 and ANGPT2 promoters is 
hSNF5-dependent, as revealed by ChIP-qPCR using 
antibodies directed against BRG-1.  
 
 
 
 
 
 
 
Discussion 
     The aim of this study was to identify the downstream targets of the chromatin remodeling 
factor hSNF5 in two different MRT cells. Our genome wide expression suggests that hSNF5 can 
function in both transcription activation and repression of genome. ySWI/SNF subunits is 
required for the activation of a number of specific genes which are involved in mating-type 
switch, sucrose and galactose fermenting(33). Genome-wide expression profiling indicates 
that the ySWI/SNF complex regulates about 6% of the genes, both positively and 
negatively(17, 42). This suggests that the ySWI/SNF complex can function in both 
transcription activation and repression. Indeed, other studies have shown that ySWI/SNF 
complex cooperates with the SAGA histone-acetyltransferase complex to displace 
nucleosomes from the promoters of target genes upon transcription activation allowing 
binding of transcription factors to promoter DNA(8, 14). Systematic RNAi knockdown survey 
of the BAP and PBAP subunits has been recently performed in Drosophila embryonic cells(28, 
30). Genome-wide expression profiling and comprehensive statistical analysis showed that 
both complexes function as holoenzymes to activate or repress expression of multiple target 
genes either cooperatively, antagonistically or separately. Strikingly, RNAi knockdown of the 
BAP subunits results in accumulation of the cells in G2/M phase of the cell cycle, whereas 
depletion of the PBAP specific subunits has no significant effect on growth and cell cycle 
progression(30). However, it is already clear that besides regulation of G2/M phase, SWI/SNF 
complexes could be involved in the control of G1/S phase via cyclin E-E2F/Rb pathway(6, 41). 
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     Other study have analyzed hSNF5-induced gene expression changes at early time points in 
rhabdoid cells (27). They studied 7 time course variations of 22,000 genes/expressed 
sequence tags upon hSNF5/INI1 induction in Mon cells. We found 78% and 80% of up-
regulated or down-regulated genes reported in these studies that were up-regulated or down-
regulated respectively in our study after reintroduce of hSNF5 in Mon cells (Table2). Recently 
it has been shown that inhibition of migration induced by hSNF5 correlates with depletion of 
RhoA activity(7). Another group showed that hSNF5 induces Interferon signalling and spindle 
checkpoint in rhabdoid tumours (29) as we showed previously(45). Others have explored the 
hSNF5-dependent expression profile changes in the nonrhabdoid mouse embryo 
fibroblasts(19). Cell cycle genes that were up-regulated in that study are down-regulated in 
our microarray data (Table3). Table 4 shows the comparison of our data with the outcome of 
array data of central nervous system embryonal tumor (34). 
     Notably these findings suggest that hSNF5 acts as a transcriptional co-activator or co-
repressor, which is required for the recruitment of the BRG1 containing SWI/SNF chromatin 
remodeling complex to the TRIM22, ETS2, ANGPT2 and MAD2L but not p14ARF, ADAM19 and 
INTGB5 genes. The mechanisms by which the SWI/SNF complexes can influence both gene 
activation and repression in vivo are not fully understood(32). The hSNF5 containing SWI/SNF 
complex activates its targets by actively disrupting chromatin structure at promoters to allow 
increased access of the general transcription machinery or sequence specific activators to 
DNA. For example hSWI/SNF fractions were shown to increase binding of TFIIA and TBP to the 
TATA sequence on nucleosomal DNA(18). Several models explain gene-specific SWI/SNF-
mediated repression. First, distinct sub-complexes like Sin3 repressor complex may mediate 
activation and repression functions of SWI/SNF differential subunit (40). A second model 
involves recruitment of the SWI/SNF complex to promoters as components of larger co-
repressor complexes. In mammals, the hBRM/BRG-1 complexes form co-repressors with 
retinoblastoma (pRB) and HDACs to block cell cycle progression at the G1-S boundary(15, 25, 
47). hSNF5 represses cyclinD1 expression in G1 through collaborations with HDAC 
complexes(48). Also, the tumor suppressor gene prohibitin represses E2F-mediated 
transcription by recruitment of BRG1 to E2F promoters(46). Ets-2 and components of 
mammalian SWI/SNF (hSNF5 and BAF57/p50 and BRG1) form a repressor complex that 
negatively regulates the BRCA1(2); again suggesting that SWI/SNF coordinates with repressor 
proteins to actively repress gene expression. A third model is that the SWI/SNF complex 
mediates gene repression by directly altering nucleosome structure in an ATP-dependent 
(SWI2/SNF2) manner to form a repressive chromatin environment (26). In all of these 
models, SWI/SNF actively represses gene expression, either directly through the ATP-
dependent chromatin remodeling functions of the complex itself, or as part of large repressor 
complexes. Thus, because of its direct involvement in both transcriptional activation as well as 
repression, hSNF5 can be thought of as transcriptionally inert but capable of mediating both 
activation and repression in a context dependent manner.  
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Table2: Genes are up and down regulated in our Mon WTSNF5+/- microarray data and Medjkani et al. data 
(Ref27) 
 
 
 
 
 
Cancer Research 2004 Our Microarray data 
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Table3: Intersection between our data and cell cycle genes in MEFs (without SNF5) (Roberts et al Ref35) 
 
 
 
 
 
PNAS 2000 data Our Microarray data 
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Table4: comparison of our data with outcome of array data of central nervous system embryonal tumour  
(Pomeroy  2002, Ref34) 
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The hSNF5 subunit of human SWI/SNF ATP-dependent
chromatin remodeling complexes is a tumor suppressor
that is inactivated in malignant rhabdoid tumors
(MRTs). Here, we report that loss of hSNF5 function in
MRT-derived cells leads to polyploidization and chromo-
somal instability. Re-expression of hSNF5 restored the
coupling between cell cycle progression and ploidy
checkpoints. In contrast, cancer-associated hSNF5 mu-
tants harboring specific single amino acid substitutions
exacerbated poly- and aneuploidization, due to abrogated
chromosome segregation. We found that hSNF5 acti-
vates the mitotic checkpoint through the p16INK4a–cy-
clinD/CDK4–pRb–E2F pathway. These results establish
that poly- and aneuploidy of tumor cells can result from
mutations in a chromatin remodeler.
Received January 12, 2005; revised version accepted January
27, 2005.
ATP-dependent chromatin remodeling factors are criti-
cal components of the elaborate machinery that controls
gene expression in eukaryotic cells (Becker and Horz
2002). The multisubunit SWI/SNF complex is the proto-
typical chromatin remodeling factor, present in all eu-
karyotes (Mohrmann and Verrijzer 2005). Human SNF5
(hSNF5, also known as Ini1, Baf47, or SmarcB1) encodes
for a universal SWI/SNF subunit and tumor suppressor
that is mutated in malignant rhabdoid tumors (MRTs)
(Versteege et al. 1998; Klochendler-Yeivin et al. 2002;
Roberts and Orkin 2004). MRTs are rare but highly ag-
gressive pediatric cancers with a high mortality rate.
Carriers of germline mutations are predisposed to vari-
ous cancers and, consistent with a classic tumor suppres-
sor phenotype, the wild-type allele is either lost or de-
leted in a large proportion of tumors (Biegel et al. 1999;
Sevenet et al. 1999a,b; Taylor et al. 2000). hSNF5 muta-
tions are also associated with a number of neoplasms
other than MRTs (Grand et al. 1999; Sevenet et al.
1999a,b; Roberts and Orkin 2004). SNF5 inactivation
studies in mice established its requirement during early
embryogenesis and its role as a tumor suppressor (Klo-
chendler-Yeivin et al. 2000; Roberts et al. 2000; Guidi et
al. 2001; Roberts et al. 2002).
Several studies found that re-expression of hSNF5 in
MRT-derived cell lines caused an accumulation in G0/
G1, cellular senescence, and apoptosis (Ae et al. 2002;
Betz et al. 2002; Versteege et al. 2002; Zhang et al. 2002;
Oruetxebarria et al. 2004). These effects are largely the
result of direct transcriptional activation of the tumor
suppressor p16INK4a by hSNF5, which appears to be
both necessary and sufficient for reduced cell prolifera-
tion and induction of cellular senescence and apoptosis
(Oruetxebarria et al. 2004). p16INK4a controls the activity
of pRb via inhibition of the cyclin D1–CDK4 kinase,
which phosphorylates pRb (Lowe and Sherr 2003). Tu-
mor suppressor pRb is a corepressor that is tethered to a
broad range of genes by the E2F transcription factors.
Hyperphosphorylation of pRb causes its dissociation
from E2F, and relieves its antiproliferative activities. In
addition to genes required for cell cycle progression from
G1 to S phase, E2Fs also regulate genes involved in mi-
tosis, spindle checkpoints, G2/M control, apoptosis, and
differentiation (Stevaux and Dyson 2002).
Besides uncontrolled cell proliferation, chromosomal
instability, which is characterized by changes in chro-
mosome number or structure, is a hallmark of cancer
cells (Rajagopalan and Lengauer 2004). Although still de-
bated, there has been increasing support for the idea that
polyploidy can lead to aneuploidy and contribute to the
development of cancer (Rajagopalan and Lengauer 2004;
Storchova and Pellman 2004). Although gross aneu-
ploidy appears to be rare, chromosomal imbalances are
commonly detected in MRTs and other hSNF5-related
cancers (Berrak et al. 2002; Mitelman et al. 2003; Rickert
and Paulus 2003; Kusafuka et al. 2004). Therefore, we
decided to investigate the role of hSNF5 in ploidy con-
trol. Our results define a critical function for this chro-
matin remodeler in the maintenance of numerical chro-
mosome stability.
Results and Discussion
hSNF5 deficiency in MRT cells leads
to polyploidization
In the majority of MRTs, hSNF5 is inactivated due to
deletions, truncating nonsense mutations, or frameshift
mutations. However, a number of point mutations, re-
sulting in single amino acid substitutions (Fig. 1A), have
been identified in tumors (Sevenet et al. 1999a,b). These
include proline 48 to serine (P48S), arginine 127 to gly-
cine (R127G), and serine 284 to leucine (S284L). In addi-
tion, we also changed serine 289 to alanine (S289A). S284
and S289 are located within one of the most highly con-
[Keywords: Chromosomal instability; chromatin; tumor suppressor;
hSNF5/INI1/Baf47/SmarcB1]
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served regions of SNF5, which forms part of direct repeat
2 (RPT2).
Wild-type or mutant hSNF5 was reintroduced in
MRT-derived G401 cells lacking the hSNF5 gene. Ex-
pression of hSNF5 was under control of the Lac repres-
sor-operator system and could be induced by the addition
of IPTG (Fig. 1B). Previously, we used these “Lac-
hSNF5” cells to establish that re-expression of hSNF5
in MRT cells induces a p16INK4a-dependent G0/G1 ar-
rest, cellular senescence, and apoptosis (Oruetxebarria et
al. 2004). It should be noted that the induced levels
of hSNF5 fall within the normal physiological range
(Oruetxebarria et al. 2004) and that hSNF5 is not re-
quired for the assembly of a SWI/SNF complex (Doan et
al. 2004; Oruetxebarria et al. 2004). Induction of tumor-
derived hSNF5 mutants still caused a reduced cell accu-
mulation, albeit not as pronounced as when wild-type
hSNF5 was expressed (Fig. 1C). As expected, addition of
IPTG to “Lac-empty” control cells, lacking the hSNF5
gene, did not affect cell accumulation. These results in-
dicated that a failed growth arrest might not fully ex-
plain the cancer association of these single amino acid
substitutions in hSNF5.
Examination of the nuclear morphology of cells ex-
pressing mutant hSNF5-S284L provided a clue towards
other processes relevant to tumor suppression by hSNF5
(Fig. 2A,B). Four days after induction of hSNF5-S284L,
the majority of cells contained multilobed nuclei or
sometimes multiple nuclei. We never observed multi-
lobed nuclei after expression of wild-type hSNF5,
whereas they occurred regularly in cells lacking hSNF5.
Next, we tested the effect of hSNF5-S284L on unrelated
cells, expressing endogenous wild-type hSNF5. In
both MRC-5V1 (Fig. 2C) and Ad5HER cells (data not
shown), expression of hSNF5-S284L induced multilobed
nuclei, whereas overexpression of wild-type hSNF5 had
no effect. Thus, the S284L substitution mutation can
have a dominant effect, which is not restricted to MRT
cells.
Because multilobed nuclei are a feature of cells that
have undergone endoreplication, we tested whether
hSNF5-S284L might promote polyploidization. The full
karyotypes of G401 MRT-derived cells that either lack
hSNF5 or express wild-type hSNF5 or hSNF5-S284L
were determined by multicolor pq-COBRA-FISH analy-
sis (Fig. 2D; Wiegant et al. 2000). About 90% of Lac-
empty cells or Lac-hSNF5 cells before induction were in
the diploid range of chromosome content, but displayed
frequent numerical chromosome aberrations. The re-
maining 10% was near tetraploid. Strikingly, after ex-
pression of wild-type hSNF5 for 96 h, the cell population
became almost perfectly diploid. The disappearance of
aneuploid cells from the cycling population suggested a
role for hSNF5 in mitotic checkpoint control. In con-
trast, hSNF5-S284L expression exacerbated poly- and an-
euploidization, resulting in ∼25% of cells in the tetra-
ploid range and almost 10% of cells that were near oc-
taploid. We note that, because mitotic cells were
obtained by a colcemid block, the karyotypes were de-
rived from cycling cells. Moreover, the presence of octa-
ploid cells demonstrated that a significant portion of tet-
raploid cells did not arrest due to the tetraploidy check-
point but re-entered mitosis.
Concomitant with polyploidization we observed cen-
trosome- and spindle amplification, as revealed by �-tu-
bulin and �-tubulin staining, respectively (Fig. 2E,F). Fol-
lowing hSNF5-S284L induction, the percentage of mi-
totic cells containing more than one spindle increased
from ∼5% to, respectively, 22% of cells with two
spindles and 11% with more than two spindles. How-
ever, mitotic cells expressing wild-type hSNF5 virtually
always contain one spindle. In summary, these results
revealed that loss of hSNF5 in MRT cells promotes poly-
and aneuploidization, whereas the cancer-associated
S284L substitution acts as a gain-of-function mutation,
exacerbating chromosomal instability. Collectively,
these observations suggest a critical function for hSNF5
during mitosis.
Mutations in hSNF5 abrogate chromosome segregation
We utilized time-lapse microscopy to determine the cell
cycle stage at which the hSNF5-S284L-induced defect
occurs (Fig. 3A). Cells expressing hSNF5-S284L enter mi-
tosis normally, as judged by rounding up of the cells and
chromosomal condensation (indicated with an arrow).
However, a significant proportion of these cells subse-
quently exited mitosis, as judged by cell flattening and
chromatin decondensation, but abstained from karyoki-
nesis and cytokinesis. Most cells that do not express
hSNF5-S284L progress normally through mitosis and
cell division. % uantification of distinct stages of mitosis
revealed a defective anaphase in hSNF5-S284L-express-
ing cells (data not shown). The aborted anaphase ap-
peared to be caused by a failure of the mitotic spindle to
connect to the kinetochores, as revealed by confocal mi-
croscopy using CREST and �-tubulin antibodies to visu-
alize kinetochores and spindles, respectively (Fig. 3B). In
cells expressing wild-type hSNF5, however, the spindles
Figure 1. Effect of wild-type or mutant hSNF5 expression in MRT
cells. (A) Schematic representation of hSNF5 depicting the two re-
peats (RPT1 and RPT2) and cancer-associated amino acid substitu-
tion mutations. (B) Constructs expressing wild-type or mutant
hSNF5-Flag were introduced in the MRT-derived cell line G401 un-
der control of the Lac repressor-operator system. Protein expression
following induction with IPTG was determined by Western blotting
with anti-Flag antibodies. (C) Cell accumulation in the presence
(filled circles) or absence (open circles) of hSNF5, induced by IPTG.
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provided an orderly connection between metaphase
chromosomes and centrosomes. Expression of hSNF5-
S289A had similar effects on mitosis as hSNF5-S284L. It
will be of interest to investigate whether S284 and S289
might be targets for phosphorylation, regulating the mi-
totic functions of hSNF5.
hSNF5 is critical for precise ploidy control
We used pq-COBRA-FISH to determine the effects of
cancer-associated mutations in hSNF5 on ploidy distri-
bution (Fig. 4A) and on numerical chromosome varia-
tion, as determined by the gain or loss of individual chro-
mosomes (Fig. 4B). Examination of cells prior to induc-
tion of hSNF5 revealed that more than half displayed
general numerical chromosomal aberrations and that
∼10% were near tetraploid. Strikingly, after hSNF5 in-
duction virtually all poly- and aneuploid cells were
purged and the cell population became almost perfectly
diploid. This dramatic effect of hSNF5 expression on nu-
merical chromosome instability was highly significant
(p % 2.0 × 10−6), as determined by the Mann-Whitney U-
test. Thus, restoration of hSNF5 expression in MRT-de-
rived cells, which lost the hSNF5 gene in the original
cancerous lesion, suffices to revert chromosomal insta-
bility. In contrast, two different cancer-associated
hSNF5 substitution mutants, hSNF5-P48S and hSNF5-
Figure 3. hSNF5-S284L induction causes an abortive cell cycle. (A)
Time-lapse microscopy of hSNF5-S284L-expressing cells, which en
ter mitosis but exit prior to cell division. Arrows indicate condensed
chromatin. (B) Failure of microtubule–kinetochore association in cells
expressing hSNF5-S284L. Kinetochores were identified with CREST
(red) antibodies and mitotic spindles with �-tubulin (green) antibodies.
Figure 2. hSNF5-S284L expression exacerbates polyploidization. (A) DNA staining with DAPI revealed an increased number of multilobed
nuclei after hSNF5-S284L expression. (B) Costaining of DNA (blue) and �-tubulin (red). (C) GFP-hSNF5-S284L but not GFP-hSNF5 induces
multilobed nuclei in MRC5 cells. The GFP signal (green) identifies the transfected cells. (D) Representative examples of pq-COBRA-FISH
analysis of Lac-hSNF5-S284L cells. Di-, tri, tetra-, and near octaploid metaphases are shown. Four Y-chromosomes, indicative of octaploidy, are
indicated by arrows. (E) Representative examples of Lac-hSNF5-S284L cells with one, two, or more mitotic spindles. (F) Visualization of
centrosomes (arrows) by �-tubulin staining.
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R127G, failed to generate a diploid cell population. Ex-
pression of either hSNF5-S284L (p < 3.6 × 10−5) or
hSNF5-S289A (p < 2 × 10−6) strongly promoted poly-
ploidization and aneuploidy. In conclusion, our analysis
of both loss-of-function and gain-of-function mutations
revealed the critical role of hSNF5 in ploidy control.
hSNF5 activates the mitotic checkpoint through the
p16INK4a–cyclinD/CDK4–pRb–E2F pathway
Our results suggested that re-expression of hSNF5 tight-
ens the mitotic checkpoint such that cell cycle progres-
sion of cells with an abnormal ploidy is blocked. To
karyotype these noncycling cells, we used the drug ca-
lyculin A to induce premature chromosome condensa-
tion of interphase cells (Bezrookove et al. 2003). Indeed,
we found that the karyotypes of noncycling hSNF5-ex-
pressing cells displayed a significantly higher degree of
chromosome gains and losses than those of mitotic cells
(p < 10−2) (Fig. 5A,B). These results suggest that the re-
duced accumulation of hSNF5-expressing cells is caused
by selective arrest and senescence of aneuploid cells. Af-
ter hSNF5 induction, only diploid cells remain cycling.
Next, we considered the pathway through which
hSNF5 controls cellular ploidy. Whole-genome expres-
sion profiling of Lac-hSNF5 cells prior to and after
hSNF5 induction revealed, among other findings,
changed expression of many E2F targets, including mi-
totic control genes. This is illustrated by the representa-
tive selection in Figure 5C. Interestingly, recent studies
established that the pRb–E2F pathway couples cell cycle
progression to the mitotic checkpoint (Hernando et al.
2004). Our earlier work had already shown that the abil-
ity of p16INK4a to inhibit CDK4 kinase activity was criti-
cal for hSNF5-induced senescence (Oruetxebarria et al.
2004). To test whether ploidy control by hSNF5 is ex-
erted via the p16INK4a–cyclinD/CDK4–pRb–E2F path-
way, we debilitated this route by expression of the
p16INK4a-insensitive CDK4R24C mutant (Rane et al.
2002). Karyotypic analysis revealed that the high level of
poly- and aneuploidy of these cells could not be reversed
by hSNF5 expression (Fig. 5D–F). Thus, derailment of the
pRb pathway blocks ploidy control by hSNF5.
Our gene expression profiling results suggested that
misexpression of mitotic checkpoint components might
cause the abnormal ploidy of MRT cells. For example,
overexpression of Mad2 and its regulator E2F1 was re-
cently implicated in mitotic defects leading to aneu-
ploidy (Hernando et al. 2004). Interestingly, in our mi-
croarray experiments, both genes were down-regulated
following hSNF5 induction. We used RT–PCR to cor-
roborate our microarray results (Fig. 5G). We found that
both Mad2 and E2F1 are highly expressed in MRT cells,
but are strongly down-regulated following hSNF5 induc-
tion. CDK4R24C expression abrogated attenuation of
these genes by hSNF5. Collectively, these results suggest
that in MRT cells, loss of hSNF5 function causes el-
evated levels of Mad2 due to unregulated E2F1 activity.
This in turn can be sufficient to cause a defective spindle
checkpoint driving aneuploidization, as shown by Her-
nando et al. (2004).
We conclude that transcriptional regulation of the
p16INK4a–cyclinD/CDK4–pRb–E2F pathway plays a criti-
cal role in ploidy control by hSNF5. However, this does
not exclude additional functions for hSNF5 in ploidy
control or other cellular processes relevant for tumori-
genesis. Moreover, a more structural role in the estab-
lishment of centromeric chromatin or in sister chroma-
tid cohesion and segregation remains possible, as has
been suggested for the SWI/SNF-related yeast RSC com-
plex (Baetz et al. 2004; Huang et al. 2004; Mohrmann and
Verrijzer 2005). Using a conditional siRNA approach, we
recently observed polyploidization of non-MRT cells due
to the loss of hSNF5 (R.G.J. Vries and C.P. Verrijzer,
unpubl.), suggesting that the mitotic functions of hSNF5
might be general and not cell-type-specific.
Inactivation of ATP-dependent chromatin remodeling
factors has been implicated in the development of dis-
tinct types of tumors (Klochendler-Yeivin et al. 2002;
Roberts and Orkin 2004). Here, we report that restora-
tion of hSNF5 expression in MRT-derived cells, which
lost the hSNF5 gene in the original cancerous lesion,
leads to the purging of poly- and aneuploid cells. We
propose that inactivation of chromatin remodeler hSNF5
causes both the selective growth advantage and the genetic
instability necessary for tumor initiation and progression.
Our finding that hSNF5 activates the mitotic checkpoint
through the p16INK4a–cyclinD/CDK4–pRb–E2F pathway
reveals a convergence of tumor suppressor pathways.
Materials and methods
Cell culture, plasmids, and mRNA expression
Generation and culture of the G401 cell lines has been described
(Oruetxebarria et al. 2004). CDK4R24C was stably expressed in Lac-
Figure 4. Restoration of wild-type hSNF5 expression, but not of
cancer-associated mutants, reverts chromosomal instability. (A)
Histogram depicting the frequency of cells with a given chromo-
some number as determined by metaphase analysis using pq-CO-
BRA-FISH. The total number of chromosomes per cell was deter-
mined either before or after the induction of hSNF5. (B) Individual
chromosome gains or losses.
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hSNF5 cells (Lac-hSNF5/CDK4R24C) from a pREP4-derived vector (Rane
et al. 2002). Mutants were generated using Q uickChange mutagenesis
(Stratagene). mRNA expression analysis was performed as described
(Oruetxebarria et al. 2004). All primer sequences will be provided upon
request. Gene expression profiling was performed using Affymetrix
U133A GeneChips, and data analyses were performed using Omniviz
software and the Ease program. An extensive description of these experi-
ments will be reported elsewhere.
Immunofluorescence and time-lapse microscopy
Cells were grown on cover slips, fixed with 4Q paraformaldehyde, and
permeabilized in PBS with 0.1Q Triton Q -100, followed by standard in-
direct immunofluorescence. Nuclei were visualized by DAPI staining.
Antibodies used: anti-Flag, F3165 (Sigma); anti-�-tubulin, T5168 (Sigma);
anti-�-tubulin, T6557 (Sigma); anti-CREST was a gift from H. Clevers
(Hubrecht Laboratory, Utrecht, The Netherlands) (Fodde et al. 2001). To
quantify centrosome- and spindle amplification, ∼1000 mitotic cells for
each condition were analyzed. Cells for time-lapse microscopy were
grown on glass-bottom culture dishes (MatTek). Two hours before trans-
fer to the 37°C microscope, medium was changed to HEPES-buffered
DMEM without Phenol red (21063-029, Life Technology).
pq-COBRA-FISH and cytogenetic analysis
Detailed cytogenetic analysis using pq-COBRA-FISH was performed es-
sentially as described (Wiegant et al. 2000). ULS reagent was provided by
Kreatech Biotechnology. Interphase cells were karyotyped following Ca-
lyculin A-induced chromosome condensation (Bezrookoove et al. 2003).
For each condition, between 20 and 60 cells were analyzed. Chromosome
copy number is depicted as histograms, and the numerical abnormalities
are presented as percentage of gain and loss for each chromosome, for
which the nearest ploidy of each cell was considered. The significance of
differences in total gain or loss of chromosomes was determined by the
Mann-Whitney U-test.
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Stable silencing of the INK4b-ARF-INK4a tumor suppressor locus occurs in a variety of human cancers,
including malignant rhabdoid tumors (MRTs). MRTs are extremely aggressive cancers caused by the loss of
the hSNF5 subunit of the SWI/SNF chromatin-remodeling complex. We found previously that, in MRT cells,
hSNF5 is required for p16INK4a induction, mitotic checkpoint activation, and cellular senescence. Here, we
investigated how the balance between Polycomb group (PcG) silencing and SWI/SNF activation affects epige-
netic control of the INK4b-ARF-INK4a locus in MRT cells. hSNF5 reexpression in MRT cells caused SWI/SNF
recruitment and activation of p15INK4b and p16INK4a, but not of p14ARF. Gene activation by hSNF5 is strictly
dependent on the SWI/SNF motor subunit BRG1. SWI/SNF mediates eviction of the PRC1 and PRC2 PcG
silencers and extensive chromatin reprogramming. Concomitant with PcG complex removal, the mixed lineage
leukemia 1 (MLL1) protein is recruited and active histone marks supplant repressive ones. Strikingly, loss of
PcG complexes is accompanied by DNA methyltransferase DNMT3B dissociation and reduced DNA methyl-
ation. Thus, various chromatin states can be modulated by SWI/SNF action. Collectively, these findings
emphasize the close interconnectivity and dynamics of diverse chromatin modifications in cancer and gene
control.
Epigenetic mechanisms confer inherited states of gene ex-
pression that involve neither alterations in the DNA sequence
nor the continuous presence of the initiating signal (16, 28).
The memory of gene expression status through cell divisions
plays an important role in development and disease (8, 11, 17,
29, 32). For example, the stable silencing of tumor suppressor
genes, such as p16INK4a, is believed to contribute to the devel-
opment of human cancers. In a variety of tumors, p16INK4a is
inactivated through epigenetic silencing, involving Polycomb
group (PcG) proteins and DNA methylation (10, 17, 36). The
principal function of p16INK4a is the induction of cellular se-
nescence, a physiologically relevant state of permanent cell
cycle arrest in response to aberrant proliferative signals (10,
25). p16INK4a acts mainly through inhibition of the Cyclin D1-
CDK4 kinase, which phosphorylates and inactivates the reti-
noblastoma tumor suppressor protein (pRb). The p16INK4a
gene is part of the INK4b-ARF-INK4a locus that encodes two
other tumor suppressor proteins, p15INK4b and p14ARF (Fig.
1A) (10). p15INK4b is related to p16INK4a and also encodes a
cyclin-dependent kinase inhibitor that activates pRb. Although
the p14ARF transcription unit overlaps with the p16INK4a gene,
it encodes a structurally unrelated protein that acts through
activation of the p53 pathway.
Malignant rhabdoid tumors (MRTs) are extremely aggres-
sive cancers of early childhood that are associated with loss of
the hSNF5 subunit of the SWI/SNF chromatin-remodeling
complex (4, 19, 30, 34, 38). hSNF5 reexpression in MRT cells
induces p16INK4a, but not p14ARF (3, 26). Accumulated evi-
dence indicates that the failure to activate p16INK4a transcrip-
tion due to the loss of hSNF5 (also known as INI1, BAF47, or
SMARCB1) is an important oncogenic step in MRTs. First, in
MRT cells induction of the epigenetically silenced p16INK4a
gene is both necessary and sufficient for hSNF5-mediated mi-
totic checkpoint activation and cellular senescence (26, 40).
Second, studies in mice have suggested that hSNF5 tumor
suppression acts in parallel to p53 (14) but interacts function-
ally with the pRb pathway (13). In conclusion, MRT cells
provide a physiologically relevant cell system to study the an-
tagonistic effects of silencing and SWI/SNF action on the chro-
matin status of the multigene INK4b-ARF-INK4a tumor sup-
pressor locus.
Genetic studies in Drosophila identified SWI/SNF as a
trithorax group (trxG) activator, which counteracts PcG-medi-
ated silencing (29, 32, 37). Significantly, the PcG protein BMI1
promotes oncogenesis in mice through silencing of the INK4a-
ARF locus (15). Both the PRC1 and the PRC2 PcG complexes
directly bind and silence the INK4a-ARF locus (5, 20). We
therefore wondered whether this is also the case in MRT cells
and, more interestingly, how SWI/SNF might overcome PcG
silencing. Current models of PcG function favor the notion
that binding of PcG silencing complexes create a chromatin
structure that is refractory to remodeling by SWI/SNF (24, 29,
32, 33). This hypothesis is mainly based on results from in vitro
experiments suggesting that PRC1-coated chromatin cannot
be remodeled by SWI/SNF (35). However, this model raises a
conundrum for genes that need to be reactivated after PcG
silencing.
Here, we explored the molecular mechanism by which res-
toration of SWI/SNF functionality through hSNF5 reexpres-
sion overcomes epigenetic silencing and mediates p16INK4a
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transcriptional activation in MRT cells. Our results reveal that
in vivo SWI/SNF activity can effectively overrule PcG complex-
induced chromatin silencing. We suggest that the antagonistic
interactions between SWI/SNF and PcG silencers involve a
dynamic equilibrium rather than a static chromatin state.
MATERIALS AND METHODS
Cell culture and lentiviral procedures. All tissue culture was performed ac-
cording to standard protocols. The hSNF5-inducible MRT-derived cell lines have
been described (26). The hSNF5 expressing lentiviral vector was generated by
replacing the green fluorescent protein (GFP) encoding sequence of pRRLsin
.sPPT.CMV.GFP.Wpre (9) with the hSNF5 cDNA (26). High-titer vector stocks
were produced in 293T cells by cotransfection of transfer vector constructs with
the packaging constructs by using standard transfection procedures (9). MON
cells were transduced with the appropriate vector. To knock down BRG1, the
cells were transduced with lentiviruses expressing short hairpin RNA (shRNA)
directed against BRG1 (clone 15549; Expression Arrest-RNAi Consortium hu-
man shRNA library purchased from Open Biosystems) for 4 days. In a control
experiment, the cells were transduced with GFP-expressing lentiviruses as de-
scribed previously. Approximately 24 h after initial viral transduction, the lenti-
virus-mediated expression of hSNF5 or GFP controls was induced for additional
72 h. For 5-aza-2�-deoxycytidine (5-azadC) treatment, MON cells were incubated
with 50 �mol of 5-azadC/liter, and the medium was refreshed every 24 h. After
approximately 48 h, hSNF5 or GFP expression was induced for an additional
48 h, and then the cells were harvested. Protein, RNA extraction and reverse
transcription-quantitative PCR (RT-qPCR) were performed as described below.
RNA purification and real-time RT-PCR analysis. Total RNA was extracted
from MRT cells by using the SV total RNA isolation system (Promega) 48 h
after hSNF5 expression was induced. cDNA was synthesized from 1 �g of
total RNA by using random hexamers and Superscript II RNase H-reverse
transcriptase (Invitrogen). Quantitative real-time PCR (MyIQ; Bio-Rad) was
performed with Sybr green I. PCR primers were designed by using Beacon
designer (Premier Biosoft). A Q-PCR core kit (Invitrogen) was used with a
400 nM concentration of each primer under the following cycling conditions:
3 min at 95°C, followed by 40 cycles of 10 s at 95°C and 45 s at 60°C. The
Usp14 gene, whose expression is hSNF5 independent, was used as an endog-
enous reference for normalization. Enrichment of specific DNA sequences
was calculated by using the comparative threshold cycle (CT) method (22).
PCR primer sequences are provided in Table 1.
Cell extracts and Western blotting. Cell extracts were prepared in radioim-
munoprecipitation assay buffer (10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1%
Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) and
assayed for protein concentration, and 50 �g of extract was resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) and then analyzed by immunoblot-
ting. Primary antibodies included SNF5 (ab12167 [Abcam]), BRG1 (ab4081
[Abcam]), SUZ12 (ab12073 [Abcam]), BMI1 (ab14389 [Abcam]), EZH2 (Sc-
25383 [Santa Cruz]), DNMT3B (IMG-184A [IMGENEX]), and histone H3
(ab1791 [Abcam]). Western blots were developed by using an ECL detection kit
(Pierce) according to the supplier’s instructions.
ChIP and MeDIP assays. Chromatin immunoprecipitations (ChIPs) were per-
formed as described by the Upstate protocol. Cross-linked chromatin was pre-
pared from �2 � 107 cells 48 h after transduction with lentiviruses expressing
either hSNF5 or GFP as a control. Cells were treated with 1% formaldehyde for
20 min at room temperature. Chromatin isolation, sonication yielding fragments
of 300 to 600 bp, and immunoprecipitations were performed according to pre-
viously established protocols. The following antibodies were used: SNF5
(ab12167 [Abcam]), BRG1 (ab4081 [Abcam]), SUZ12 (ab12073 [Abcam]), BMI1
(ab14389 [Abcam]), EZH2 (Sc-25383 [Santa Cruz]), DNMT3B (IMG-184A
[IMGENEX]), POL II (Sc-899 [Santa Cruz]), mixed lineage leukemia 1 (MLL1;
A300-086A [Bethyl Laboratories]), Histone H3 (ab1791 [Abcam]), H3-K4me3
(ab12209 [Abcam]), and H3-K27me3 (catalog no. 07-449 [Upstate]). The abun-
dance of specific DNA sequences in the immunoprecipitates was determined by
qPCR and corrected for the independently determined amplification curves of
each primer set. ChIP using species- and isotype-matched immunoglobulins
directed against an unrelated protein (glutathione S-transferase [GST]) were
used to determine background levels. For methylated DNA immunoprecipitate
(MeDIP) assays, genomic DNA was prepared by overnight proteinase K treat-
ment, phenol-chloroform extraction, and ethanol precipitation. Genomic DNA
was digested with MboI, and 4 �g of fragmented DNA was used for a standard
MeDIP assay. After denaturation at 95°C for 10 min, the reaction was quenched
on ice, and 500 �l of MeIP buffer (phosphate-buffered saline–0.05% Triton
FIG. 1. Reexpression of hSNF5 in MRT cells induces p15INK4b and
p16INK4a but not p14ARF. (A) Organization of the human INK4b-ARF-
INK4a locus (not drawn to scale). The genomic locus spans approximately 40
kbp of human chromosome 9 and encodes three distinct proteins: p15INK4b,
p14ARF, and p16INK4a. The 5� and 3� untranslated regions (yellow boxes), the
coding sequences of p15INK4b (green), p14ARF (blue), and p16INK4a (red) are
indicated. (B) Western immunoblotting analysis of hSNF5 expression in
MON cells transduced with lentiviruses expressing either GFP (lane1) or
hSNF5 (lane2) and either noninduced (lane 3) or induced (lane 4) G401-
derived Lac-hSNF5 cells. Cell lysates were resolved by SDS-PAGE and an-
alyzed by Western immunoblotting with antibodies directed against hSNF5.
Histone H3 serves as a loading control. (C) RT-qPCR analysis of gene
expression inMRT cells reveals hSNF5-dependent induction of p15INK4b and
p16INK4a, whereas p14ARF transcription remains unaffected. Cells were col-
lected 48 h after transduction with lentiviruses expressing either GFP (yellow
bars) or hSNF5 (blue bars). RT-qPCR analysis of isolated mRNA was used
to determine the relative expression levels of p15INK4b, p16INK4a, p14ARF, and
USP14 (a control gene that is independent of hSNF5). mRNA levels were
plotted as percentage of USP14 mRNA � 0.006. The bar graphs represent
the mean of three independent biological replicates, each analyzed by three
separate qPCR reactions. The standard deviations are indicated. (D) RNA
Pol II promoter binding was analyzed by ChIP-qPCR. Cross-linked chroma-
tin was prepared from MRT cells lacking hSNF5 but expressing GFP (light
green bars) or from cells expressing hSNF5 (dark green bars). All ChIP data
presented here are the result of at least three independent experiments. The
abundance of specific DNA sequences in the immunoprecipitates was deter-
mined by qPCR and corrected for the independently determined amplifica-
tion curves for each primer set. Background levels were determined by ChIP
using species and isotype-matched immunoglobulins directed against an un-
related protein (GST). ChIPs with antibodies directed against RNA Pol II
were analyzed by qPCR using primer sets corresponding to the p15INK4b,
p14ARF, and p16INK4a promoters. ChIP signal levels for each region are pre-
sented as a percentage of input chromatin.
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X-100), 50 �l of salmon sperm DNA–protein G-agarose beads (Upstate), and 10
�g of anti-5-methylcytosine monoclonal antibody (Eurogentec) was added. As a
negative control, DNA fragments were incubated with nonspecific mouse immu-
noglobulin G. After an overnight incubation on a rotating wheel at 4°C, beads
were washed with 700 �l of MeIP buffer and resuspended in 100 �l and treated
with proteinase K for 3 h at 50°C. Finally, DNA was purified by conventional
phenol-chloroform extraction, followed by ethanol precipitation and analysis by
qPCR. The enrichment of specific DNA sequences was calculated by using the
comparative CTmethod (22). PCR primer sequences are provided in Table 1. All
data presented are the result of at least three independent ChIP or MeDIP
experiments and triplicate qPCR reactions. The results were averaged, and
standard errors were determined by using the R free software (http://www.r
-project.org). The ChIP and MeDIP levels for each region are presented as the
percentage of input chromatin. ChIPs using antibodies directed against H3-
K27me3 or H3-K4me3 were normalized against histone H3 density.
RESULTS
hSNF5 is required for selective recruitment of BRG1 to the
p15INK4b and p16INK4a promoters. We utilized two distinct
strategies to reexpress hSNF5 in MRT cells: the previously
described Lac repressor-operator system (26) and transduction
with hSNF5-expressing lentiviruses. Samples were taken 48 h
after induction of hSNF5 expression in two different MRT-
derived cell lines: MON and G401. We note that hSNF5 is not
essential for SWI/SNF complex integrity (7, 23, 26). Lentiviral
transduction resulted in expression levels that were compara-
ble to that obtained using the Lac repressor operator system
(Fig. 1B). Moreover, we previously showed that the levels of
induced exogenous hSNF5 expression were comparable to the
endogenous levels in a variety of cell lines (7, 23, 26). Below,
we present results obtained for MON cells transduced with
lentiviruses expressing either hSNF5 or GFP as a control.
However, all results presented here were consistently observed
for both cell lines and either delivery system.
To investigate the effect of hSNF5 on expression of the
INK4b-ARF-INK4a locus, we quantified mRNA levels by RT-
qPCR (Fig. 1C). In full agreement with our previous Western
blotting results (26), we observed a clear induction of p16INK4a,
but not p14ARF mRNA levels. In addition, we found that
p15INK4b was upregulated. ChIP experiments revealed that
hSNF5 expression triggers RNA polymerase II (RNA Pol II)
recruitment to the p15INK4b and p16INK4a promoters, but not to
p14ARF (Fig. 1D). We conclude that in the context of hSNF5
reexpression in MRT cells, p14ARF is not induced coordinately
with p15INK4b and p16INK4a. Thus, the coregulation of the
INK4b-ARF-INK4a locus observed in selective cell lines (12) is
not a general phenomenon.
To gain insight into the mechanism of p15INK4b and p16INK4a
activation by hSNF5, we analyzed the chromatin status at the
INK4b-ARF-INK4a locus. For qPCR we used primer sets cor-
responding to the promoter areas of p15INK4b (primer set A)
and p14ARF (primer set B), an intergenic control (primer set
C), whereas we probed the p16INK4a locus at a higher resolu-
tion (primer sets D to I [Fig. 2, bottom]). ChIPs directed
against hSNF5 revealed strong binding to the p15INK4b and
p16INK4a promoters when hSNF5 is expressed (green bars; Fig.
2A). The p14ARF promoter was not bound by hSNF5, as re-
flected by the low background signal, also present in cells
devoid of hSNF5 (yellow bars). Importantly, hSNF5 was
strictly required to bring BRG1, the central SWI/SNF motor
subunit, to the p15INK4b and p16INK4a promoters (Fig. 2B). We
note that hSNF5 expression does not influence BRG1 levels in
the cell (Fig. 3A) (26). Finally, these ChIPs demonstrated that
SWI/SNF recruitment is limited to the p15INK4b and p16INK4a
promoter areas and does not spread across the locus.
Does hSNF5 mediate gene activation by itself, or does its
function depend on the chromatin remodeling activity of SWI/
SNF? To investigate this question, we used lentiviral expressed
shRNAs to deplete MON cells for BRG1, the central ATPase
that is critical for chromatin remodeling (Fig. 3A). Western
TABLE 1. Q-PCR primers used for ChIP, mRNA expression, or
DIP assay along the INK4-ARF locus
Technique and primer
(location)
Primer
set Sequence (5�–3�)
ChIP
p15INK4b-Pm A GGCAGTGGTGAACATTCC
GCCCAAAGATGCTAGGAC
p14ARF-Pm B CGCCGTGTCCAGATGTCG
TGCTCTATCCGCCAATCAGG
p16INK4a (�8.7 kb) C ACTAGGCTTGTCCCACTTGC
TCAGTTCCTCTCTCCATT
CTCC
p16INK4a (�0.6 kb) D CCCGTCCGTATTAAATA
AACC
GACTGCTCTCTCCTTCCC
p16INK4a (�0.3 kb) E GGGCTCTCACAACTAGG
AAAG
GGGTGTTTGGTGTCAT
AGGG
p16INK4a (�85 bp) F CCCCTTGCCTGGAAAGATAC
AGCCCCTCCTCTTTCTTCCT
p16INK4a (�0.5 kb) G CTGGAGGACGAAGTTTGC
AGGAGGAGGTCTGTGA
TTAC
p16INK4a (�1.5 kb) H GTGTTTCTCCTCTCCCTA
CTCC
CCGGGTTCAAGCTGTTGGC
p16INK4a (�5.6 kb) I ACCAAGACTTCGCTGACC
CAAGGAGGACCATAATTC
TACC
mRNA expression
p15INK4b TAGTGGAGAAGGTGCG
ACAG
GCGCTGCCCATCATCATG
p14ARF GGTTTTCGTGGTTCACATCC
CCTAGACGCTGGCTCCTC
p16INK4a CCCCTTGCCTGGAAAGATAC
AGCCCCTCCTCTTTCTTCCT
USP14 AACGCTAAAGGATGATGAT
TGGG
TTTGGCTGAGGGTTCTT
CTGG
DIP assay
p15INK4b AGCAGCGTGGGAAAGA
AGGG
CTTGTTCTCCTCGCGCA
TTCC
p14ARF CGCCGTGTCCAGATGTCG
TGCTCTATCCGCCAATCAGG
p16INK4a GGGCTCTCACAACTAGG
AAAG
GGGTGTTTGGTGTCAT
AGGG
H19 GCGAGCCGTAAGCACAGC
GCCGATTCCCATCCAGT
TGAC
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immunoblot analysis of extracts from mock-treated cells (lanes
1 and 2) or cells transduced with lentiviruses expressing
shRNAs directed against BRG1 (lanes 3 and 4) revealed a dra-
matic shRNA-mediated loss of BRG1. Next, we used lentiviral
transduction of viruses expressing either GFP (lanes 1 and 3)
or hSNF5 (lanes 2 and 4) to test the effect of hSNF5 reexpres-
sion in cells depleted of BRG1. Western immunoblotting con-
firmed our earlier observation (26) that hSNF5 reexpression
did not influence BRG1 levels (Fig. 3A, compare lanes 1 and
2). Antibodies directed against histone H3 were used as a
loading control. In agreement with our earlier results, hSNF5
expression in mock-treated cells led to a robust induction of
both 15INK4b and p16INK4a, but not of p14ARF, as revealed by
RT-qPCR (Fig. 3B). However, in BRG1-depleted cells hSNF5
could no longer activate 15INK4b and p16INK4a expression. Sur-
prisingly, the low level of p14ARF expression was reduced fur-
ther due to the loss of BRG1, indicating a potential role for
BRG1, but not hSNF5. We conclude that hSNF5-mediated
induction of 15INK4b and p16INK4a is critically dependent on
BRG1, the key catalytic subunit of SWI/SNF.
SWI/SNF displaces PcG silencing complexes. Overexpres-
sion of the PcG protein BMI1 promotes oncogenesis in mice
through silencing of the INK4a-ARF locus (15). Growth of
normal and cancerous prostate cells is controlled by PcG pro-
tein CBX7-dependent repression of INK4a-ARF (2). Re-
cently, it was observed that both PcG complexes PRC1 and
PRC2 can directly bind and silence the INK4a-ARF locus (5,
20). Because hSNF5 expression in MRT cells leads to SWI/
SNF recruitment to the p15INK4b and p16INK4a promoters, we
tested its effect on PcG complex binding. First, we established
whether in MRT cells PcG silencers occupy the INK4b-ARF-
INK4a locus by ChIPs directed against the PRC1 subunit
BMI1 and the PRC2 subunits EZH2 and Suz12 (Fig. 4A to C).
We observed strong binding of PcG silencers to the p16INK4a
promoter region (primer sets E and F) in the absence of
FIG. 2. hSNF5 mediates BRG1 recruitment to the p15INK4b and
p16INK4a promoters. (A) ChIP-qPCR analysis of hSNF5 binding to the
INK4b-ARF-INK4a locus revealed that hSNF5 binds directly to the
p15INK4b and p16INKa promoters, but not to p14ARF. Cross-linked chro-
matin was isolated from MRT cells that either lack (light green bars)
or express (dark green bars) hSNF5. qPCR primer sets correspond to
the p15INK4b promoter (A), the p14ARF promoter (B), an intergenic
control region (C), and various regions of the p16INK4a locus (sets D to
I). Primer sets E and F cover the p16INK4a promoter. The positions of
the amplified regions on the INK4b-ARF-INK4a locus are indicated at
the bottom. (B) BRG-1 binding to the p15INK4b and p16INK4a promot-
ers is hSNF5 dependent, as revealed by ChIP-qPCR with antibodies
directed against BRG-1. The procedures were as described in the
legend to Fig. 1.
FIG. 3. BRG1 is required for hSNF5-mediated induction of
p15INK4b and p16INK4a. (A) Western blot analysis of the BRG1 protein
levels in MON cell extracts prepared 4 days after BRG1 knockdown
using lentiviral transduction with viruses expressing shRNA targeting
BRG1 mRNA (clone 15549; Open Biosystems; top panel, lanes 3 and
4). As a control, cells were transduced with lentiviruses expressing
GFP. One day after transduction with either GFP- or shRNA-express-
ing lentiviruses, cells were transduced again with viruses expressing
either GFP (middle panel, lanes 1 and 3) or hSNF5 (lanes 2 and 3).
Cell extracts were prepared 72 h after hSNF5 expression. Histone H3
serves as a loading control. (B) Loss of BRG1 abrogates transcrip-
tional activation of p15INK4b and p16INK4a by hSNF5. Relative expres-
sion levels of p15INK4b, p14ARF, and p16INK4a in these cells were deter-
mined by RT-qPCR of isolated mRNA, 72 h after hSNF5 expression.
The bar graphs represent the mean of three independent experiments,
each analyzed in triplicate by RT-qPCR.
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hSNF5. Outside this domain of �0.8 kb, PcG protein binding
tapers off across the locus. Relatively low amounts of PcG
proteins were detected at the p14ARF and p15INK4b promoters.
Strikingly, hSNF5 expression strongly reduces the binding of
both PRC1 and PRC2. We conclude that during p16INK4a
activation, SWI/SNF mediates the eviction of PcG silencing
complexes. The PRC2 subunit EZH2 catalyzes histone H3
lysine 27 trimethylation (H3-K27me3), a chromatin mark as-
sociated with gene repression (29, 32). Although this could be
due to ChIP efficiency, the H3-K27me3 histone mark appears
to spread more broadly than PRC2 (Fig. 4D). Clearly, H3-
K27me3 is not a stable mark but is reduced upon hSNF5
expression and removal of PRC2. This is likely to be the result
of the action of the recently identified H3-K27me3 demethyl-
ases (1, 21). Finally, we note that the loss of PcG protein
binding was not due to a change in their expression, as revealed
by Western blotting (Fig. 4E). In conclusion, our results dem-
FIG. 4. Restoration of SWI/SNF causes eviction of PcG silencers and
loss of H3-K27 methylation. ChIPs using antibodies directed against BMI1
(A), EZH2 (B), SUZ12 (C), and H3-K27me3 (D) were performed. Cross-
linked chromatin was isolated from MRT cells that either lack (yellow bars)
or express (dark green bars) hSNF5. ChIPs were analyzed by qPCR using
primer sets specific for the regions indicated by A to I along the INK4b-ARF-
INK4a locus, revealing that PcG silencer binding peaks at the p16INK4a pro-
moter. After hSNF5 induction both PRC1 (BMI1) and PRC2 (EZH2 and
SUZ12) were removed, and H3-K27me3 was strongly reduced. H3-K27me3
ChIPs were normalized to H3 ChIP. Procedures were as described in the
legend to Fig. 1. (E) hSNF5 expression does not affect BMI1, SUZ12, and
EZH2 levels.Western immunoblotting analysis of BMI1, SUZ12, andEZH2
expression in MON cells transduced by either GFP- or SNF5-expressing
lentiviruses. Cell lysates were resolved by SDS-PAGE and analyzed byWest-
ern immunoblotting with antibodies to BMI1, SUZ12, and EZH2, respec-
tively. Histone H3 serves as a loading control.
FIG. 5. hSNF5 induced recruitment of H3-K4 methylase MLL1.
ChIPs with antibodies directed against H3-K4me3 (A) and MLL1
(B) reveal increased H3-K4me3 and MLL1 binding at p15INK4b and
p16INK4a after hSNF5 expression. Cross-linked chromatin was isolated
from MRT cells that either lack (yellow bars) or express (dark green
bars) hSNF5. ChIPs were analyzed by qPCR using the primer sets
specific for the regions indicated by A to I along the INK4b-ARF-
INK4a locus. Histone H3-K4me3 ChIPs were normalized to histone
H3 ChIP. The procedures were as described in the legend to Fig. 1.
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at the p15INK4b promoter were comparably low, again we ob-
served a clear reduction. These effects were gene selective,
because CpG methylation at p14ARF or the imprinted H19
locus remained unchanged. Next, we examined the distribution
of the DNAmethyltransferase DNMT3B, which has previously
been associated with PcG silencing (31, 39). ChIPs revealed
that, similar to the PcG silencers, DNMT3B binding peaks at
the p16INK4a promoter region and tapers off to a low level
across the locus. However, concomitant with the drop in CpG
methylation, DNMT3B is evicted from the locus after SWI/
SNF binding (Fig. 6B). Western immunoblotting demon-
strated that the loss of DNMT3B binding is not caused by a
reduced expression (Fig. 6C). We conclude that, similar to the
chromatin association of PcG silencers, DNA methylation can
be highly dynamic and modulated by SWI/SNF recruitment.
Next, we tested the effect of the DNA methylation inhibitor
5-azadC on the expression of the INK4b-ARF-INK4a locus in
MRT cells. We incubated MON MRT cells with 5-azadC,
followed by transduction with either GFP- or hSNF5-express-
ing lentiviruses. Expression analysis by RT-qPCR revealed that
the addition of 5-azadC resulted in a robust induction of
p15INK4b and p16INK4a, but not of p14ARF. Thus, treatment with
a DNA methylation inhibitor leads to transcriptional derepres-
sion, supporting the functional importance of CpG methyl-
ation in p15INK4b and p16INK4a silencing. When 5-azadC treat-
ment was combined with hSNF5 reexpression, we observed
modestly additive stimulation of p15INK4b and p16INK4a tran-
scription, whereas p14ARF remained unaffected. The absence
of synergism could be interpreted as a suggestion that removal
of CpG methylation and SWI/SNF action ultimately have sim-
ilar consequences for the local chromatin structure. Again,
these findings emphasize the close interconnectivity of various
chromatin structure modulating activities.
DISCUSSION
The loss of hSNF5 in MRT cells precludes SWI/SNF binding
to the p15INK4b and p16INK4a promoters, which are both stably
silenced in these cells. By reexpressing hSNF5 in MRT cells,
we created a switch allowing us to study the effect of SWI/SNF
recruitment to a silenced locus bound by PcG silencers. Reex-
pression of hSNF5 in MRT cells overcomes epigenetic silenc-
ing and mediates transcriptional activation of p15INK4b and
p16INK4a. In contrast, p14ARF is not induced, demonstrating
that the INK4b-ARF-INK4a locus is not coordinately regulated
in MRT cells. Because SWI/SNF itself lacks sequence-specific
DNA-binding activity, an important future goal is the identi-
fication of promoter binding recruiters. An issue that has re-
mained unresolved for a considerable time is whether hSNF5
functions as part of the SWI/SNF complex or if it acts inde-
pendently. shRNA-mediated depletion of BRG1 revealed that
hSNF5 was completely dependent on the motor subunit of the
SWI/SNF complex to activate either p15INK4b or p16INK4a.
Thus, it appears that gene activation by hSNF5 is dependent on
BRG1-mediated chromatin remodeling. These results dovetail
well with our functional dissection of Drosophila SWI/SNF
remodelers in genome wide expression control (7, 23, 26). Both
studies suggest that SWI/SNF subunits do not function outside
the remodeling complexes.
Although the whole INK4b-ARF-INK4a locus is inactive, it is
not evenly coated by PcG silencing complexes. Instead, we
found that PRC1 and PRC2 binding peaks at the repressed
p16INK4a promoter. These results indicate that the �0.8-kb
p16INK4a promoter area might function as a nucleation site for
PcG complex recruitment. The H3-K27me3 mark appears to
spread more broadly than the PcG proteins, indicative of a
“kiss-and-go” mechanism of histone methylation by PRC2. A
similar difference in the pattern of distribution of H3-K27me3
and PRC2 has been observed for Drosophila PREs and asso-
ciated genes (18, 27). In contrast to the purported primacy of
PRC1 prebinding over SWI/SNF action (35), we found that in
MRT cells PRC1 could be effectively displaced by SWI/SNF.
In fact, SWI/SNF binding initiates a cascade of chromatin
reprogramming, which completely resets the epigenetic status
of p15INK4b and p16INK4a but leaves p14ARF largely unaffected.
The trxG activators SWI/SNF and MLL1 supplant their antag-
onists PRC1, PRC2, and the DNA methyltransferase
DNMT3B. Concomitant with RNA Pol II recruitment and
gene transcription, active histone marks replace repressive
ones, and DNA methylation at the p16INK4a promoter is
strongly reduced. We speculate that during stem cell differen-
tiation, SWI/SNF remodelers might play a comparable role in
removal of PcG silencers from genes that need to be expressed.
Previous studies have suggested a functional association be-
tween PcG silencing and CpG methylation by DNA methyl-
transferases such as DNMT3B (31, 39). Here, we observed that
DNMT3B was displaced by SWI/SNF action concomitantly
with the PcG silencing complexes. Moreover, we found that
addition of the DNA methylation inhibitor 5-azadC leads to
the transcriptional derepression of p15INK4b and p16INK4a,
whereas p14ARF remained unaffected. These results support
the functional importance of CpG methylation for the silenc-
ing of these genes in MRT cells and might have therapeutic
implications. Combining the 5-azadC treatment with hSNF5
expression in MRT cells resulted in modestly additive stimu-
lation of p15INK4b and p16INK4a transcription. We interpret this
absence of synergistic activation as an indication that the re-
moval of CpG methylation and SWI/SNF action start a cascade
that results in similar changes in chromatin structure. Collec-
tively, these findings emphasize the intertwined dynamics of
diverse chromatin marks and SWI/SNF function during tran-
scriptional regulation.
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SUMMARY 
The INK4b-ARF-INK4a tumor suppressor locus controls the balance between progenitor cell 
renewal and cancer. Here, we investigated how chromatin structure modulates differential 
expression of the human INK4b-ARF-INK4a locus during cellular differentiation, aging and 
senescence. p15INK4b and p16INK4a, but not p14ARF, are coordinately up-regulated following 
differentiation of hematopoietic progenitor cells, in aging fibroblasts and senescent malignant 
rhabdoid tumor cells. Following progenitor cell differentiation and aging, Polycomb group 
(PcG) silencer EZH2 is down-regulated, causing reduced locus occupancy and induction of 
p15INK4b and p16INK4a. EZH2 controls the formation of a ~40 kb repressive chromatin loop 
linking INK4b and INK4a, but excluding ARF. Attenuated EZH2 expression causes loop opening 
and de-repression of p15INK4b and p16INK4a. Our results support a looping mechanism of long-
range locus control rather than continuous spreading of PcG silencing. We conclude that PcG 
proteins regulate higher order chromatin structure dynamically to balance differentiation and 
proliferation of human cells. 
 
INTRODUCTION 
Development and homeostasis require the coordinate regulation of cell proliferation and 
differentiation. The INK4b-ARF-INK4a tumor suppressor locus plays a central role in 
controlling the balance between progenitor cell renewal and cancer (13, 15, 17, 25). This 
locus encodes three cell cycle inhibitory proteins: p15INK4b, p14ARF and p16INK4a. p15INK4b and 
p16INK4a are closely related proteins and both act through inhibition of the cyclin-dependent  
kinases CDK4 and CDK6, which promote proliferation (9, 22).  p14ARF is structurally and 
functionally unrelated to  p15INK4b or p16INK4a,  and works primarily through activation of the 
p53 pathway.  A multitude of studies have suggested a role for the INK4b-ARF-INK4a locus in 
cancer suppression and promotion of aging (9). In particular p16INK4a, has been proposed to 
control the equilibrium between proliferation of progenitor cells and tissue renewal on the one 
hand and the risk of tumorigenesis on the other. Perhaps not surprising, the regulation of the 
INK4b-ARF-INK4a locus is highly complex. Coordinate regulation of the whole locus, as well as 
individual patterns of gene expression, have been described (1, 9, 14). Thus, the INK4b-ARF-
INK4a locus appears to be expressed differentially, depending on the circumstances.  
 The polycomb group (PcG) silencers form an important class of transcriptional 
corepressors that regulate expression of the INK4b-ARF-INK4a locus . This was first suggested 
by the finding that the PcG protein BMI1 promotes oncogenesis in mice through silencing of 
INK4a (12). Since then, other PcG silencers have also been implicated in silencing of the 
INK4b-ARF-INK4a locus, including the histone H3 lysine 27 (H3K27) methyltransferase EZH2 
(1). PcG proteins function as part of larger multi-protein assemblages, referred to as 
Polycomb repressive complexes (PRCs). PRC1-like complexes, which include assemblages with 
BMI1 as a subunit, form one major class. Recent research in flies uncovered that PSC, the fly 
BMI1 homolog, is also part of an alternate complex named dRAF (18). PRC2-like complexes 
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that harbor histone H3K27 methylases, such as EZH2, form the second major class. However, 
it is important to stress that there is likely to be a greater variety of PRCs and possible 
enzymatic activities (26). Both PRC1 and PRC2 complexes directly bind and silence the INK4a-
ARF locus (1, 6, 14, 16). Although the developmental roles of many PcG proteins await further 
analysis, recent research has emphasized their importance in dynamic gene control during 
differentiation of precursor cells, cancer and senescence (2, 7, 28-31,1, 6, 14, 29)). In 
particular, several studies have shown the importance of EZH2 for dynamic regulation of gene 
silencing orchestrating the differentiation of progenitor cells.  
Here, we have addressed the role of PcG silencers in the regulation of the human 
INK4b-ARF-INK4a locus during cellular aging, differentiation of progenitor cells and cellular 
senescence of human cancer cells. During these physiological processes we noted a 
remarkable pattern of INK4b-ARF-INK4a expression:  p15INK4b and p16INK4a were coordinately 
induced, whereas p14ARF remained unaltered. We found that EZH2 controlled the selective de-
repression of p15INK4b and p16INK4a. Our results support a looping mechanism of long-range 
control rather than “blanket” spreading across the INK4b-ARF-INK4a locus. We conclude that 
higher order chromatin conformation of the INK4b-ARF-INK4a locus underlies the coupling of 
cell differentiation to proliferation control. 
 
RESULTS 
Differential induction of the human INK4b-ARF-INK4a locus during aging, 
differentiation and senescence 
 
To investigate the effects of cellular aging on expression of the human INK4b-ARF-INK4a 
locus, we compared p15INK4b, p14ARF and p16INK4a expression in neonatal versus adult human 
diploid fibroblasts (HDFs). We also compared human embryonic fibroblasts (HEFs) with a low 
passage number with older cells. We noted that in aging cells the proliferative capacity 
diminished. The proliferation rate of adult HDFs is 2-3 fold slower than that of neonatal HDFs. 
Likewise during culturing of HEFs, we observed a gradual up to 2-3-fold increase in doubling 
time as the passage number becomes higher. To monitor INK4b-ARF-INK4a expression, we 
extracted RNA and used reverse transcription followed by real-time quantitative PCR (RT-
qPCR) with gene-selective primers (Figure 1B and C). In HDFs and in HEFs, we detected a 
strong up-regulation of p15INK4b and p16INK4a, but not of p14ARF, in old (blue) versus young cells 
(yellow).  
To study the expression of the INK4b-ARF-INK4a locus in cells with a broad versus 
restricted potential for differentiation, we compared CD34+ with CD34- cells isolated from 
human umbilical cord blood (Figure 1D). CD34+ cells comprise immature committed 
hematopoietic progenitor cells, including short term- hematopoietic stem cells, multipotent 
progenitors and common myeloid progenitors. The pool of mature CD34- cells is formed to a 
large extend by a variety of more highly differentiated cells, including lymphoblasts, late 
hematopoietic progenitors, and mature cells such as late erythroblasts and granulocytes. A 
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direct comparison of immature CD34+ cells (yellow) with mature CD34- cells (green), revealed 
up-regulation of p15INK4b and p16INK4a, but not of p14ARF, following differentiation. When the 
isolated CD34+ cells were cultured for 6 weeks, the majority (~80%) matured and became 
CD34-, as revealed by FACS analysis and cell staining (see Figure D, bottom panels).  
 
 
Figure 1.Gene regulation of INK4-ARF during aging, differentiation and senescence 
(A) Organization of the human INK4b-ARF-INK4a locus (not drawn to scale). The genomic locus spans approximately 40 Kbp 
of human chromosome 9, and encodes three distinct proteins, p15INK4b, p14ARF and p16INK4a. The 5’ and 3’ untranslated 
regions (yellow boxes), the coding sequences of p15INK4b (green), p14ARF (blue) and p16INK4a (red) are indicated. (B) RT-qPCR 
analysis of gene expression in Human Diploid Fibroblast reveals induction of p15INK4b and p16INK4a, in adult cells (blue bar) 
compared to neonatal cells (yellow bar) whereas p14ARF transcription remains unaffected. (C) RT-qPCR analysis of gene 
expression in Human Embryonic Fibroblast (TIG3) reveals the induction of p15INK4b and p16INK4a, in the old cells (at passage 
Doubling: PDL: 64, blue bar) compared to the young cells (PDL: 26, yellow bar), whereas p14ARF transcription remains 
unaffected.  (D) RT-qPCR analysis of gene expression in Committed progenitor cells, derived from umbilical cord blood after 
cell sorting with CD34 marker, reveals induction of p15INK4b and p16INK4a, in matured cells (CD34-, green bar) and immature 
cells were kept 6 weeks in culture, blue bar) compared to immature cells (CD34+, yellow bar) whereas p14ARF transcription 
remains unaffected (upper part), fluorescence activated cell sorter (FACS) graphs (Middle part). In the lower panels, cells 
were cytocentrifuged onto glass slides and stained with cytologic dyes. (E) RT-qPCR analysis of gene expression in 
Megakaryocyte Erythrocyte progenitor (MEP) cells derived from human fetal liver reveals induction of p15INK4b and p16INK4a in 
differentiated cells toward the Erythrocyte (blue bar) compared to proliferative cells (yellow bar), whereas p14ARF transcription 
remains unaffected. RT-qPCR analysis of isolated mRNA was used to determine the relative expression levels of p15INK4b, 
p16INK4a, p14ARF and GAPDH.  E) RT-qPCR analysis of gene expression in MRT cells reveals hSNF5-dependent induction of 
p15INK4b and p16INK4a, whereas p14ARF transcription remains unaffected. Cells were collected 48 hours following transduction 
with lentiviruses expressing either GFP (yellow bars) or hSNF5 (blue bars). RT-qPCR analysis of isolated mRNA was used to 
determine the relative expression levels of p15INK4b, p16INK4a, p14ARF and GAPDH. mRNA levels were plotted as percentage of 
GAPDH mRNA. The bar graphs represent the mean of three independent biological replicates, each analyzed by three 
separate qPCR reactions. Standard deviations are indicated.  
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Again cell differentiation was accompanied by a robust induction of p15INK4b and a 
particularly strong up-regulation of p16INK4a. In contrast, p14ARF expression remained 
unaltered. As an alternative way to study the effects of cell differentiation, we isolated 
megakaryocyte and erythrocyte progenitor (MEP) cells from human fetal liver and induced 
differentiation towards erythrocytes (Figure 1E bottom).  When we compared proliferating 
MEPs with their progenitors differentiating towards erythrocytes, we detected a clear induction 
of p15INK4b and p16INK4a, but not of p14ARF. We conclude that differentiation of human MEP and 
CD34- multi-potent progenitor cells is accompanied with selective up-regulation of p15INK4b and 
p16INK4a. 
As a model for senescence, we used human malignant rhabdoid tumor (MRT) cells 
that are caused by a loss of the hSNF5 subunit of the SWI/SNF chromatin remodeling 
complex. Re-expression of hSNF5 in MRT cells restores SWI/SNF recruitment to INK4b and 
INK4a, causing eviction of PRCs and loss of silencing (14). Consequently, these cells first 
undergo a G1/S cell cycle arrest and later become senescent (Figure 1F). In contrast to 
p15INK4b and p16INK4a, p14ARF expression remained unaltered.  
In conclusion, here we demonstrated coordinate induction of human p15INK4b and 
p16INK4a, but not p14ARF, during cellular aging, multi-potent progenitor cell differentiation or 
induction of senescence. 
 
 
EZH2 is down-regulated during progenitor cell differentiation and aging  
Because the PcG silencers EZH2 and BMI1 play important roles in repression of the INK4b-
ARF-INK4a locus, we investigated their expression during aging and cellular differentiation.  
RT-qPCR and Western immunoblotting revealed clear down-regulation of EZH2 in aging HDFs 
whereas BMI1 levels remained stable (Figure 2A). When we compared proliferating MEPs with 
differentiating cells we again observed reduction of EZH2, but not of BMI1 (Figure 2B). 
Likewise, CD34+ progenitor cells, isolated from umbilical cord blood, expressed much higher 
levels of EZH2 than mature CD34- cells (Figure 2). When CD34+ cells were cultured for 6 
weeks, they matured and lost CD34 expression. Concomitant with differentiation, EZH2 
expression was strongly attenuated, whereas BMI1 levels remained stable. We conclude that 
during aging of HDFs and differentiation of hematopoietic progenitor cells, expression of the 
PRC2 subunit EZH2 is down-regulated, whereas levels of the PRC1 subunit BMI1 remain 
constant. Obviously, reduction of EZH2 provides an attractive explanation for de-repression of 
INK4a and INK4b. However, hSNF5-dependent induction of p16INK4a and p15INK4b in MRT cells 
does not involve down-regulation of EZH2 (Figure 2D). In MRT cells, re-expression of SNF5 
enables SWI/SNF recruitment to INK4a and INK4b leading to eviction of PRCs and de-
repression (14). 
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Figure 2. Induction of p15INK4b & p16INK4a is accompanied by down-regulation of E(z)h2 
(A-C) RT-qPCR analysis of gene expression in Human Diploid Fibroblast, Megakaryocyte-Erythrocyte progenitor, Committed 
progenitor cells reveals reduction of EZH2, during aging and differentiation respectively (left side panel) in adult cells (blue 
bar) compared to neonatal cells (yellow bar). Western immunoblotting analysis of BMI1 and EZH2 expression in HDF, MEP 
and Committed progenitor cells revealed reduction of EZH2 during the aging and differentiation, while the BMI-1 level didn’t 
change. Histone H3 serves as a loading control. (D) hSNF5 expression does not affect BMI1 and EZH2 levels. Western 
immunoblotting analysis of BMI and EZH2 expression in MON cells transduced by either GFP- or SNF5 expressing lentiviruses. 
Cell lysates were resolved by SDS-PAGE and analyzed by Western immunoblotting using antibodies against BMI1 and EZH2 
respectively. Histone H3 serves as a loading control. (E) RNA pol II promoter binding was analyzed by ChIP-qPCR. Cross-
linked chromatin was prepared from HDF- neonatal (light green bars), and HDF-adult (dark green bars). ChIPs with antibodies 
directed against RNA pol II were analyzed by qPCR using primer sets corresponding to the p15INK4b, p14ARF and p16INK4a 
promoters. ChIP signal levels for each region are presented as percentage of input chromatin. (F-G) Down-regulation of 
E(z)h2 and reduced locus occupancy of PcG repressors. ChIPs using antibodies directed against (F) EZH2 and (G) BMI1. 
Cross-linked chromatin was isolated from HDF cells neonatal (light green bars) or adult (dark green bars). ChIPs were 
analyzed by qPCR using primer sets specific for the regions indicated by A-M along the INK4b-ARF-INK4a locus, revealing that 
PcG silencer binding peaks at the p16INK4a promoter and 3 kb upstream of p15INK4b. During aging both PRC1 (BMI1) and PRC2 
(EZH2) are removed or strongly reduced.   QPCR primer sets correspond to the upstream of  p15INK4b promoter (A-H), the 
p14ARF promoter (I), an intergenic control region (J), and various regions of the p16INK4a locus (sets K-M). Primer sets K and L 
cover the p16INK4a promoter. The positions of the amplified regions on the INK4b-ARF-INK4a locus are indicated at the 
bottom. 
 
To examine the effects of EZH2 down-regulation in aging HDFs, we determined RNA 
Pol II, EZH2 and BMI1 occupancy of the INK4b-ARF-INK4a locus by chromatin 
immunoprecipitations (ChIPs) monitored by qPCR. Cross-linked chromatin was prepared from 
neonatal HDF (light yellow bars), and adult cells (dark green bars). ChIPs with antibodies 
directed against RNA pol II revealed increased recruitment upon aging, in agreement with 
enhanced transcription (Figure 2E). Next, we established the pattern of binding of PcG 
silencers to the INK4b-ARF-INK4a locus in neonatal HDFs by ChIPs using antibodies directed 
against EZH2 and BMI1 (Figure 2F and G). We observed strong binding of EZH2 and BMI1 to 
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two well defined regions: the p16INK4a promoter region (primer sets K and L) and an area 
~3kb upstream of the INK4b promoter (primer sets C and D). The peaks of PcG binding are 
confined to ~0.8 kb areas. More detailed mapping of binding to the INK4a locus revealed a 
pattern similar to what we published earlier for MRT cells (data not shown, (14). Outside the 
two domains upstream of INK4b and INK4a, PcG protein binding across the INK4b-ARF-INK4a 
locus was low. Although only EZH2 was down-regulated in aging HDFs, both EZH2 and BMI1 
occupancy at INK4a and INK4b was strongly reduced. Together, these results show that 
attenuation of EZH2 is accompanied by a loss of both PRC1 and PRC2-binding, recruitment of 
RNA Pol II and induction of INK4a and INK4b. Importantly, ARF expression remained 
unaffected and is not co-regulated with INK4a and INK4b in the human cells studied here. Our 
results suggest a critical role for EZH2 in the selective regulation of INK4a and INK4b 
expression. 
 
EZH2 is required for coordinate silencing of p15INK4b and p16INK4a 
To test whether EZH2 is critical for silencing of INK4a and INK4b, we used a shRNA strategy 
to attenuate its levels in neonatal HDFs.  Cells were transduced with lentiviruses expressing 
either shRNAs targeting EZH2 mRNA or a scrambled control. Three days following 
transduction, EZH2 levels were effectively knocked down in cells treated with the appropriate 
shRNA (Figure 3A). However, BMI1 levels remained unaffected. Loss of EZH2 caused a strong 
induction of p16INK4a and p14INK4b, but not of ARF (Figure 3B). Likewise, RNA Pol II was 
selectively recruited to the INK4a and INK4b loci, as revealed by ChIP-qPCR (figure 3C). 
Depletion of EZH2 not only caused dramatically reduced binding of itself, but also of BMI1 to 
INK4a and INK4b (Figure 3 D and E). Taken together, these results suggest that EZH2 
attenuation is sufficient for dissociation of PcG silencers from the INK4b and INK4a loci, RNA 
Pol II recruitment and induction of p16INK4a and p14INK4b. 
  
 
A repressive chromatin loop, linking INK4a and INK4b, is released during aging, 
cellular differentiation, and senescence   
Because of their coordinate regulation by PcG silencers, we wondered whether INK4a and 
INK4b might be in close physical proximity, in spite of being separated by ~35 kb of 
intervening DNA. We used chromatin conformation capture (3C) technology in combination 
with qPCR (5, 33) to investigate the three-dimensional conformation of the human INK4b-
ARF-INK4a locus, during aging, differentiation and senescence. We first compared the higher-
order chromatin structure in neonatal versus adult HDFs (Figure 4A). Cells were cross-linked 
with formaldehyde, followed by chromatin isolation, and restriction digestion with EcoR1. 
Samples were ligated under conditions that favor the union of DNA fragments that are 
physically connected and qPCR across junctions was used to determine the relative cross- 
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Figure 3.   E(z)h2 is required for coordinate silencing  of  p15INK4b and p16INK4a  
(A) RT-qPCR analysis of gene expression and western blot analysis of the EZH2 protein levels in HDF-neonatal cell extracts 
prepared 3 days after EZH2 knock down using lentiviral transduction with viruses expressing shRNA targeting EZH2 mRNA 
(Clone TRCN0000040073 and TRCN0000040075; Open Biosystems) As a control cells were trasnduced with scramble. Histone 
H3 serves as a loading control. (B) Loss of EZH2 causes transcriptional activation of p15INK4b and p16INK4a. Relative expression 
levels of p15INK4b, p14ARF and p16INK4a in these cells were determined by RT-qPCR of isolated mRNA, 72 hours following EZH2 
knock down. The bar graphs represent the mean of three independent experiments, each analyzed in triplicate by RT-qPCR. 
(C) RNA pol II promoter binding was analyzed by ChIP-qPCR. Cross-linked chromatin was prepared from HDF-Neonatal 
control (light green bars), and HDF-neonatalEZH2 KD (dark green bars). All ChIP data presented in this study are the result 
of at least three independent experiments. (D-E) E(z)h2 depletion (KD) causes loss of PcG  repressors on the INK4b and  
INK4a loci. ChIPs using antibodies directed against (D) EZH2 and (E) BMI1. Cross-linked chromatin was isolated from HDF 
neonatal cells transduced either with scramble (light green bars) or EZH2KD (dark green bars) lentiviral vectors. ChIPs were 
analyzed by qPCR using primer sets specific for the regions indicated by A-M along the INK4b-ARF-INK4a locus, revealing that 
PcG silencer binding peaks at the p16INK4a promoter and 3 kb upstream of p15INK4b and will be removed or reduced upon 
depletion of EZH2.Procedures were as described in the legend to Fig. 2.  
 
linking frequency between restriction fragments. All 3C data presented here are the result of 3 
fully independent biological replicate experiments. Cross-linking frequencies were determined 
of 10 suitable EcoRI fragments across almost 70 kb of DNA encompassing the INK4b-ARF-
INK4a locus. The ‘constant’ primer and the TaqMan probe were designed in the EcoRI 
fragment -4 to -2 kb upstream of INK4b, harboring the PRC-binding sequences (Figure 4A). 
Plotting of the ligation frequencies to this “bait” fragment (grey bar) revealed a clear peak at 
fragment 9 corresponding to the INK4a promoter proximal region, overlapping the PRC-
binding region. These experiments were complimented by 3C analysis using a “bait” fragment 
near the INK4a promoter. Now, we observed a peak at fragment 2, encompassing the PRC-
binding domain upstream of the INK4b promoter (Figure 4B). We conclude that in neonatal 
HDFs, the repressed INK4b-ARF-INK4a locus has a looped structure. The loop is formed by 
interaction of the PRC-binding regions: one upstream of INK4b and the second formed by the 
INK4a promoter region. Within this higher-order chromatin structure, the almost 40 kb of 
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intervening DNA including the ARF promoter and first exon loops out. What structure is 
adopted by the INK4b-ARF-INK4a locus in adult HDFs, when both INK4b and INK4a are 
expressed? Strikingly, 3C-qPCR analysis in adult HDFs revealed a loss of long-range 
interaction between INK4a and INK4b, suggesting the locus adopted a linear conformation 
(Figure 4A-B). These results suggest that during aging, the repressive chromatin loop 
dissolves concomitant with EZH2 attenuation and increased transcription of INK4a and INK4b. 
To study the effects of cellular differentiation, we undertook a similar 3C analysis of 
chromatin structure comparing undifferentiated with differentiating MEPs (Figure 4C and D). 
3C-qPCR analysis revealed clear evidence for a chromatin loop between INK4a and INK4b in 
undifferentiated, proliferating MEPs. When these progenitor cells were induced to differentiate 
towards erythocytes, the silent chromatin loop dissolved, concomitant with INK4a and INK4b 
de-repression. Finally, we compared proliferating MON MRT cells, lacking hSNF5, with arrested 
cells after hSNF5 expression. As we have shown above (Figure 2D), in these cells EZH2 levels 
remain stable. Rather, PRCs are removed from INK4a and INK4b in a SWI/SNF-dependent 
manner, leading to comprehensive chromatin reprogramming (14). Following hSNF5 
expression and PRC removal, the repressive chromatin loop is released and the INK4b-ARF-
INK4a locus assumes a linear conformation (Figure 4E and F). 
 
In summary, our results show that in young and progenitor cells the repressed 
INK4b-ARF-INK4a locus assumes a ~40 kb looped conformation. The chromatin loop links the 
PRC-binding regions of INK4a and INK4b, whilst excluding ARF. In aging or differentiating 
cells, the loop dissolves and expression of INK4a and INK4b is induced. The loss of looping is 
concomitant with loss of PRC-binding, which in aging HDFs and differentiating progenitor cells 
is caused by in down regulation of EZH2. Consequently, it is tempting to speculate that EZH2 
is critical for loop formation. In MRT cells going into senescence, EZH2 levels remain stable, 
but the PRCs are removed from INKa and INK4b regulatory domains by SWI/SNF action. This 
duly leads to release of the repressive loop and gene activation, suggesting PRC-binding is 
required for looping. 
 
EZH2 is required for chromatin looping 
To test whether EZH2 is crucial for loop formation, we transduced neonatal HDFs with 
lentiviruses expressing either a shRNA targeting EZH2 mRNA or a scrambled control. As 
shown above, depletion of EZH2 leads to a loss of PRC binding to INK4a and INK4b upstream 
regions (Figure 3). 3C-qPCR analysis revealed that loss of EZH2 also results in release of the 
repressive chromatin loop that links INK4a and INK4b (Figure 5A and B). In MRT cells, hSNF5 
re-expression leads to SWI/SNF-mediated eviction of PRCs at INK4a and INK4b. This alternate 
mechanism of PRC removal also leads to loss of chromatin looping between INK4a and INK4b 
(Figure 4E and F). Nevertheless, in these cells looping is still EZH2-dependent. Depletion of 
EZH2 in the absence of hSNF5 expression, also led to loss of the repressive chromatin loop 
(Figure 5C and D). Taken together, these results support the notion that PRC binding is critical 
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for chromatin looping at the INK4b-ARF-INK4a locus. When PRC binding is lost, either due to 
diminished EZH2 levels in aging or differentiating cells or because of SWI/SNF action in MRT 
cells, the repressive chromatin loop is released, allowing up-regulation of INK4a and INK4b. 
 
 
Figure 4. A repressive loop between p15INK4b & p16INK4b is resolved upon differentiation, aging or senescence   
 3C-qPCR analysis of long-distance interactions at the Human INK4-ARF locus. The relative level of each ligation product 
(fragments 1 to 10) has been plotted from position 21.932731 to 22.009.342 on chromosome 9 according to UCSC Genome 
Browser at http://genome.ucsc.edu/cgi-bin/hgTracks (see map below graphs). The ‘constant’ primer and the TaqMan probe 
were designed in the ECORI fragment (-4 to -2 kb upstream of INK4b  or +36 kb to +37 kb downstream of INK4b) containing 
the polycomb binding region at INK4b and INK4a respectively (see Fig2.E-G). The locations of the constant fragment (gray 
segment) and candidate interacting fragments (red segments) are shown in the map. Restriction sites that will be used in the 
3C assay are depicted as small vertical bars in red. The value of relative crosslinking frequency is plotted to y-axis and the 
locations of various EcoRI sites used for the 3C analysis are plotted on the X-axis. The data were normalized to ERCC3 for 
normalizing crosslinking frequency. Three independent assays were performed for each sample. 3C-qPCR assays were 
performed on (A-B) HDF-Neonatal (Light purple line) or HDF-Adult (dark purple line) , (C-D) MEP cells proliferative Light 
purple line)or differentiated cells Light purple line) and (E-F) MRT cells were collected 48 hours following transduction with 
lentiviruses expressing either GFP Light purple line) or hSNF5 Light purple line). Three independent assays were performed 
for each sample. Error bars, S.D. of three independent experiments. 
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Figure 5. Looping between p15INK4b & p16INK4b is E(z)h2-dependent. 3C-qPCR assays were performed on (A-B) HDF-
neonatal cells were collected 72 hours following transduction with lentiviruses expressing either scramble (light purple line) or 
shRNA targeting EZH2 mRNA (dark purple line); and (C-D) MRT cells transduced with lentiviruses expressing either GFP (light 
purple line) or hSNF5 (dark purple line) and collected after 48 hours. Procedures were as described in the legend to Fig. 5. 
 
DISCUSSION 
Two classic problems in gene expression control are the mechanism of long range regulation 
and the regulation of multi-gene loci. Here, we studied how PcG silencers control the 
expression of the human INK4b-ARF-INK4a tumor suppressor locus during a variety of 
physiological processes. Our analysis led to the following conclusions: (1) During 
differentiation of human hematopoietic progenitor cells, in aging fibroblasts and following 
hSNF5-induced senescence of MRT cells, the INK4b-ARF-INK4a locus becomes differentially 
de-repressed.  p15INK4b and p16INK4a are coordinately up-regulated, whereas p14ARF levels 
remain unaltered. (2) This is caused by a down-regulation of EZH2 in differentiating 
hematopoietic progenitor cells and aging fibroblasts, leading to loss of PRC-binding.  (3) Our 
ChIP-qPCR analysis revealed non-homogeneous PRC binding to the INK4b-ARF-INK4a locus. 
EZH2 and BMI1 binding peaks at two well defined regions of ~800 bp: one overlapping the 
p16INK4a promoter region and the second area located ~3kb upstream of the p15INK4b 
promoter. (4) In MRT cells a different mechanism is operating.  Re-expression of hSNF5 
allows SWI/SNF to mediate PRC removal and loss of repression (14). (5) EZH2 is required for 
the formation of a ~40 kb chromatin loop linking INK4b and INK4a, but excluding ARF. 
Waning of EZH2 expression causes release of the repressive chromatin loop and up-regulation 
of p15INK4b and p16INK4a. Thus, EZH2 levels determine the higher order chromatin structure and 
differential expression of the INK4b-ARF-INK4a locus, which in turn couples human progenitor 
cell differentiation to proliferation control. (6) Collectively, our findings support a looping 
A B 
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mechanism that couples INK4b and INK4a expression control, but are difficult to reconcile 
with models invoking continuous spreading of PcG silencers. 
 Our results and recent studies (3, 4, 7), emphasize a crucial role for EZH2 in 
orchestrating progenitor cell differentiation and proliferation control. Similar to our findings in 
human hematopoietic progenitor cells and aging fibroblast, Ezhkova et al (2009), observed  
de-repression of INK4a and INK4b due to EZH2 down-regulation, which controlled the balance 
between the proliferative basal layer of progenitor cells and non-proliferating differentiated 
epidermal cells. The importance of EZH2 levels in balancing progenitor cell proliferation and 
differentiation might have sinister consequences. EZH2 is over-expressed in a variety of 
tumors (32), thus potentially blocking the tumor suppression function of INK4a and INK4b. In 
these cells, EZH2 seems to promote de-differentiation and uncontrolled proliferation. This is 
the opposite of its function during normal development. Together with early studies in 
Drosophila, these observations emphasize the importance of PcG protein dosage and 
regulation. It is interesting to note that in MRT cells, EZH2 levels are not elevated. In these 
cells the SWI/SNF chromatin remodeler is crippled due to loss of hSNF5 and unable to evict 
PRCs from the INK4b and INK4a regulatory elements (14). Thus, loss of function of a trxG 
antagonist might have similar consequences as over-expression of a PcG silencer. 
Previously, two studies promoted a continuous spreading of either 
heterochromatinization (10) or blanketing of the locus by PcG proteins (1). However, the data 
in the latter study actually revealed a clear peak of PRC binding at the INK4a promoter, which 
tapers off and is near background at the ARF gene. Based on the physiological processes 
studied here, we favor a discontinuous looping mechanism of INK4b-ARF-INK4a locus control 
over models invoking continuous spreading of silencers. Firstly, we observe two distinct peaks 
of PRC binding: ~3 kb upstream of INK4b and at the INK4a promoter. Outside these well 
defined areas PRC binding is near background levels, and we detected no significant PRC-
binding at ARF. Secondly, during cell differentiation and aging, INK4a and INK4b are 
coordinately de-repressed through EZH2 attenuation, whereas ARF remained unaffected. 
Finally, the PRC-bound INK4a and INK4b regulatory regions are linked in nuclear space. Loss 
of PRC-binding causes a release of the chromatin loop and up-regulation of INK4a and INK4b. 
These findings for the INK4b-ARF-INK4a locus dove-tail well with other studies revealing PcG-
mediated chromatin looping (19, 23, 34). We conclude that PcG proteins dynamically alter the 
higher order chromatin structure of the INK4b-ARF-INK4a locus to balance differentiation and 
proliferation of human cells. 
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EXPERIMENTAL PROCEDURES 
Cell culture and lentiviral procedures 
All tissue cultures were according to standard protocols. The human diploid embryonic 
fibroblast TIG3 were obtained from the Health Science Research Resource Bank (Osaka, Japan 
(http://cellbank.nibio.go.jp/celldata/jcrb0506.htm) and the Human diploid fibroblast Neonatal 
and Adult (purchased from Cascade Biologics ) were grown in DMEM supplemented with 10% 
(v/v) FCS. The hSNF5 expressing lentiviral vector was generated by replacing the GFP 
encoding sequence of pRRLsin.sPPT.CMV.GFP.Wpre (8) with the hSNF5 cDNA (27). High titer 
vector stocks were produced in 293T cells by co-transfection of transfer vector constructs with 
the packaging constructs using standard transfection procedures (8). Mon cells were 
transduced with the appropriate vector. To knock down EZH2, the cells were transduced with 
lentiviruses expressing shRNA directed against EZH2 (Clone TRCN0000040073 and 
TRCN0000040075; Expression ArrestTM-The RNAi consortium (TRC) Human shRNA library 
purchased from Open Biosystems) for 3 days. In a control experiment, the cells were 
transduced with scramble (non-targeting) lentiviruses as described before. 
 
Isolation of mononuclear cells from Human umbilical cord blood. 
Human umbilical cord blood samples (UCB) were collected from umbilical cord vein after full-
term delivery by the nursing staff of the department Obstetrics and Gynecology at the Sint 
Franciscus Hospital (Rotterdam, The Netherlands). Informed consent for taking the samples 
for clinical study was obtained. UCB was collected in sterile flasks containing 10 ml 1% 
heparin in H+H (Hanks + Hepes osmolarity 300), which had been stored at room 
temperature. Low-density cells were isolated from UCB by using Ficoll Hypaque density 
centrifugation (1.077g/cm2, Lymphoprep, Nycomed Pharma, Oslo, Norway). The cell 
suspension were centrifuged at 600 g for 15 minutes, then mononuclear cell (MNC) band at 
the interface were removed, washed twice with Hanks Balanced Salt Solution (HBSS, Gibco, 
Breda, The Netherlands). The accumulated cells immediately used to CD34+ isolation. The 
CD34+ cells were isolated by indirect CD34+ Microbead kit (Miltenyi Biotec). Isolated CD34+ 
cells had a purity of about 85-95%. 
The CD34+ cells were cultured in density of 1-3 x 104/ml in serum free medium. The medium 
was made of enriched DMEM which contains 1% (wt/vol) BSA, 0.3mg/L human transferrin, 
0.1μmol/L sodium selenite, 1mg/L nucleosides (cytidine, adenosine, uridine, guanosine, 2’-
deoxycytidine, 2’-deoxyaenosine, thymidine and 2’-deoxyguanosine, Sigma), 0.1mmol/L ß-
mercaptoethanol, 15μmol/L linoleic acid and 15μmol /L cholesterol, 100 U/mL penicillin, and 
100μg/mL streptomycin(24). The incubation condition was a humidified atmosphere of 10% 
CO2 and temperature of 37 °C. For stimulating cell expansion and proliferation, medium was 
supplemented with 100ng/ml stem cell factor (SCF), 100 ng/ml Flt3-L, and 20 ng/ml 
trombopoietin (TPO). The Cells have been kept in culture for 6 weeks and every week medium 
was refreshed. 
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Isolation of mononuclear cells from fetal liver.  
Human fetal tissues were obtained from elective abortions of patients who had previously 
signed consent forms for research studies, under a protocol approved by the Medical Ethical 
Commissions of the Academic Medical Center of Amsterdam and the Erasmus University 
Medical Center of Rotterdam. Fetal livers of fetus from were sterilely dissected and teased into 
PBS containing 0.5 mg/ml collagenase Type IV (Sigma ) using forceps and scissors. Cell 
suspensions were digested for 30 min at 37 °C with continuous stirring and were then filtered 
through a 70- m nylon mesh. Briefly, fetal livers of 8-22 weeks of human embryos were 
resuspended in serum-free stem cell medium (StemSpan; Stem Cell Technologies, Vancouver, 
BC,Canada).  For initial expansion, 5 ×106 cells/mL were cultivated in serum-free medium 
(StemSpan; Stem Cell Technologies, Vancouver, BC, Canada) supplemented with Epo (2 U/mL 
Erypo Janssen- Cilag, Baar, Switzerland), the synthetic glucocorticoid Dex (1 µM; Sigma, St 
Louis, MO) SCF (100 ng/mL; R&D Systems, Minneapolis, MN), and lipids (40 ng /mL 
cholesterol-rich lipid mix; Sigma) for about 5 days, the cells were fed every day by partial 
medium changes. From day 5 on, a small population of expanding erythroid progenitors 
became visible in cytospins, around day 7 as an increasing population of large, non-adherent 
cells ( 12 µm in diameter). The resulting proerythroblast culture was expanded by daily 
partial medium changes and addition of fresh factors, keeping cell density between 1.5–2 × 
10 6 cells/ml. Proliferation kinetics and size distribution of the cell populations were monitored 
daily in an electronic cell counter (CASY-1, Schärfe-System, Reutlingen, Germany). To induce 
terminal differentiation, proliferating erythroblasts were washed in ice-cold PBS and reseeded 
at 1-1.5 x 106 cells/mL in StemSpan supplemented with Epo (0.5mg/ml human transferring 
Holo (1 mg/mL; SCIPAC Ltd, UK)(20). Differentiating erythroblasts were maintained at 2 to 3 
x 106 cells/ml by daily cell counts and partial medium changes. We harvested the cells 48 
hours after induction. 
 
RNA purification and Real- time RT-PCR analysis 
Total RNA was extracted from all cells using the SV Total RNA Isolation System (Promega). 
cDNA was synthesized from 1 g of total RNA using random hexamers and SuperscriptTM II 
RNase H-Reverse Transcriptase (Invitrogen). Quantitative real-time PCR (MyIQ, Bio Rad) was 
performed using SYBR Green I. PCR primers were designed by Beacon designer (Premier 
Biosoft). The qPCR Core Kit (Invitrogen) was used with 400 nM of each primer under the 
following cycling conditions: 3 min. 95°C followed by 40 cycles of 10 seconds at 95°C and 45 
seconds at 60°C. The Gapdh gene was used as an endogenous reference for normalization. 
Enrichment of specific DNA sequences was calculated using the comparative CT method (21). 
PCR primer sequences are provided in Table 1. 
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Table1. Primers used for (A) ChIP, (B) mRNA expression,  along the INK4-ARF locus  
A: Primers used for ChIP (q PCR) along the INK4-ARF locus 
Primer set Location    Sequence 
 
A  P15 INK4b (-3,982)  5’- AGTCCTAAGCCCAATACCTCAC 
5’- CTGCCTCTTCACATAGTCATCC 
B  P15 INK4b (-3,575)  5’- ATCACGGAGCAATAAACCCAAC 
     5’- CAAGAGAAACAGCGACCTAACC 
C  P15 INK4b (-3,072)  5’- GGGTGGGCTGTTTCTGGAC 
5’- CCTCACGGGCAAGACCATC 
D  P15 INK4b (-2,860)  5’- CCCACTATGTTCCCATCCACTTC 
5’- CCTCACGGGCAAGACCATC 
E  P15 INK4b (-1,476)  5’- GACACATGCCACAGAGGAG 
5’- AGAAGACGAGAAGAGAAATCAAAC 
F  P15 INK4b (-1,065)  5’- AGAAACTGAAGACTAGGAAATGGG 
5’- CTGGACAGGGAAGGGAACC 
G  P15 INK4b (-1,065)  5’- ACTTGCGGTTCTCTTCCTATCC 
5’- TGTGGTGCTGGGCTTGTC 
H  P15 INK4b-Pm  5’-GGCAGTGGTGAACATTCC 
5’-GCCCAAAGATGCTAGGAC 
I  P14 ARF-Pm   5’-CGCCGTGTCCAGATGTCG 
     5’-TGCTCTATCCGCCAATCAGG 
J  P16 INK4a (-8.7 kb)  5’-ACTAGGCTTGTCCCACTTGC 
     5’-TCAGTTCCTCTCTCCATTCTCC 
K  P16 INK4a (-0.3 Kb)  5’-GGGCTCTCACAACTAGGAAAG 
     5’-GGGTGTTTGGTGTCATAGGG 
L  P16 INK4a (+85 bp)  5’-CCCCTTGCCTGGAAAGATAC 
     5’-AGCCCCTCCTCTTTCTTCCT 
M  P16 INK4a (+5.6 Kb)  5’- ACCAAGACTTCGCTGACC 
     5’-CAAGGAGGACCATAATTCTACC 
B: Primers used for mRNA expression (q PCR) of the INK4-ARF locus 
P15 INK4b   5’- ATCACATGAGGTCAGGAGTTCG 
   5’- CCAGGTTCAAGCGAGTCTCC 
P14 ARF   5’- GGTTTTCGTGGTTCACATCC 
   5’- CCTAGACGCTGGCTCCTC 
P16 INK4a   5’-CCCCTTGCCTGGAAAGATAC 
   5’-AGCCCCTCCTCTTTCTTCCT 
GAPDH   5’- GCCAAAAGGGTCATCATCTC 
   5’- GGTGCTAAGCAGTTGGTGGT 
 
ChIP assays 
 
ChIPs were performed as described by the Upstate protocol (http://www.upstate.com). Cross-
linked chromatin was prepared from ~2x107 cells 48h following transduction with lentiviruses 
expressing either hSNF5 or GFP as a control for MRT cells or from HDF-Neonatal and adult. 
Cells were treated with 1% formaldehyde for 20 min at room temperature. Chromatin 
isolation, sonication yielding fragments of 300−600 bp and immunoprecipitations were 
performed according to protocol. All data presented are the result of at least 3 independent 
ChIP experiments. The following antibodies were used: BMI1 (Abcam; ab14389), EZH2 (Santa 
Cruz; Sc-25383), POL II (Santa Cruz; Sc-899). The abundance of specific DNA sequences in 
the immunoprecipitates was determined by qPCR and corrected for the independently 
determined amplification curves of each primer set. ChIP using species and isotype-matched 
immunoglobins directed against an unrelated protein (GST) were used to determine 
background levels analysed by qPCR as described above. Enrichment of specific DNA 
sequences was calculated using the comparative CT method (21). PCR primer sequences are 
provided in Table 1. ChIP levels for each region are presented as percentage of input 
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chromatin. Statistical analysis of expression data and ChIP was performed using the R free 
software (http://www.r-project.org/). 
 
 
Cell extracts and western blotting  
  
Cell extracts were prepared in RIPA buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet 
P-40, 1% NaDOC, 0.1% SDS), assayed for protein concentration, 50 µg to 150 µg of extract 
was resolved by 6-20% (Bmi1), 6-8% (EZH2) and 6-12% SDS-PAGE, and transferred to 0.45 
µm nitrocellulose membrane. We lysed 1 volume of committed progenitor cells directly in 1 
volume of 2xLoading buffer (1xTris.Cl/SDS pH6.8, 20% glycerol, 4% SDS, O.2M DTT, 0.001% 
bromophenol blue) and resolved it by SDS-PAGE. The membranes were blocked for 1 hour in 
T-PBS with 5% milk and 0.1% Tween20 and incubated in primary- (overnight) and secondary 
(1 hour) antibody. Primary antibodies:  SUZ12 (Abcam, ab12073), BMI1 (Abcam; ab14389), 
EZH2 (Santa Cruz; Sc-25383) and Histone H3 (Abcam; ab1791). Western blots were 
developed with the ECL detection kit (PIERCE) or visualized with the IRDye 680/800CW (LI-
COR) and ODYSSEY Infrared Imaging System according to the supplier’s instructions. 
 
Chromatin Conformation Capture Assay 
 
The 3C-qPCR assay was performed as described(11). We prepared nuclei from 107 MEPs, HDF 
(Neonatal- Adult) and Mon cells. Formaldehyde-fixed nuclei were digested with EcoRI 
overnight, followed by ligation with T4 DNA ligase at 16 °C for 4 h. Cross links were reversed 
and DNA was extensively purified. The PCR control template, primer efficiency and ligation 
efficiency were determined as described (11) by digesting and ligating a BAC clone, which 
encompassed the entire INK4-ARF locus. To correct for differences in quality and quantity of 
templates, ligation frequencies between the fragments were normalized to a fragment in the 
human Ercc3 locus. Quantification of ligated products was performed by real-time qPCR with 
Taqman probe designed in the fragment that contains the polycomb binding region to INK4b 
and INK4a respectively (see Fig2.E-G). The primers and probes sequences are listed in table 
2. The amplification conditions used in 3C assays are available on request. Crosslinking 
frequencies were calculated using the equation described previously (35) . 
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Table2. Primers used for 3C-qPCR analysis of (A) P15 INK4b, (B) P16 INK4a and (C) and ERCC3  
A: Primers used for 3C-q PCR along the INK4-ARF locus, fixed fragment at P15INK4b 
Constant primer  5’- CAGGTTGAGCAGGTTGGTTT 
Probe   5’FAM- TCTAAAGCTTCACACTTGATCTTCCAAAGCCCCTT-3’BHQR 
EcoRI Fragment number  Forward primer Sequence 
1    5’- CCAACCTTAAACTACTGCTGAAAC 
2    5’- GGAAGTCTGCCTATATGGGTTATC 
3    5’- CTAAGGGGGTGGGGAGAC 
4    5’- TGGTCATATTCAGTACTCACCTCA 
5    5’- GTCCTGACTCCTACTCTGTTATCC 
6    5’- CTGCCCAATACCTGTTCTCTTTC 
7    5’- CCTTTCTTTCCTTAGGATGATGCC 
8    5’- ATTATTCCTCCATTGCCTTTGCC 
9    5’- GGAGACAGGACAGTATTTGAAGC  
10    5’- GGGCAGCATTTGCTATCCTA 
B: Primers used for 3C-q PCR along the INK4-ARF locus, fixed fragment at P16INK4a 
Constant primer  5’- CTGCCCCTTTGCTATTTTGC 
Probe   5’FAM- CCGAACTTCTGCGGAGCTGTCGTC-3’BHQR 
EcoRI Fragment number  Forward primer Sequence 
1    5’- GGCTCCCATCAACATATCTAACTC 
2    5’- CAGGTTGAGCAGGTTGGTTT 
3    5’- CTAAGGGGGTGGGGAGAC 
4    5’- GAGACGGGATTCCTCAACCAC 
5    5’- GTCCTGACTCCTACTCTGTTATCC 
6    5’- CTGCCCAATACCTGTTCTCTTTC 
7    5’- CCTTTCTTTCCTTAGGATGATGCC 
8    5’- ATTATTCCTCCATTGCCTTTGCC 
9    5’- AGTGGAGCCTACAGTAATCATTTG 
 10    5’- TCTTTGGCTTCTATTCCCTAGA 
C: Primers used for 3C-q PCR along the ERCC3 locus 
Constant primer  5’- TCTTACCTGTTGGCCACTGACA 
Probe   5’FAM- AGTTGTTCCTCCCAGGTCACATCCCAC-3’BHQR 
Test primer  5’- GTCTGACCTTGCCCAGTGATAG 
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Discussion and Future Prospect 
     Chromatin is a dynamic structure that modulates the access of regulatory factors to the 
genetic material of eukaryotes. The regulated alteration of chromatin structure, termed 
remodelling, can be accomplished by covalent modification of histones or by the action of 
ATP-dependent remodeling complexes. Remodelers are DNA-translocating motors that utilize 
the energy of ATP to disrupt histone-DNA contacts(14, 33, 44, 45, 62, 66, 67).  
     The multi-subunit SWI/SNF ATP-dependent chromatin remodelling complexes are highly 
conserved molecular motors that play crucial roles in diverse cellular processes, including 
expression and duplication of the genome. Human SNF5/INI1 is a universal SWI/SNF subunit 
and tumour-suppressor, lost in malignant rhabdoid tumours (MRTs), rare but highly 
aggressive paediatric cancers(3, 48, 49, 59).  
     Previously our group found that re-expression of hSNF5 in MRT cells caused an 
accumulation in G0/G1, cellular senescence and apoptosis. Cellular senescence is largely the 
result of direct transcriptional activation of the tumour-suppressor p16INK4a by hSNF5(41). 
hSNF5 acts as a transcriptional co-activator, which is required for the recruitment of the BRG1 
containing SWI/SNF chromatin remodeling complex to the p16INK4a promoter. The increased 
p16INK4a levels result in inhibition of the cyclin D1-CDK4 complex, thus retaining pRb in its 
hypophosphorylated antiproliferative state (41). Loss of hSNF5 function in MRT cells promotes 
chromosomal instability as a result of compromised mitosis (61). Because cancers resulting 
from loss of hSNF5 are so extremely aggressive, insight in the pathways involved are critical 
to understanding these and might be relevant to understanding other forms of cancer. 
     In chapter 2, we performed genome-wide gene expression profiling to address the role of 
hSNF5 in tumorigenesis. We anticipate that this investigation will help us to gain insight into 
the corruption of cellular pathways resulting from loss of hSNF5 tumour suppressor in MRTs. 
Our genome wide expression analysis suggests that hSNF5 can function in both transcription 
activation and repression of the genome. Whole genome expression profiling of hSNF5 cells 
revealed expression change of many E2F targets, including mitotic control genes and pre-
replication complex. This study identified hSNF5/INI1 target genes and provided evidence that 
hSNF5/INI1 may modulate cell cycle control through the regulation of the p16 INK4A-
cyclinD/CDK4-pRb-E2F pathway. We have shown that the majority of the up-regulated genes 
encoded proteins with functions in extracellular matrix remodelling, adhesion or cell migration 
(SERPINE2, ITGB5, MAP1B),  apoptosis (DR6,FAS, CASP4, GAS6, ADAM19), and cancer 
related pathway or other specialized functions ( CDKN2A, ETS2 and TRIM22).Those genes did 
not change or were down-regulated upon induction of mutant SNF5. shRNA knock down 
analysis of candidate effectors coupled with Chromatin immunoprecipitation studies (as we 
have done for ETS2, MAD2L1, TRIM22 and CDKN2A) will be done to determine the direct 
targets of SNF5 and to address the role of hSNF5 in tumourigenesis. 
     In Chapter 3 we report that cancer associated S284L substitution in hSNF5 causes 
polyploidy and aneuploidy due to failure in interaction between mitotic spindles and 
kinetochores, resulting in abrogation of chromosome segregation. In contrast re-expression of 
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wild type hSNF5 promotes accurate chromosome segregation and tightening of the mitotic 
check point. These observations suggest a critical function for hSNF5 in mitosis. This study 
once more draws attention to the fact that tetraploidization precedes aneuploidization(15, 54). 
Indeed tetraploid cells have a greater chance of aberrant cellular division than diploid cells. 
We have seen a distinct cleavage failure or untimely exit from mitosis. As well, abnormal 
mitotic spindle pole formation in cancer associated hSNF5 mutation results in tetraploid cells 
and doubled centrosome number. The relationship between centrosome aberration and 
aneuploidy and their function during cell cycle progression has been reviewed by many 
groups(4, 39) (53). Whole genome expression profiling showed that MAD2 and E2F1, which 
have been implicated in mitotic defects leading to aneuploidy(21), are both down-regulated 
following hSNF5 induction. These results suggested that misexpression of mitotic checkpoint 
components might cause the abnormal ploidy of MRT cells. 
     The SWI SNF related yeast RSC complex, containing the hSNF5 orthologue SNR1, has 
been implicated in kinetochore function, cohesion loading onto chromosomal arms, and 2 
micron episome segregation (1, 22-24, 64). As hSWI/SNF5 colocalizes with kinetochore 
proteins, hSNF5 may be involved in establishment of a specialized centromeric chromatin 
structure or in the control of sister chromatid cohesion and segregation(65). 
     Using conditional siRNA approaches, we extended our analysis to non- MRT cells and again 
observed polyploidization due to the loss of hSNF5. We therefore propose that the mitotic 
functions of hSNF5 are general and not cell-type specific. 
     Inactivation of ATP- dependent chromatin remodeling factors has been implicated in the 
development of distinct types of tumors (29, 30, 43). In this chapter we describe a novel role 
for hSNF5 in maintenance of chromosomal stability. We propose that inactivation of hSNF5 
promotes tumourigenesis through at least two distinct mechanisms: the previously described, 
compromised transcriptional activation of p16Ink4a mediated proliferation control(41), and 
defective mitosis resulting in polyploidization and numerical chromosome instability. 
     The aim of chapter 4 was to identify the mechanism of hSNF5-dependent transcriptional 
control of the INK4b-ARF-INK4a locus in MRT cells. The INK4b-ARF-INK4a locus is implicated 
in various types of cancer and encodes three distinct proteins, p15INK4b, p14ARF and p16INK4a 
(reviewed in (19, 51)). The Ink4a-Arf locus responds to stress signals, limiting cell 
proliferation and modulating  apoptosis (reviewed in (34)). hSNF5 acts as a transcriptional co-
activator, which is required for the recruitment of the BRG1 containing SWI/SNF chromatin 
remodelling complex to the and p16INK4a promoter but not  p14ARF. Our results suggest that, at 
least in these MRT cells, hSNF5 is critical for the recruitment of the SWI/SNF complex to the 
activated p16INK4a promoter as well as the p15INK4b promoter.  
     It is still of interest to identify the other DNA binding regulators that activate p16INK4a 
through association with the hSNF5 chromatin-remodelling factor. The SWI/SNF complexes 
lack sequence specific DNA binding, and are therefore thought to be recruited to specific 
promoters via interactions with DNA binding proteins.  ETS2 is a transcriptional activator of 
p16INK4a which has been shown to bind to the p16INK4a promoter(40). ChIP data revealed that 
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ETS2 and SNF5 are co-recruited to the P16 promoter in MRT cells (Figure1). shRNA knock 
down analysis of ETS2, and studies of p16INK4a activation upon induction of hSNF5  will be 
useful to address the co-recruitment of hSNF5 and ETS2 to p16INK4a promoter and examine 
role of ETS2 and hSNF5 in activation of p16INK4a. 
 
Figure1. hSNF5 and ETS2 are co-recruited to the p16INK4a Promoter.  
(A) Conservation of ETS2 binding site at p16INK4a promoter during evolution (B) ETS2 binding to the p16INK4a promoter is 
hSNF5-dependent, as revealed by ChIP-qPCR using antibodies directed against ETS2.  ChIPs using antibodies directed against 
ETS2. Cross-linked chromatin was prepared from MRT cells lacking hSNF5, but expressing GFP (light green bars), or cells 
expressing hSNF5 (dark green bars). 
     
     Previously, a number of reports have demonstrated a role for Polycomb silencers, including 
PRC1 and PRC2 upstream of p15INK4b, p14ARF and p16INK4a (6, 10, 18, 25) . Therefore, it 
appears that SWI/SNF and PcG proteins act antagonistically on this locus. However, while PcG 
proteins suppress the INK4a/ARF locus, hSNF5 selectively activates p15INK4b and p16INK4a. Our 
results now clearly establish that PRC1 and PRC2 mainly act upstream of p16INK4a and 
specifically localize within a region spanning approximately 800 bp, even though H3K27 
trimethylation covers a larger domain. Interestingly, restoration of SWI/SNF in MRT cells 
causes removal of Polycomb silencers (PRC1 and PRC2) from the p16 INK4a promoter. This is 
not consistent with a model in which PRC1 blocks SWI/SNF mediated chromatin remodeling as 
has been previously reported from experiments conducted in vitro (50). Instead, our data 
suggest that silencing by PcG complexes is a less rigid more dynamic process subject to 
removal in response to SWI/SNF expression.   
     We found that concomitant with the decrease in H3-K27me3, the active H3-K4me3 mark is 
strongly induced at p16INK4a and p15INK4b. The prominent H3-K4me3 methyltransferase MLL1 is 
the human homologue of Drosophila trx, the founding member of the trxG (7). ChIPs revealed 
that hSNF5 expression triggers MLL1 binding to the INK4b and INK4a loci. Because MLL1 
translocations are associated with highly aggressive lymphoid and myeloid infant leukemia 
(7), it will be of interest to investigate whether the oncogenic MLL1 fusion proteins are 
defective in p16INK4a activation. Collectively, our results show that during hSNF5-mediated 
p16INK4a activation, the trxG activators SWI/SNF and MLL1 replace the PcG silencers PRC1 and 
PRC2. We conclude that the antagonism between PcG and trxG proteins is not limited to fly 
development but also operates in human cancer cells. 
      Notably these findings and our latest finding suggest that, at least in MRT cells and 
neonatal fibroblast the mechanisms that control the activation or suppression of the INK4b-
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ARF-INK4a locus are not the same for all three genes within the locus. As we have shown in 
chapter 4 and 5, p16INK4a and p15INK4b are both induced upon induction of hSNF5 or during 
aging and differentiation, while p14Arf remains unchanged. This contrasts existing models in 
which the control of all genes within this locus is proposed to occur through a region 1 kb 
upstream of p15 termed regulatory domain (RD)(20).  
     Hypermethylation of CpG island sequences are a nearly universal somatic genome 
alteration in cancer. DNA methylation, occurring on cytosine bases in CpG dinucleotides, is an 
important epigenetic mechanism of gene regulation in eukaryotic cells. The CpG island of the 
p16 INK4a promoter is hypermethylated in various cancers (38). Alterations of SWI/SNF 
remodeling complex activity in various mammalian cells and organs have been implicated in 
transcriptional silencing through site-specific genomic methylation(2, 12, 17). Our results 
demonstrate that hSNF5, a core subunit of SWI/SNF induces demethylation of p16INK4a to 
promote transcriptional activation.       
     DNMT3b is involved in de-novo methylation during development. Our data also reveals 
that induction of hSNF5 causes removal of DNMT3b from the p16 INK4a promoter, an 
observation, which may explain alterations of methylation in this region. Higher expression of 
DNMT3b has been demonstrated in human oesophageal squamous cell carcinoma, which is 
correlated with low expression of p16 INK4a (52). Disruption of DNMT1 and DNMT3b resulted in 
demethylation of the p16 INK4a in other human cancer cells (42). DNMT3b has also been shown 
to interact with hSNF2H (ISWI), another ATP-dependent chromatin-remodelling enzyme(16). 
     EZH2 has been shown to serve as a recruitment platform for DNA methyltransferases(60) 
Our results demonstrate that re-expression of hSNF5 in MRT cells results in not only removal 
of Polycomb silencers (PRC1 and PRC2) but also of DNA methyltransferases from the p16INK4a 
promoter. This is in agreement with two recently published observations which claimed that 
aberrant silencing in cancer cells is caused by de novo meyhylation of the Polycomb-marked 
genes by DNA methyltransferases (46, 63). 
     The main conclusion from our work is a model for reactivation of the p16INK4a –Rb pathway 
by the SWI/SNF complex in MRT cells, which emphasizes the close interconnectivity of 
epigenetic pathways; i.e. polycomb silencing, histone methylation, DNA methylation and ATP-
dependent chromatin remodeling. 
     In chapter5 we have tried to delineate the mechanism behind INK4/ARF transcription 
during differentiation, aging and cancer. In order to answer this question we analyzed the 
spatial organization of the INK4/ARF locus in vitro to detect the frequency of possible 
interactions between these genomic loci by 3C (Capturing Chromosome Conformation) 
technology(11). 3C analysis revealed that at least in Mon cells, Neonatal fibroblasts and 
Megakaryocyte-Erythrocyte progenitor cells, there is a physical and spatial interaction 
between p15INK4b and p16INK4a but not p14ARF. Importantly, p15INK4b loses its physical 
interaction with p16INK4a upon induction of hSNF5, upon aging, as well as differentiation. We 
examined whether PcG complexes mediate this long-range gene silencing.  
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Mammalian Polycomb group (PcG)  proteins are essential transcription silencers that control 
multiple developmental processes, including stem cell self-renewal and differentiation, and 
have been implicated in several types of cancers (5, 32, 35, 58). However, it is not clear how 
PcG proteins and specifically those bound to downstream regions exert their repression over 
target genes. Long-range chromatin interactions by chromatin looping are thought to be one 
of the potential mechanisms to explain PcG action over broad distances in cis (8, 9, 26, 47). 
The first direct evidence comes from work in Drosophila showing that all major PcG-bound 
elements at the BX-C multi-gene locus—including PREs and core promoters—physically 
associate by chromatin long-range interactions in the repressed state (31). Recently it has 
been shown that the PcGs and histone marks help to silence target genes via the looping 
process in human cells (56, 57). Previously we showed that restoration of SWI/SNF causes 
removal of Polycomb silencers from the p16INK4a  locus(27). Further we showed that PcGs also 
bind to 3 kb upstream of p15INK4b in the repressed state and are removed upon induction of 
hSNF5 during aging and differentiation. Notably, we showed that YY1 and PcG silencers 
concomitantly bind to the Ink4a/b locus. Strikingly, induction of hSNF5 leads to the removal of 
YY1 and PcG proteins (Fig2). YY1 is the human homolog of Drosophila Pleiohomeotic (PHO) - a 
key sequence specific DNA binding recruiter of PcG complex. 
 
Figure2. Restoration of SWI/SNF Causes Removal of YY1 from p15INK4b and p16INK4a Promoters.  
Restoration of SWI/SNF Causes Removal of YY1 from INK4a/b locus.  ChIPs using antibodies directed against YY1. Cross-
linked chromatin was prepared from MRT cells lacking hSNF5, but expressing GFP (light green bars), or cells expressing 
hSNF5 (dark green bars). ChIPs were analyzed by qPCR using primer sets specific for the regions indicated by A-M along the 
INK4b-ARF-INK4a locus, revealing that YY1 binding peaks at the p16INK4a promoter and 3 kb upstream of p15INK4b. Upon 
induction of hSNF5 YY1 is removed or strongly reduced.   QPCR primer sets correspond to the upstream of  p15INK4b promoter 
(A-H), the p14ARF promoter (I), an intergenic control region (J), and various regions of the p16INK4a locus (sets K-M). Primer 
sets K and L cover the p16INK4a promoter. The positions of the amplified regions on the INK4b-ARF-INK4a locus are indicated 
at the bottom.  
 
     To test if PcG proteins can silence the locus through the looping process, we applied RNA 
interference to deplete Ezh2, the catalytic component of the Polycomb repressive complex2 
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(PRC2) in Mon cells and Neonatal fibroblasts. We found that the loop resolved and 
transcription was activated in response to Ezh2 depletion. Our data provide strong evidence 
that PcGs play a role in generating the repressive loop at the INK4/ARF locus. In conclusion, 
we found that coordinate induction of p15INK4b and p16INK4a but not p14ARF during 
differentiation or aging is accompanied by down-regulation of EZH2 and reduced locus 
occupancy of PcG repressors. EZH2 is required for coordinate silencing of p15INK4b and 
p16INK4a. EZH2 depletion (KD) causes loss of PcG repressors on the INK4b and INK4a loci and 
resolution of the repressive loop. Therefore looping between p15INK4b and p16INK4a is EZH2-
dependent. It has been shown that depletion of EZH2 subunit of PRC2 in response to stress 
causes the loss of H3K27me3, displacement of BMI1 subunit of the Polycomb-Repressive 
Complex1 (PRC1) and transcription activation of INK4a (6). In agreement with this we showed 
that depletion of EZH2 during aging and differentiation causes displacement of BMI1 and 
activation of Ink4a and Ink4b (this thesis).  
     It is well established that the Ink4/Arf locus is activated during organismal aging in both 
rodents and humans, and the levels of p16Ink4a constitute an impressively good overall 
biomarker of aging (28). It has been shown that p16Ink4a both serves as a brake for the 
proliferation of cancer cells, and also limits the long-term renewal of stem cells (Reviewed in 
(13) ). EZH2 is accumulated in the undifferentiated progenitor cell population such as 
hematopoietic cells (55). In agreement, we showed that depletion of EZH2 during aging and 
differentiation results in resolution of the repressive loop in MEP, HDF and MRT cells and thus 
regulates the expression of p16 Ink4a. 
 
Finally, the PRC-bound INK4a and INK4b regulatory regions are linked in nuclear 
space. Loss of PRC-binding causes a release of the chromatin loop and up-regulation of INK4a 
and INK4b. These findings for the INK4b-ARF-INK4a locus dove-tail well with other studies 
revealing PcG-mediated chromatin looping (31, 36, 37). We conclude that PcG proteins 
dynamically alter the higher order chromatin structure of the INK4b-ARF-INK4a locus to 
balance differentiation and proliferation of human cells. 
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 Chromatin is a highly dynamic structure that plays a key role in the orchestration of gene 
expression patterns during cellular differentiation and development. The regulated alteration 
of chromatin structure, termed remodeling can be accomplished by covalent modification of 
histones or by the action of ATP-dependent remodeling complexes.   
     hSNF5/INI1 is a subunit of the ATP-dependent hSWI-SNF chromatin-remodelling complex. 
This gene is a tumour suppressor gene frequently mutated in malignant rhabdoid tumours 
(MRT). We have developed MRT-derived G401 cell lines lacking genomic hSNF5 gene, which 
can express wild type or mutant hSNF5 (S284L) upon induction. We also transduced wild type 
hSNF5 to parental malignant rhabdoid MON cell lines lacking endogenous hSNF5. In chapter2 
we studied time course variation (24h, 48h and 5 days) of 22,500 genes/expressed sequence 
tags upon hSNF5/INI1 or mutant hSNF5 (S284L) induction or transfection. Our genome wide 
expression suggests that hSNF5 can function in both transcription activation and repression of 
genes. Whole genome expression profiling of hSNF5 cells revealed expression change of many 
E2F targets, including mitotic control genes and pre-replication complex. This study identifies 
hSNF5/INI1 target genes and provides evidence that hSNF5/INI1 may modulate cell cycle 
control through the regulation of the p16 INK4A-cyclinD/CDK4-pRb-E2F pathway.  
     In chapter3, we report that loss of hSNF5 function in MRT-derived cells leads to 
polyploidization and chromosomal instability. Re-expression of hSNF5 restored the coupling 
between cell cycle progression and ploidy checkpoints. In contrast, cancer-associated hSNF5 
mutants harbouring specific single amino acid substitutions exacerbated poly- and 
aneuploidization, due to abrogated chromosome segregation. We found that hSNF5 activates 
the mitotic checkpoint through the p16INK4a-cyclinD/CDK4-pRb-E2F pathway. These results 
establish that poly- and aneuploidy of tumour cells can result from mutations in a chromatin 
remodeler. 
 
     In chapter4, we investigated how the balance between Polycomb group (PcG) silencing 
and SWI/SNF activation affects epigenetic control of the INK4b-ARF-INK4a locus in MRT cells. 
hSNF5 re-expression in MRT cells caused SWI/SNF recruitment and activation of p15INK4b and 
p16INK4a, but not of p14ARF. Gene activation by hSNF5 is strictly dependent on the SWI/SNF 
motor subunit BRG1. SWI/SNF mediates eviction of the PRC1 and PRC2 PcG silencers and 
extensive chromatin reprogramming. Concomitant with PcG complex removal, the mixed 
lineage leukemia 1 (MLL1) protein is recruited and active histone marks supplant repressive 
ones. Strikingly, loss of PcG complexes is accompanied by DNA methyltransferase DNMT3B 
dissociation and reduced DNA methylation. Thus, various chromatin states can be modulated 
by SWI/SNF action. Collectively, these findings emphasize the close interconnectivity and 
dynamics of diverse chromatin modifications in cancer and gene control. 
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     In chapter5 we have tried to delineate the mechanism behind the INK4/ARF transcription 
during differentiation, aging and cancer. We analyzed the spatial organization of the INK4/ARF 
locus in vitro to detect the frequency of possible interactions between these genomic loci by 
3C (Capturing Chromosome Conformation) technology. 3C analysis revealed that at least in 
Mon cells, Neonatal fibroblasts and Megakaryocyte-Erythrocyte progenitor cells, there is a 
physical and spatial interaction between p15INK4b and p16INK4a but not p14ARF. Importantly, 
p15INK4b loses its physical interaction with p16INK4a upon induction of hSNF5, upon aging as well 
as differentiation. We applied RNA interference to deplete EZH2, the catalytic component of 
the Polycomb  Repressive Complex2 (PRC2) in Mon cells and Neonatal fibroblasts, and we 
found EZH2 mediates this long-range gene silencing.  Our data provide strong evidence that 
PcGs play a role in generating the repressive loop at the INK4/ARF locus. In conclusion we 
found that coordinate induction of p15INK4b and p16INK4a but not p14ARF during differentiation or 
aging is accompanied by down-regulation of EZH2 and reduced locus occupancy of PcG 
repressors. EZH2 depletion causes loss of PcG repressors on the INK4b and INK4a loci and 
resolution of the repressive loop. Therefore looping between p15INK4b and p16INK4a is EZH2-
dependent. 
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Chromatine is een zeer dynamische structuur die een belangrijke functie rol spelt bij de 
regulatie van genexpressive gedurende cellulaire differentiatie en ontwikkeling. De 
gereguleerde verandering van de chromatine structuur, remodeling genoemd, kan worden 
gerealiseerd door covalente modificaties van de histonen of door de activiteit van ATP 
afhankelijke remodeling complexen.  
   hSNF5/INI1 maakt deel uit van het ATP afhankelijke hSWI-SNF chromatine remodelling 
complex. Het gen is een tumor suppressor dat vaak is gemuteerd in Malignant Rhabdoid 
Tumours (MRT). We hebben een MRT afgeleide cel lijn, G401 waarin het hSNF5 gen mist, die 
een wild type of mutante hSNF5 tot expressie kan brengen na inductie. We hebben ook wild 
type hSNF5 ingebracht in de malignant rhabdoid MON cel lijn. In hoofdstuk 2 hebben we een 
tijd reeks gedaan (1, 2, en 5 dagen) waarin we de genexpressie van 22500 genen hebben 
bekeken na inductie of transfectie van hSNF5 en de mutant hSNF5 (S284L). Onze genomische 
expressie studie suggereert dat hSNF5 een functie heeft in zowel transcriptie aktivatie als 
repressie. Het genomische expressie profiel van de hSNF5 geïnduceerde cellen liet een 
verandering zien in het expressie patroon van veel E2F gereguleerde genen, waaronder genen 
belangrijk tijdens de mitose and genen van het pre-replicatie complex. Deze studie heeft 
hSNF5/INI1 gereguleerde genen geïdentificeerd en laat zien dat hSNF5/INI1 de cel cyclus kan 
contoleren door de regulatie van de p16 INK4A-cyclinD/CDK4-pRb-E2F route.  
     In hoofdstuk 3 laten we zien dat het verlies van de functie van hSNF5 in MRT afgeleide 
cellen leidt tot polyploidi en chromosomale instabiliteit. Hernieuwde expressie van hSNF5 
herstelt de koppeling tussen de cel cyclus progressie en ploidi controle punten. In 
tegenstelling hiertoe leidde kanker geassocieerde mutaties tot een verergering van de 
aneuploidi en polyploidi door een verstoring van de chromosoom segregatie. We vonden dat 
hSNF5 de mitotische controle punten activeerde via de p16 INK4a-cyclinD/CDK4-pRb-E2F 
signaal route. Deze resultaten laten zien dat poly- en anueploidy het resultaat kunnen zijn van 
mutatie in een chromatine remodeller.  
 
     In hoofdstuk 4 onderzoeken we hoe de balance tussen inactivatie van genexpressie door 
de Polycomb groep (PcG) en activatie door SWI/SNF activiteit de epigenetische controle van 
de INK4b-ARF-INK4a locus in MRT celllen beinvloed. Hernieuwde expressie van hSNF5 in MRT 
cellen veroorzaakte het recruiteren van SWI/SNF en de activatie van p15INK4b en p16INK4a, 
maar niet van p14ARF. De activatie door hSNF5 is volkomen afhankelijk van de SWI/SNF 
katalitische eiwit BRG1. SWI/SNF medieerd de verwijdering van PcG repressoren en 
veroorzaakt uitgebreide chromatine herprogrameringen. Tegelijkertijd met de verwijdering 
van het PcG complex, word het Mixed Lineage Leukemia 1 (MLL1) eiwit gerecuiteerd en 
worden zo repressieve histonen labels vervangen door actitieve markeringen. Verassend is dat 
het verlies van PcG complexen vergezeld word door de dissociatie van de DNA 
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methyltranferase DNMT3B en verlaagde DNA methylering. Samengevat, SWI-SNF activiteit 
moduleert het chromatine in verschillende stadia. Deze resultaten benadrukken de 
verbondenheid en dynamiek van de verschillende chromatine modificaties in gen regulatie 
tijdens kanker.  
 
  In hoofdstuk 5 hebben we geprobeerd het mechanisme dat tengrondslag ligt aan de 
regulatie van INK4A-ARF expressie tijdens differentiatie, kanker en veroudering op te 
helderen. We hebben de ruimtelijke organisatie van de INK4/ARF locus in vitro geanalyseerd 
om de frequentie van de interactie tussen de verschillende regios van de INK4A/ARF locus te 
bepalen met behulp van 3C technologie (Capturing Chromosome Conformation) technologie. 
3C analyse liet zien dat er in Mon cellen, Neonatale fibroblasten en de Megakaryocyte-
Erythrocyte voorlopers een directe fysieke interactie is tussen p15INK4b en p16INK4a, maar niet 
met p14ARF. Belangrijk is dat deze interactie verloren gaat na inductie van hSNF5 in MRT 
cellen, bij differentiatie en veroudering. We hebben RNA interferentie toegepast om Ezh2, de 
katalitische component van het Polycomb Repressieve Complex 2 (PRC2) te verwijderen in 
Mon cellen en Neonatale fibroblasten. Wij vonden hierbij dat EZH2 noodzakelijk is voor de 
repressieve chromatine loop. Deze resultaten vormen sterke aanwijzingen dat PcG eiwitten, 
en met name EZH2, een belangrijke rol spelen bij het vormen van een repressieve verbinding 
in de INK4/ARF locus. Concluderend hebben wij beschreven dat gecoördineerde inductie van 
p15INK4b en p16INK4a maar niet p14ARF gedurende differentiatie of veroudering vergezeld gaat 
met velaging van EZH2 en een verlies van PcG repressors op de locus. Dus is de verbinding 
tussen p15INK4b and p16INK4a afhankelijk van E(z)h2. Wij concluderen dat een PcG eiwit 
afhankelijke chromatiene loop een belangrijke rol speeld bij het koppelen van cel differentiatie 
en proliferatie. 
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